

CITATION REPORT

List of articles citing

Haemodynamic definitions and updated clinical classification of pulmonary hypertension

DOI: 10.1183/13993003.01913-2018

European Respiratory Journal, 2019, 53, .

Source: <https://exaly.com/paper-pdf/74765940/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2116	Comparing effectiveness of prognostic tests in idiopathic pulmonary fibrosis. 2019 , 13, 993-1004		1
2115	Handlungsempfehlung nach der S2k-Leitlinie Pulmonalerterielle Hypertonie (PAH) im Kindes- und Jugendalter 2019 , 167, 637-640		1
2114	Novel Therapeutic Approaches of Pulmonary Arterial Hypertension. 2019 , 28, 112-117		1
2113	Pulmonary Hypertension in COPD: A Case Study and Review of the Literature. 2019 , 55,		2
2112	Collaborative Cardiology and Pulmonary Management of Pulmonary Hypertension. 2019 , 156, 200-202		2
2111	Bosentan for Treatment of Pediatric Idiopathic Pulmonary Arterial Hypertension: State-of-the-Art. 2019 , 7, 302		6
2110	Mildly increased pulmonary arterial pressure: a new disease entity or just a marker of poor prognosis?. 2019 , 21, 1057-1061		6
2109	Connective Tissue Disease-Associated Interstitial Lung Disease: Evaluation and Management. 2019 , 40, 617-636		6
2108	Clinical outcomes and survival following lung transplantation in patients with lymphangioleiomyomatosis. 2019 , 38, 949-955		17
2107	Characterization of -Mutated Rat, a Novel Model of Pulmonary Hypertension. 2019 , 125, 678-695		42
2106	Screening for pulmonary arterial hypertension in systemic sclerosis. 2019 , 28,		21
2105	Systolic Dysfunction in Systemic Sclerosis: Prevalence and Prognostic Implications. 2019 , 1, 258-266		5
2104	Pulmonary hypertension and valvular heart disease. 2019 , 44, 491-501		8
2103	Pulmonary hypertension in HFpEF and HFrEF: Pathophysiology, diagnosis, treatment approaches. 2019 , 44, 483-490		9
2102	Treatment of pediatric pulmonary arterial hypertension: A focus on the NO-sGC-cGMP pathway. 2019 , 54, 1516-1526		11
2101	Chronisch thromboembolische pulmonale Hypertonie aktuelle Diagnostik und Therapie. 2019 , 16, 294-302		
2100	Pulmonary Hypertension in Advanced Heart Failure: Assessment and Management of the Failing RV and LV. 2019 , 16, 119-129		2

2099	Pulmonary capillary surface area in supine exercising humans: demonstration of vascular recruitment. 2019 , 317, L361-L368		4
2098	EXPRESS: Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors. 2019 , 2045894019865704		4
2097	Reduced diffusing capacity for carbon monoxide predicts borderline pulmonary arterial pressure in patients with systemic sclerosis. 2019 , 39, 1883-1887		2
2096	2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. 2019 , 38, 879-901		133
2095	A retrospective study of schistosomiasis-associated pulmonary hypertension from an endemic area in Brazil. 2019 , 24, 100387		1
2094	Lysyl-oxidase in systemic sclerosis-associated pulmonary arterial hypertension: a future still to be written. 2019 , 58, 1523-1525		
2093	Efficacy and Safety of the Use of Pulmonary Arterial Hypertension Pharmacotherapy in Patients with Pulmonary Hypertension Secondary to Left Heart Disease: A Systematic Review. 2019 , 39, 929-945		4
2092	Pulmonary Arterial Hypertension Due to NPR-C Mutation: A Novel Paradigm for Normal and Pathologic Remodeling?. 2019 , 20,		9
2091	Endothelial-to-mesenchymal transition: Pathogenesis and therapeutic targets for chronic pulmonary and vascular diseases. 2019 , 168, 100-107		17
2090	Pulmonary hypertension at high altitude. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	9
2089	Physical activity in incident patients with pulmonary arterial and chronic thromboembolic hypertension. 2019 , 197, 617-625		4
2088	Impact of the revised haemodynamic definition on the diagnosis of pulmonary hypertension in patients with systemic sclerosis. <i>European Respiratory Journal</i> , 2019 , 54,	13.6	24
2087	Pharmacotherapy for pulmonary arterial hypertension. 2019 , 11, S1767-S1781		27
2086	Evaluation and classification of pulmonary arterial hypertension. 2019 , 11, S1789-S1799		17
2085	Non-Invasive Approach for Evaluation of Pulmonary Hypertension Using Extracellular Vesicle-Associated Small Non-Coding RNA. 2019 , 9,		13
2084	Pulmonary Complications of Portal Hypertension. 2019 , 23, 683-711		9
2083	Metabolomics of exercise pulmonary hypertension are intermediate between controls and patients with pulmonary arterial hypertension. 2019 , 9, 2045894019882623		8
2082	Pulmonary Hypertension and Thoracic Surgery: Impact and Treatment Options. 2019 , 9, 436-445		1

2081	Efficacy of immunosuppressants with bridge vasodilator therapy in severe lupus erythematosus-associated pulmonary arterial hypertension. 2019 , 6, 1322-1325	5
2080	Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study). 2019 , 21, 217	20
2079	Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. 2019 , 7, 780-790	61
2078	Clinical and laboratory predictions of myocardial inflammation as detected by cardiac magnetic resonance imaging in patients with systemic sclerosis: A pilot study. 2019 , 22, 2125-2133	0
2077	Hypoxic Pulmonary Vasoconstriction and the Diffusing Capacity in Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis. 2019 , 8, e013310	4
2076	Chronisch thromboembolische pulmonale Hypertonie. 2019 , 11, 32-40	
2075	Practical management of riociguat in patients with pulmonary arterial hypertension. 2019 , 13, 1753466619868238	
2074	Borderline pulmonary hypertension is associated with exercise intolerance and increased risk for acute exacerbation in patients with interstitial lung disease. 2019 , 19, 167	5
2073	Molecular Characteristics and Treatment of Endothelial Dysfunction in Patients with COPD: A Review Article. 2019 , 20,	18
2072	Debating the new haemodynamic definition of pulmonary hypertension: much ado about nothing?. <i>European Respiratory Journal</i> , 2019 , 54,	13.6 5
2071	Epidemiology and initial management of pulmonary arterial hypertension: real-world data from the Hellenic pulmOnary hyPertension rEgistry (HOPE). 2019 , 9, 2045894019877157	17
2070	Association of Mild Echocardiographic Pulmonary Hypertension With Mortality and Right Ventricular Function. 2019 , 4, 1112-1121	31
2069	Reduction in pulmonary artery pressures with use of sacubitril/valsartan. 2019 , 20, 187-190	8
2068	A Nationwide multicenter registry and biobank program for deep phenotyping of idiopathic and hereditary pulmonary arterial hypertension in Korea: the PAH platform for deep phenotyping in Korean subjects (PHOENIKS) cohort. 2019 , 25, 21	5
2067	NADPH oxidase in the vasculature: Expression, regulation and signalling pathways; role in normal cardiovascular physiology and its dysregulation in hypertension. 2019 , 145, 385-427	45
2066	Extracorporeal life support bridge for pulmonary hypertension: A high-volume single-center experience. 2019 , 38, 1275-1285	18
2065	Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. 2019 , 38, 1286-1295	22
2064	Etiology of Exercise-Induced Pulmonary Hypertension Can Be Differentiated by Echocardiography - Insight From Patients With Chronic Pulmonary Thromboembolism With Normal Resting Hemodynamics by Balloon Pulmonary Angioplasty. 2019 , 83, 2527-2536	3

2063	Diagnosis of chronic thromboembolic pulmonary hypertension: A Canadian Thoracic Society clinical practice guideline update. 2019 , 3, 177-198		7
2062	Potential role of exercise echocardiography and right heart catheterization in the detection of early pulmonary vascular disease in patients with systemic sclerosis.. 2019 , 4, 219-224		1
2061	Balloon pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension: is Europe behind?. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	10
2060	Dynamic right ventricular-pulmonary arterial uncoupling during maximum incremental exercise in exercise pulmonary hypertension and pulmonary arterial hypertension. 2019 , 9, 2045894019862435		26
2059	Pulmonary vascular disease and pulmonary hypertension. 2019 , 25, 304-312		5
2058	Mean platelet volume as a predictor of pulmonary hypertension in patients with stable COPD. 2019 , 14, 1099-1108		7
2057	Cardiomyopathy in Children: Classification and Diagnosis: A Scientific Statement From the American Heart Association. 2019 , 140, e9-e68		80
2056	A Case of Sudden Death Due to Persistent Severe Pulmonary Arterial Hypertension After Late Atrial Septal Defect Closure. 2019 , 64, 1916-1920		1
2055	Correspondence on the debate regarding the haemodynamic definition of pulmonary hypertension. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	0
2054	Oxidation of PKGI β mediates an endogenous adaptation to pulmonary hypertension. 2019 , 116, 13016-13025		8
2053	Does Glycine catabolism Drive Pulmonary Hypertension?. 2019 , 139, 2256-2259		0
2052	Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension incidence in Latvia in 2018. 2019 , 65, e9-e10		2
2051	Imaging of Pulmonary Hypertension: Pictorial Essay. 2019 , 156, 211-227		23
2050	Noninvasive estimation of pulmonary vascular resistance improves portopulmonary hypertension screening in liver transplant candidates. 2019 , 33, e13585		4
2049	Practical approach to establishing pulmonary rehabilitation for people with non-COPD diagnoses. 2019 , 24, 879-888		10
2048	Pulmonary Hypertension in Patients with Heart Failure with Preserved Ejection Fraction. Where to Draw the Line. 2019 , 200, 278-279		3
2047	Pulmonary Hypertension in Children with Sickle Cell Disease: a Review of the Current Literature. 2019 , 7, 33-44		
2046	Regulation of Smooth Muscle Cell Proliferation by NADPH Oxidases in Pulmonary Hypertension. 2019 , 8,		10

2045	Key inflammatory pathways underlying vascular remodeling in pulmonary hypertension. 2019 , 44, 130-137		8
2044	Pulmonary Hypertension in HIV. 2019 , 35, 288-298		14
2043	Management of Pulmonary Arterial Hypertension in the ICU. 2019 , 32, 303-313		5
2042	Distinct plasma gradients of microRNA-204 in the pulmonary circulation of patients suffering from WHO Groups I and II pulmonary hypertension. 2019 , 9, 2045894019840646		12
2041	Identifying Patients with Pulmonary Arterial Hypertension Using Administrative Claims Algorithms. 2019 , 16, 797-806		18
2040	Can patients be discharged after VSD closure?. 2019 , 282, 45-46		
2039	Early histological changes of pulmonary arterial hypertension disclosed by invasive cardiopulmonary exercise testing. 2019 , 9, 2045894019845615		2
2038	Real-World Data for Pulmonary Arterial Hypertension. 2019 , 155, 653-654		
2037	The pulmonary haemodynamics during exercise - research network (PEX-NET) ERS Clinical Research Collaboration: investigating the prognostic relevance of exercise haemodynamics. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	2
2036	The new haemodynamic definition of pulmonary hypertension: evidence prevails, finally!. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	29
2035	Response: Still puzzling about a clear definition of pulmonary arterial hypertension in newborns. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	2
2034	Proposed new pulmonary hypertension definition: is 4 mm(Hg) worth re-writing medical textbooks?. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	17
2033	Understanding the Similarities and Differences between Hepatic and Pulmonary Veno-Occlusive Disease. 2019 , 189, 1159-1175		14
2032	Early intervention: should we conduct therapeutic trials for mild pulmonary hypertension before onset of symptoms?. 2019 , 9, 2045894019845615		4
2031	The Search for Disease-Modifying Therapies in Pulmonary Hypertension. 2019 , 24, 334-354		17
2030	Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis. 2019 , 71, 1339-1349		34
2029	Treatment of pulmonary arterial hypertension: A review of drugs available for advanced therapy. 2019 , 25,		
2028	Clot regression effects of rivaroxaban in the treatment of venous thromboembolism in patients with cancer (CRERIT-VTE cancer): study protocol. 2019 , 9, e031698		1

2027	Smooth muscle cytochrome b5 reductase 3 deficiency accelerates pulmonary hypertension development in sickle cell mice. 2019 , 3, 4104-4116	7
2026	Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation. 2019 , 5,	9
2025	Updates in pulmonary hypertension and other pulmonary vascular diseases. 2019 , 15, 241-243	1
2024	Pulmonary arterial hypertension: the case for a bioelectronic treatment. 2019 , 5, 20	7
2023	American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. 2019 , 3, 3867-3897	41
2022	Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations. 2019 , 28,	20
2021	Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue. 2019 , 28,	37
2020	The ever-expanding phenotypical spectrum of human TBX4 mutations: from toe to lung. <i>European Respiratory Journal</i> , 2019 , 54,	13.6 5
2019	Diagnostic accuracy of transthoracic echocardiography for pulmonary hypertension: a systematic review and meta-analysis. 2019 , 9, e033084	15
2018	End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings. 2019 , 3, 4002-4020	11
2017	Pulmonary hypertension and chronic lung disease: where are we headed?. 2019 , 28,	11
2016	Balloon angioplasty or stent implantation for pulmonary vein stenosis caused by fibrosing mediastinitis: a systematic review. 2019 , 9, 520-528	4
2015	Novel risk genes and mechanisms implicated by exome sequencing of 2572 individuals with pulmonary arterial hypertension. 2019 , 11, 69	45
2014	Endothelin-1: An Emerging Biomarker for Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction. 2019 , 143, 134-135	
2013	Exploring a physiotherapy well-being review to deliver community-based rehabilitation in patients with pulmonary hypertension. 2019 , 9, 2045894019885356	3
2012	The relationship between endothelial progenitor cells and pulmonary arterial hypertension in children with congenital heart disease. 2019 , 19, 502	5
2011	Therapeutic Challenges And Advances In The Management Of Systemic Sclerosis-Related Pulmonary Arterial Hypertension (SSc-PAH). 2019 , 15, 1427-1442	6
2010	Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure. 2019 , 10, 125-170	39

2009	Screening strategies for pulmonary arterial hypertension. 2019 , 21, K9-K20	16
2008	Management of pulmonary arterial hypertension in patients aged over 65 years. 2019 , 21, K29-K36	5
2007	My life with pulmonary arterial hypertension: a patient perspective. 2019 , 21, K54-K59	5
2006	Beyond the World Symposium on Pulmonary Hypertension: practical management of pulmonary arterial hypertension and evolving concepts. 2019 , 21, K1-K3	0
2005	The revised definition of pulmonary hypertension: exploring the impact on patient management. 2019 , 21, K4-K8	26
2004	Pulmonary arterial hypertension. 2019 , 14, 14-22	2
2003	The Biological Bases of Group 2 Pulmonary Hypertension. 2019 , 20,	11
2002	Pulmonary Arterial Hypertension: a Pharmacotherapeutic Update. 2019 , 21, 141	27
2001	Orotracheal treprostinil administration attenuates bleomycin-induced lung injury, vascular remodeling, and fibrosis in mice. 2019 , 9, 2045894019881954	12
2000	Pulmonary artery involvement in Takayasu's arteritis: diagnosis before pulmonary hypertension. 2019 , 19, 225	12
1999	In Reply. 2019 , 134, 882	
1998	Pulmonary hypertension with massive megalosplenia: A case report. 2019 , 98, e14594	1
1997	The prognostic value of DLCO and pulmonary blood flow in patients with pulmonary hypertension. 2019 , 9, 2045894019894531	6
1996	Matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertension. 2019 , 9, 2045894019895414	10
1995	"Anagrelide-induced pulmonary arterial hypertension": a rare case of drug-induced pulmonary arterial hypertension. 2019 , 9, 2045894019896682	2
1994	Features of radiological and physiological findings in pulmonary capillary hemangiomatosis: an updated pooled analysis of confirmed diagnostic cases. 2019 , 9, 2045894019896696	1
1993	Drug-Induced Pulmonary Arterial Hypertension: Mechanisms and Clinical Management. 2019 , 33, 725-738	2
1992	Pulmonary Hypertension and Pregnancy. 2019 , 134, 974-987	15

1991	The global view. 2019 , 25, 391-397		2
1990	The role of rehabilitation in patients with pulmonary arterial hypertension. 2019 , 25, 398-404		3
1989	ACOG Practice Bulletin No. 212: Pregnancy and Heart Disease. 2019 , 134, 881-882		11
1988	Cardiac Imaging in Liver Transplantation Candidates: Current Knowledge and Future Perspectives. 2019 , 8,		3
1987	Pulmonary Arterial Hypertension In Systemic Sclerosis: Challenges In Diagnosis, Screening And Treatment. 2019 , 11, 323-333		8
1986	Un an apr� le congr� mondial, quels changements dans la prise en charge de l'hypertension pulmonaire ?. 2019 , 11, 123-128		
1985	Early Diagnosis in Pulmonary Arterial Hypertension: The Search for the Holy Grail. 2019 , 199, 1306-1307		3
1984	Risk stratification and medical therapy of pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	316
1983	Pulmonary hypertension due to left heart disease. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	209
1982	Chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	263
1981	Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	209
1980	An overview of the 6th World Symposium on Pulmonary Hypertension. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	182
1979	Neutralization of CXCL12 attenuates established pulmonary hypertension in rats. 2020 , 116, 686-697		25
1978	NFU1, Iron-Sulfur Biogenesis, and Pulmonary Arterial Hypertension: A (Metabolic) Shift in Our Thinking. 2020 , 62, 136-138		6
1977	Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension. 2020 , 201, 148-157		29
1976	Impact of the New Pulmonary Hypertension Definition on Heart Transplant Outcomes: Expanding the Hemodynamic Risk Profile. 2020 , 157, 151-161		12
1975	A new treatment for severe pulmonary arterial hypertension based on an old idea: inhibition of 5-lipoxygenase. 2020 , 10, 2045894019882635		3
1974	Multiple roles of macrophage migration inhibitory factor in pulmonary hypertension. 2020 , 318, L1-L9		7

1973	Pulmonary arterial hypertension in systemic sclerosis-when criteria and pathobiology differ. 2020 , 59, 1177-1179	2
1972	Variation in the definition of pulmonary hypertension and clinical indications for the use of nitric oxide in neonatal clinical trials. 2020 , 109, 930-934	3
1971	Mimickers of chronic thromboembolic pulmonary hypertension on imaging tests: a review. 2020 , 10, 2045894019882620	10
1970	Molecular genetic framework underlying pulmonary arterial hypertension. 2020 , 17, 85-95	86
1969	Highlights of high-resolution computed tomography imaging in evaluation of complications and co-morbidities in idiopathic pulmonary fibrosis. 2020 , 61, 204-218	
1968	When Pulmonary Hypertension Complicates Heart Failure. 2020 , 16, 53-60	8
1967	Maternal Diabetes Mellitus and Persistent Pulmonary Hypertension of the Newborn: Accumulated Evidence From Observational Studies. 2020 , 44, 327-334.e3	1
1966	Cardiopulmonary exercise testing in a combined screening approach to individuate pulmonary arterial hypertension in systemic sclerosis. 2020 , 59, 1581-1586	7
1965	Neue h̄thodynamische Definition der pulmonalen Hypertonie. 2020 , 168, 252-256	0
1964	Interaction between PGI and ET-1 pathways in vascular smooth muscle from Group-III pulmonary hypertension patients. 2020 , 146, 106388	3
1963	Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease. 2020 , 177, 5467-5488	34
1962	Bronchodilation induced by PGE is impaired in Group III pulmonary hypertension. 2020 , 177, 161-174	5
1961	Association of right atrial conduit phase with right ventricular lusitropic function in pulmonary hypertension. 2020 , 36, 633-642	7
1960	The role of cardiopulmonary exercise testing and training in patients with pulmonary hypertension: making the case for this assessment and intervention to be considered a standard of care. 2020 , 14, 317-327	1
1959	Diagnostik und Therapie der kardialen Sarkoidose. 2020 , 14, 14-25	0
1958	Long noncoding RNAs: emerging roles in pulmonary hypertension. 2020 , 25, 795-815	13
1957	Right ventricular function correlates of right atrial strain in pulmonary hypertension: a combined cardiac magnetic resonance and conductance catheter study. 2020 , 318, H156-H164	18
1956	Exercise Pulmonary Hypertension Predicts Clinical Outcomes in Patients With Dyspnea on Effort. 2020 , 75, 17-26	33

1955	Exercise Pulmonary Hypertension Is Back. 2020 , 75, 27-28	2
1954	Enfermedad tromboembólica crítica pulmonar. 2020 , 56, 314-321	3
1953	PPAR α is a gatekeeper for extracellular matrix and vascular cell homeostasis: beneficial role in pulmonary hypertension and renal/cardiac/pulmonary fibrosis. 2020 , 29, 171-179	22
1952	Sickle cell disease: at the crossroads of pulmonary hypertension and diastolic heart failure. 2020 , 106, 562-568	13
1951	Intensity and quality of exertional dyspnoea in patients with stable pulmonary hypertension. <i>European Respiratory Journal</i> , 2020 , 55,	13.6 16
1950	Handlungsempfehlung zur PAH auf Basis, nicht aber unter alleiniger Berücksichtigung der AWMF-Sk2-Leitlinie. 2020 , 168, 51-52	
1949	Diagnosis and Management of Pulmonary Hypertension in the Modern Era: Insights from the 6th World Symposium. 2020 , 6, 9-22	11
1948	Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension. 2020 , 79, 370-378	24
1947	Cocaine Use and Pulmonary Hypertension. 2020 , 125, 282-288	7
1946	Chronic inflammation within the vascular wall in pulmonary arterial hypertension: more than a spectator. 2020 , 116, 885-893	35
1945	Pulmonary Arterial Hypertension: A Palliative Medicine Review of the Disease, Its Therapies, and Drug Interactions. 2020 , 59, 932-943	6
1944	Lower DLco% identifies exercise pulmonary hypertension in patients with parenchymal lung disease referred for dyspnea. 2020 , 10, 2045894019891912	7
1943	High geographic prevalence of pulmonary artery hypertension: associations with ethnicity, drug use, and altitude. 2020 , 10, 2045894019894534	5
1942	Association between splenectomy and portal hypertension in the development of pulmonary hypertension. 2020 , 10, 2045894019895426	2
1941	Extract of <i>Salvia przewalskii</i> Repair Tissue Damage in Chronic Hypoxia Maybe through the RhoA-ROCK Signalling Pathway. 2020 , 43, 432-439	5
1940	Right Ventricular Failure Post-Implantation of Left Ventricular Assist Device: Prevalence, Pathophysiology, and Predictors. 2020 , 66, 610-619	13
1939	Carfilzomib-Induced Pulmonary Hypertension. 2020 , 27, e693-e694	
1938	Is There Value in Repeating Inhaled Nitric Oxide Vasoreactivity Tests in Patients with Pulmonary Arterial Hypertension?. 2020 , 198, 87-94	3

1937	Insulin-like growth factor binding protein-2: a new circulating indicator of pulmonary arterial hypertension severity and survival. 2020 , 18, 268	4
1936	Pathological Mechanisms and Potential Therapeutic Targets of Pulmonary Arterial Hypertension: A Review. 2020 , 11, 1623-1639	9
1935	Excess Protein O-GlcNAcylation Links Metabolic Derangements to Right Ventricular Dysfunction in Pulmonary Arterial Hypertension. 2020 , 21,	6
1934	Comorbid Conditions in Chronic Obstructive Pulmonary Disease: Potential Therapeutic Targets for Unmet Needs. 2020 , 9,	4
1933	Computed Tomography Angiography-Based Pulmonary Artery Volumetry as a Diagnostic Tool for Pulmonary Hypertension. 2020 , 44, 681-686	
1932	Pregnancy and pulmonary arterial hypertension-improving surveillance and outcomes with multidisciplinary care and N terminal pro-brain natriuretic peptide trends. 2020 , 1-7	4
1931	Pharmacologic therapy for pulmonary artery hypertension. 2020 , 35, 643-656	1
1930	Dynamic right ventricular function response to incremental exercise in pulmonary hypertension. 2020 , 10, 2045894020950187	3
1929	Comparative effectiveness of endothelin receptor antagonists on mortality in patients with pulmonary arterial hypertension in a US Medicare population: a retrospective database analysis. 2020 , 10, 204589402095415	
1928	Fick principle and exercise pulmonary hemodynamic determinants of the six-minute walk distance in pulmonary hypertension. 2020 , 10, 2045894020957576	2
1927	New Insights Into Heat Shock Protein 90 in the Pathogenesis of Pulmonary Arterial Hypertension. 2020 , 11, 1081	1
1926	Beyond the Diagnosis of Group IV Pulmonary Hypertension: Chronic Thromboembolic Pulmonary Hypertension Mimickers. 2020 , 2, 1999-2003	
1925	Evaluation and management of pulmonary arterial hypertension. 2020 , 171, 106099	9
1924	Pressures at an All-Time High. 2020 , 142, 1294-1298	
1923	Claims-Based Algorithms for Identifying Patients With Pulmonary Hypertension: A Comparison of Decision Rules and Machine-Learning Approaches. 2020 , 9, e016648	6
1922	Pulmonary hypertension associated with left-sided heart failure. 2020 , 35, 610-619	4
1921	Stem/Progenitor Cells and Pulmonary Arterial Hypertension. 2021 , 41, 167-178	6
1920	Overview of Riociguat and Its Role in the Treatment of Pulmonary Hypertension. 2020 , 897190020961291	1

1919	Vasoconstrictor Mechanisms in Chronic Hypoxia-Induced Pulmonary Hypertension: Role of Oxidant Signaling. 2020 , 9,	12
1918	DNA Damage and Repair in Pulmonary Arterial Hypertension. 2020 , 11,	6
1917	The beneficial effects of angiotensin-converting enzyme II (ACE2) activator in pulmonary hypertension secondary to left ventricular dysfunction. 2020 , 17, 2594-2602	3
1916	Proteomic Analysis of KCNK3 Loss of Expression Identified Dysregulated Pathways in Pulmonary Vascular Cells. 2020 , 21,	7
1915	Multimodality Imaging of Pulmonary Hypertension. 2020 , 22, 1	
1914	Right heart catheterization for pulmonary hypertension during the coronavirus disease 2019 pandemic. 2020 , 10, 2045894020948783	1
1913	Burden of pulmonary hypertension in patients with portal hypertension in the United States: a retrospective database study. 2020 , 10, 2045894020962917	3
1912	Large Granular Lymphocyte Leukemia and Precapillary Pulmonary Hypertension. 2020 , 158, 2602-2609	1
1911	Niclosamide attenuates lung vascular remodeling in experimental pulmonary arterial hypertension. 2020 , 887, 173438	4
1910	Long-term monitoring of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society Position Statement. 2020 , 4, 147-155	2
1909	Right atrial strain is a surrogate of coupling in the right heart. 2020 , 21, 863-864	1
1908	Computed Tomography in the Evaluation of Pulmonary Hypertension. 2020 , 2, 17-36	
1907	Beneficial effects of riociguat on hemodynamic responses to exercise in CTEPH patients after balloon pulmonary angioplasty - A randomized controlled study. 2020 , 29, 100579	2
1906	Pulmonary artery pressure as a method for assessing hydration status in an anuric hemodialysis patient - a case report. 2020 , 21, 266	
1905	Canadian Cardiovascular Society/Canadian Thoracic Society Position Statement on Pulmonary Hypertension. 2020 , 36, 977-992	12
1904	Heart-lung transplantation for idiopathic pulmonary arterial hypertension and giant pulmonary artery aneurysm - case report. 2020 , 15, 169	2
1903	Guidelines for the Treatment of Pulmonary Arterial Hypertension. 2020 , 198, 581-596	16
1902	The Elephant Man Meets Pulmonary Hypertension. A Cautionary Tale. 2020 , 202, 789-791	

1901	Pulmonal-arterielle Hypertonie und chronisch-thromboembolische pulmonale Hypertonie: Eine immunologische Perspektive. 2020 , 8, 126-139	
1900	Cardiopulmonary Hemodynamics in Pulmonary Hypertension and Heart Failure: JACC Review Topic of the Week. 2020 , 76, 2671-2681	19
1899	Whole Exome Sequence Analysis Provides Novel Insights into the Genetic Framework of Childhood-Onset Pulmonary Arterial Hypertension. 2020 , 11,	4
1898	Prognostic importance of Kidney, Heart and Interstitial lung diseases (KHI triad) in PH: A machine learning study. 2020 , 113, 630-641	0
1897	Pulmonary hypertension secondary to pulmonary fibrosis: clinical data, histopathology and molecular insights. 2020 , 21, 303	11
1896	Cardiac Magnetic Resonance in Pulmonary Hypertension-an Update. 2020 , 13, 30	3
1895	A 13-Year-Old Male With Diagnosed Idiopathic Pulmonary Hypertension: Is it Really Idiopathic?. 2020 , 158, e295-e298	
1894	Update on noninvasive imaging of right ventricle dysfunction in pulmonary hypertension. 2020 , 10, 1604-1624	4
1893	Diagnosis and treatment of right ventricular dysfunction in congenital heart disease. 2020 , 10, 1625-1645	3
1892	Narrative review of sleep and pulmonary hypertension. 2020 , 12, S191-S201	1
1891	Safety and efficacy of the endothelin receptor antagonist macitentan in pediatric pulmonary hypertension. 2020 , 10, 1675-1685	10
1890	Pulmonary hypertension complicating pregnancy: cardiac remodeling and residual concerns. 2020 , 1-6	1
1889	Caregiver Burden in Patients with Pulmonary Hypertension. 2021 , 30, 994-1000	2
1888	Animal models of right heart failure. 2020 , 10, 1561-1579	4
1887	Micro-RNA Analysis in Pulmonary Arterial Hypertension: Current Knowledge and Challenges. 2020 , 5, 1149-1162	11
1886	'There and Back Again'-Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension. 2020 , 11,	3
1885	Epigenetic Regulation of Pulmonary Arterial Hypertension-Induced Vascular and Right Ventricular Remodeling: New Opportunities?. 2020 , 21,	8
1884	Neurohormonal Modulation as a Therapeutic Target in Pulmonary Hypertension. 2020 , 9,	4

1883	SCUBE1 Controls BMPR2-Relevant Pulmonary Endothelial Function: Implications for Diagnostic Marker Development in Pulmonary Arterial Hypertension. 2020 , 5, 1073-1092	1
1882	Surgery for Pulmonary Vascular Disease. 2020 , 113-117	1
1881	ATS Core Curriculum 2020. Adult Pulmonary Medicine. 2020 , 1, 416-435	
1880	Initial Experience With Patent Ductus Arteriosus Ligation in Pre-term Infants With Bidirectional Shunt Pattern. 2020 , 8, 591441	1
1879	Critical care of patients with pulmonary arterial hypertension. 2020 , 26, 414-421	1
1878	Effect of Coronavirus Disease 2019 in Pulmonary Circulation. The Particular Scenario of Precapillary Pulmonary Hypertension. 2020 , 10,	12
1877	Hemodynamics in Adults With the Shone Complex. 2020 , 130, 137-142	3
1876	An update on sarcoidosis-associated pulmonary hypertension. 2020 , 26, 582-590	6
1875	Mean platelet volume combined red cell distribution width as biomarker of chronic obstructive pulmonary disease with pulmonary heart disease. 2020 , 14, 1122-1130	4
1874	The course of COVID-19 in a 55-year-old patient diagnosed with severe idiopathic pulmonary arterial hypertension. 2020 , 10, 2045894020936659	4
1873	Incident pulmonary arterial hypertension associated with Bosutinib. 2020 , 10, 2045894020936913	3
1872	Invasive Hemodynamic Characteristics in Patients Undergoing Transcatheter Tricuspid Valve-In-Valve Implantation for Treatment of Tricuspid Stenosis. 2020 , 11, 411-416	1
1871	Comparative effectiveness of oral prostacyclin pathway drugs on hospitalization in patients with pulmonary hypertension in the United States: a retrospective database analysis. 2020 , 10, 2045894020911831	2
1870	Anti-synthetase syndrome-associated pulmonary veno-occlusive disease. 2020 , 10, 2045894020935289	1
1869	Screening and Identification of Therapeutic Targets for Pulmonary Arterial Hypertension Through Microarray Technology. 2020 , 11, 782	3
1868	Room for improvement in pulmonary capillary wedge pressure reporting: a review of hemodynamic tracings at a large academic medical center. 2020 , 10, 2045894020929157	3
1867	Impact of the updated hemodynamic definitions on diagnosis rates of pulmonary hypertension. 2020 , 10, 2045894020931299	2
1866	Pulmonary hypertension in patients with interstitial pneumonia with autoimmune features. 2020 , 10, 2045894020944117	1

1865	The dangerous and contradictory prognostic significance of PVR. 2020 , 7, 2398-2405	2
1864	Comparative accuracy of non-invasive imaging versus right heart catheterization for the diagnosis of pulmonary hypertension: A systematic review and meta-analysis. 2020 , 29, 100568	3
1863	Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. 2020 , 8, 873-884	41
1862	Pulmonary hypertension thresholds: time to lower further?. 2020 , 8, 834-836	0
1861	Transcatheter tricuspid valve repair in patients with pulmonary hypertension. 2020 , 41, 2811-2812	3
1860	Use of Treprostinil in Pediatric Pulmonary Hypertension: Case Reports and Review of the Literature. 2020 , 76, 23-31	1
1859	Beyond the genome: challenges and potential for epigenetics-driven therapeutic approaches in pulmonary arterial hypertension. 2020 , 98, 631-646	1
1858	Pulmonary arterial hypertension in breast cancer patients on HER2-targeted therapy: a review of FDA Adverse Events Reporting System data. 2020 , 6,	2
1857	Evolving spectrum of treatment for CTEPH. 2020 , 26, 406-413	4
1856	How low should we go? Potential benefits and ramifications of the pulmonary hypertension hemodynamic definitions proposed by the 6th World Symposium. 2020 , 26, 384-390	2
1855	Sarcoidosis-Associated Pulmonary Hypertension. 2020 , 41, 659-672	3
1854	A Notch3-Marked Subpopulation of Vascular Smooth Muscle Cells Is the Cell of Origin for Occlusive Pulmonary Vascular Lesions. 2020 , 142, 1545-1561	20
1853	Management of chronic respiratory complications in children and adolescents with sickle cell disease. 2020 , 29,	3
1852	Current Understanding of Circulating Biomarkers in Pulmonary Hypertension Due to Left Heart Disease. 2020 , 7, 570016	1
1851	Genetics and Genomics of Pediatric Pulmonary Arterial Hypertension. 2020 , 11,	8
1850	Chronic Thromboembolic Pulmonary Hypertension: JACC Focus Seminar. 2020 , 76, 2155-2169	13
1849	Is pulmonary arterial hypertension associated with interferon- β therapy for multiple sclerosis reversible? A case study to explore the complexity. 2020 , 6,	
1848	Prognostic Value of Gamma-Glutamyltransferase in Male Patients With Idiopathic Pulmonary Arterial Hypertension. 2020 , 7, 580908	1

1847	Preventive treatment with ginsenoside Rb1 ameliorates monocrotaline-induced pulmonary arterial hypertension in rats and involves store-operated calcium entry inhibition. 2020 , 58, 1055-1063	2
1846	Position statement from the Canadian Thoracic Society (CTS) on clinical triage thresholds in respiratory disease patients in the event of a major surge during the COVID-19 pandemic. 2020 , 4, 214-225	2
1845	The Roles of CCN1/CYR61 in Pulmonary Diseases. 2020 , 21,	5
1844	Perivascular Inflammation in Pulmonary Arterial Hypertension. 2020 , 9,	24
1843	Controversies and advances in connective tissue disease-related pulmonary arterial hypertension. 2020 , 23, 1269-1275	
1842	Efficacy of the thromboxane receptor antagonist NTP42 alone, or in combination with sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension. 2020 , 889, 173658	3
1841	Sex-Dependent Changes in Right Ventricular Gene Expression in Response to Pressure Overload in a Rat Model of Pulmonary Trunk Banding. 2020 , 8,	0
1840	Riociguat in the Treatment of Chronic Thromboembolic Pulmonary Hypertension: An Evidence-Based Review of Its Place in Therapy. 2020 , 15, 31-40	1
1839	Pediatric Pulmonary Arterial Hypertension. 2020 , 67, 903-921	2
1838	Purinergic Dysfunction in Pulmonary Arterial Hypertension. 2020 , 9, e017404	6
1837	Exercise Hemodynamics in the Prognosis of Patients with Pulmonary Arterial Hypertension. 2020 , 99, 678-685	1
1836	Cardiac Magnetic Resonance Imaging in Pulmonary Arterial Hypertension: Ready for Clinical Practice and Guidelines?. 2020 , 17, 181-191	1
1835	Chinese medicinal plants for the potential management of high-altitude pulmonary oedema and pulmonary hypertension. 2020 , 58, 815-827	5
1834	Altitude Travel in Patients With Pulmonary Hypertension: Randomized Pilot-Trial Evaluating Nocturnal Oxygen Therapy. 2020 , 7, 502	3
1833	Prevalence and clinical features of bone morphogenetic protein receptor type 2 mutation in Korean idiopathic pulmonary arterial hypertension patients: The PILGRIM explorative cohort. 2020 , 15, e0238698	5
1832	Therapeutic Benefit of the Association of Lodenafil with Mesenchymal Stem Cells on Hypoxia-induced Pulmonary Hypertension in Rats. 2020 , 9,	1
1831	Diagnostic and prognostic markers and treatment of connective tissue disease-associated pulmonary arterial hypertension: current recommendations and recent advances. 2020 , 16, 993-1004	4
1830	Focused Update on Pulmonary Hypertension in Children-Selected Topics of Interest for the Adult Cardiologist. 2020 , 56,	

1829	Recommendations for participation in competitive sport in adolescent and adult athletes with Congenital Heart Disease (CHD): position statement of the Sports Cardiology & Exercise Section of the European Association of Preventive Cardiology (EAPC), the European Society of Cardiology (ESC) Working Group on Adult Congenital Heart Disease and the Sports Cardiology, Physical	28
1828	Prévalence and characteristics of portopulmonary hypertension in cirrhotic patients who congenital underwent both hepatic vein and pulmonary artery catheterization. 2020 , 50, 1244-1254	6
1827	Pulmonary vasculopathy in explanted lungs from patients with interstitial lung disease undergoing lung transplantation. 2020 , 7,	5
1826	Adaptive and innate immune mechanisms in cardiac fibrosis complicating pulmonary arterial hypertension. 2020 , 8, e14532	3
1825	Pulmonary Vascular Disease and Cardiopulmonary Exercise Testing. 2020 , 11, 964	6
1824	Pulmonary Hypertension: A Brief Guide for Clinicians. 2020 , 95, 1978-1988	38
1823	The Role and Regulation of Pulmonary Artery Smooth Muscle Cells in Pulmonary Hypertension. 2020 , 2020, 1478291	2
1822	Inpatient Palliative Care Use in Patients With Pulmonary Arterial Hypertension: Temporal Trends, Predictors, and Outcomes. 2020 , 158, 2568-2578	8
1821	Altered Airway Microbiota Composition in Patients With Pulmonary Hypertension. 2020 , 76, 1589-1599	8
1820	[Current Aspects of Definition and Diagnosis of Pulmonary Hypertension]. 2020 , 74, 847-863	1
1819	Characterization of rare ABCC8 variants identified in Spanish pulmonary arterial hypertension patients. 2020 , 10, 15135	7
1818	Implication of Potassium Channels in the Pathophysiology of Pulmonary Arterial Hypertension. 2020 , 10,	7
1817	Association Between Systemic and Pulmonary Vascular Dysfunction in COPD. 2020 , 15, 2037-2047	8
1816	Right ventricle in heart failure with preserved ejection fraction. 2020 , 106, 1798-1804	4
1815	Exacerbated inflammatory signaling underlies aberrant response to BMP9 in pulmonary arterial hypertension lung endothelial cells. 2020 , 23, 699-714	14
1814	Metformin in Pulmonary Hypertension in Left Heart Disease. 2020 , 7, 425	0
1813	One for the Ages. 2020 , 158, 856-857	
1812	Elevated Pulmonary Artery Systolic Pressure is Associated with Poor Survival of Patients with Non-Small Cell Lung Cancer. 2020 , 12, 6363-6371	0

1811	Prevalence and outcomes of pulmonary hypertension after percutaneous closure of atrial septal defect: a systematic review and meta-analysis. 2020 , 29,	3
1810	Schistosomiasis Pulmonary Arterial Hypertension. 2020 , 11, 608883	9
1809	Physical Activity and Mental Health of Patients with Pulmonary Hypertension during the COVID-19 Pandemic. 2020 , 9,	4
1808	Medical Image-Based Hemodynamic Analyses in a Study of the Pulmonary Artery in Children With Pulmonary Hypertension Related to Congenital Heart Disease. 2020 , 8, 521936	1
1807	Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives. 2020 , 63, 15153-15186	5
1806	Echocardiography to Screen for Pulmonary Hypertension in CKD. 2020 , 5, 2275-2283	1
1805	Ventilaci3n no invasiva y foramen oval: una causa de hipoxemia parad3jica. 2020 , 2, 299-300	
1804	Recommendations for genetic testing in cardiology: Review of major international guidelines. 2020 , 39, 597-610	
1803	Cardiac manifestations of rheumatological disease: a synopsis for the cardiologist. 2021 , 107, 1173-1181	1
1802	Diagnostic utility of sub-maximum cardiopulmonary exercise testing in the ambulatory setting for heart failure with preserved ejection fraction. 2020 , 10, 2045894020972273	1
1801	Predictors of Mortality in Patients with Interstitial Lung Disease-Associated Pulmonary Hypertension. 2020 , 9,	6
1800	Extracellular Vesicles as Unique Signaling Messengers: Role in Lung Diseases. 2020 , 11, 1351-1369	3
1799	Pulmonary hypertension associated with congenital heart disease; clinical decision scenario. 2020 , 31, 101286	0
1798	Heart rate monitoring improves clinical assessment during 6-min walk. 2020 , 10, 2045894020972572	2
1797	Emerging Mechanisms of Pulmonary Vasoconstriction in SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) and Potential Therapeutic Targets. 2020 , 21,	17
1796	Pulmonary thromboendarterectomy in Portugal: Initial experience. 2020 , 39, 505-512	2
1795	Portopulmonary Hypertension: From Bench to Bedside. 2020 , 7, 569413	10
1794	Normal and Abnormal Relationships of Pulmonary Artery to Wedge Pressure During Exercise. 2020 , 9, e016339	4

1793	Detection of Pulmonary Hypertension by Combining Echocardiography and Chest Radiography. 2020 ,		0
1792	Pulmonary Hypertension Due to Left Heart Disease: Diagnosis, Pathophysiology, and Therapy. 2020 , 75, 1397-1408		21
1791	Pulmonary arterial hypertension with below threshold pulmonary vascular resistance. <i>European Respiratory Journal</i> , 2020 , 56,	13.6	6
1790	New Insights into the Implication of Mitochondrial Dysfunction in Tissue, Peripheral Blood Mononuclear Cells, and Platelets during Lung Diseases. 2020 , 9,		4
1789	Exercise intolerance in chronic thromboembolic pulmonary hypertension after pulmonary angioplasty. <i>European Respiratory Journal</i> , 2020 , 56,	13.6	11
1788	Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	17
1787	TBX4 syndrome: a systemic disease highlighted by pulmonary arterial hypertension in its most severe form. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	2
1786	BNP/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing?. 2020 , 29,		15
1785	Clinical characteristics and outcomes of 566 Thais with systemic sclerosis: A cohort study. 2020 , 23, 945-957		7
1784	Quantifying the Influence of Wedge Pressure, Age, and Heart Rate on the Systolic Thresholds for Detection of Pulmonary Hypertension. 2020 , 9, e016265		4
1783	Cardiac function and pulmonary hypertension in Central Asian highlanders at 3250 m. <i>European Respiratory Journal</i> , 2020 , 56,	13.6	8
1782	Pulmonary hypertension in low- and middle-income countries with focus on sub-Saharan Africa. 2020 , 10, 316-324		8
1781	Challenges and Special Aspects of Pulmonary Hypertension in Middle- to Low-Income Regions: JACC State-of-the-Art Review. 2020 , 75, 2463-2477		12
1780	Multi-Beat Right Ventricular-Arterial Coupling Predicts Clinical Worsening in Pulmonary Arterial Hypertension. 2020 , 9, e016031		14
1779	Persistent exercise intolerance after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	6
1778	Severe Pulmonary Hypertension Management Across Europe (PHAROS): an ERS Clinical Research Collaboration. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	1
1777	Exercise Echocardiography as a Screening Tool in Systemic Sclerosis. 2020 , 47, 643-645		1
1776	ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension. 2020 , 12,		39

1775	Chronic thromboembolic pulmonary hypertension: interventional approaches. 2020 , 106, 1525-1531		1
1774	Repeatability of Pulmonary Pressure Measurements in Patients with Pulmonary Hypertension. 2020 , 17, 1028-1030		3
1773	Which patients are SaPHe in sarcoidosis-associated pulmonary hypertension?. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	1
1772	Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry. 2020 , 9,		8
1771	An update on the diagnosis and treatment of pediatric pulmonary hypertension. 2020 , 21, 1253-1268		1
1770	Pulmonary capillary haemangiomatosis: a distinct entity?. 2020 , 29,		9
1769	RNA-Binding Proteins in Pulmonary Hypertension. 2020 , 21,		3
1768	Performance and Interpretation of Invasive Hemodynamic Exercise Testing. 2020 , 158, 2119-2129		13
1767	Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1. 2020 , 202, 843-852		4
1766	Sodium Tanshinone II Sulfonate A Ameliorates Hypoxia-Induced Pulmonary Hypertension. 2020 , 11, 687		5
1765	Post-Intensive Care Unit Follow-up of Pulmonary Embolism. 2020 , 36, 561-570		2
1764	Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors. <i>European Respiratory Journal</i> , 2020 , 56,	13.6	11
1763	Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review. 2020 , 78, 17-25		13
1762	TBX4 variants and pulmonary diseases: getting out of the 'Box'. 2020 , 26, 277-284		3
1761	The evolution of the : ready for the new decade!. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	
1760	Pulmonary Arterial Hypertension and Specialty Care Centers: We Had a Feeling; Now We Have Data. 2020 , 158, 28-30		1
1759	Advances in the diagnosis and treatment of HIV-associated pulmonary arterial hypertension. 2020 , 8, 169-177		
1758	Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension. 2020 , 22, 127		11

1757	Sex Differences in Right Ventricular-Pulmonary Arterial Coupling in Pulmonary Arterial Hypertension. 2020 , 202, 1042-1046	19
1756	Effects of Different Types of Exercise Training on Pulmonary Arterial Hypertension: A Systematic Review. 2020 , 9,	8
1755	Pulmonary chronic thromboembolic disease.. 2020 , 56, 314-321	1
1754	Right Heart Failure: Causes and Clinical Epidemiology. 2020 , 38, 175-183	4
1753	Right Heart Failure in Pulmonary Hypertension. 2020 , 38, 243-255	14
1752	The Genetic Epidemiology of Pediatric Pulmonary Arterial Hypertension. 2020 , 225, 65-73.e5	8
1751	Investigational pharmacotherapy and immunotherapy of pulmonary arterial hypertension: An update. 2020 , 129, 110355	6
1750	Advanced Diagnosis and Therapy for Pulmonary Arterial Hypertension. 2020 , 10, 2040003	2
1749	The Myths and Realities of Portopulmonary Hypertension. 2020 , 72, 1455-1460	6
1748	Congenital Heart Disease and Pulmonary Hypertension. 2020 , 38, 445-456	3
1747	Contemporary approaches in the use of extracorporeal membrane oxygenation to support patients waiting for lung transplantation. 2020 , 9, 29-41	7
1746	Single nucleotide polymorphisms of the HIF1A gene are associated with susceptibility to pulmonary arterial hypertension in systemic sclerosis and contribute to SSc-PAH disease severity. 2020 , 23, 674-680	2
1745	Cytochrome P450 Epoxygenase-Dependent Activation of TRPV4 Channel Participates in Enhanced Serotonin-Induced Pulmonary Vasoconstriction in Chronic Hypoxic Pulmonary Hypertension. 2020 , 2020, 8927381	3
1744	: A New Section of Highlighting Invasive emodynamics. 2020 , 13, e006927	
1743	Phenotype and outcome of pulmonary arterial hypertension patients carrying a mutation. <i>European Respiratory Journal</i> , 2020 , 55,	13.6 11
1742	Pulmonary vascular disease: pulmonary thromboembolism and pulmonary hypertension. 2020 , 48, 288-293	
1741	Pulmonary Hypertension and Extracorporeal Membrane Oxygenation-Disparate Causes, Worse Outcomes. 2020 , 21, 294-295	
1740	A cancer amidst us: the plexiform lesion in pulmonary arterial hypertension. 2020 , 318, L1142-L1144	1

1739	The Utility of Plasma Vascular Biomarkers in Systemic Sclerosis: A Prospective Longitudinal Analysis. 2020 , 72, 1341-1349	1
1738	Novel Mutations and Decreased Expression of the Epigenetic Regulator in Pulmonary Arterial Hypertension. 2020 , 141, 1986-2000	28
1737	Vascular toxic effects of cancer therapies. 2020 , 17, 503-522	55
1736	Diagnosis and Management of Pulmonary Hypertension in Patients With CKD. 2020 , 75, 935-945	10
1735	Treating pulmonary hypertension in the elderly. 2020 , 21, 1193-1200	2
1734	Management of systemic sclerosis: the first five years. 2020 , 32, 228-237	15
1733	Trichloroethylene increases pulmonary endothelial permeability: implication for pulmonary veno-occlusive disease. 2020 , 10, 2045894020907884	1
1732	Transcriptional profiling of lung cell populations in idiopathic pulmonary arterial hypertension. 2020 , 10,	26
1731	Mitochondria in the Pulmonary Vasculature in Health and Disease: Oxygen-Sensing, Metabolism, and Dynamics. 2020 , 10, 713-765	21
1730	Imaging of Chronic Thromboembolic Disease. 2020 , 198, 245-255	6
1729	Diffusing Capacity Is an Independent Predictor of Outcomes in Pulmonary Hypertension Associated With COPD. 2020 , 158, 722-734	11
1728	Comorbidity in idiopathic pulmonary fibrosis - what can biomarkers tell us?. 2020 , 14, 1753466620910092	4
1727	Association of Disease Subtype and Duration with Echocardiographic Evidence of Pulmonary Hypertension in Myeloproliferative Neoplasm. 2020 , 29, 486-491	2
1726	Pulmonary Hypertension by the Method of Paul Wood. 2020 , 158, 1164-1171	2
1725	Approach to Pulmonary Arteriovenous Malformations: A Comprehensive Update. 2020 , 9,	23
1724	MicroRNA-17 as a potential diagnostic biomarker in pulmonary arterial hypertension. 2020 , 48, 300060520920430	3
1723	Cardiovascular Risk in Systemic Sclerosis. 2020 , 6, 282-298	
1722	Remodeling Matrix Synthesis in a Rat Model of Aortocaval Fistula and the Cyclic Stretch: Impaction in Pulmonary Arterial Hypertension-Congenital Heart Disease. 2020 , 21,	1

1721	Overexpression of PD-1 on Peripheral Blood Lymphocytes in Patients with Idiopathic Pulmonary Arterial Hypertension and Its Association with High Viral Loads of Epstein-Barr Virus and Poor Clinical Parameters. 2020 , 9,	4
1720	Endothelial Cells and Endothelium. 2020 ,	0
1719	Updated Perspectives on Pulmonary Hypertension in COPD. 2020 , 15, 1315-1324	9
1718	Pulmonary artery to ascending aorta ratio by echocardiography: A strong predictor for presence and severity of pulmonary hypertension. 2020 , 15, e0235716	1
1717	A novel BMPR2 mutation with widely disparate heritable pulmonary arterial hypertension clinical phenotype. 2020 , 10, 2045894020931315	2
1716	Complications in Idiopathic Pulmonary Fibrosis: Focus on Their Clinical and Radiological Features. 2020 , 10,	4
1715	Nutraceuticals in the Treatment of Pulmonary Arterial Hypertension. 2020 , 21,	3
1714	Age-related differences in hemodynamics and functional status in pulmonary arterial hypertension: Baseline results from the Pulmonary Hypertension Association Registry. 2020 , 39, 945-953	4
1713	Novel Therapeutic Approaches for Pulmonary Manifestations of Systemic Sclerosis. 2020 , 202, 878-880	
1712	Trends in systemic sclerosis and systemic sclerosis-related pulmonary arterial hypertension mortality in the USA. 2020 , 6,	3
1711	Pulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment. 2020 , 21,	8
1710	Noninfectious pulmonary complications of haematopoietic stem cell transplantation. 2020 , 29,	13
1709	Integrative analyses of gene expression profile reveal potential crucial roles of mitotic cell cycle and microtubule cytoskeleton in pulmonary artery hypertension. 2020 , 13, 86	8
1708	Kv7 Channels in Lung Diseases. 2020 , 11, 634	4
1707	Postpartum Pulmonary Hypertension Masquerading as Submassive Pulmonary Embolism: A Case Report and a Literature Review. 2020 , 2020, 8899562	
1706	Adding an important piece to the pulmonary vascular resistance puzzle in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2020 , 56,	13.6 1
1705	Evaluation of the Impact of an Echocardiographic Diagnosis of Pulmonary Hypertension on Patient Outcomes. 2020 , 2, 328-336	3
1704	Mechanisms of Exercise Limitation and Prevalence of Pulmonary Hypertension in Pulmonary Langerhans Cell Histiocytosis. 2020 , 158, 2440-2448	6

1703	Pulmonary arterial hypertension associated with primary Sjögren's syndrome: a multicentre cohort study from China. <i>European Respiratory Journal</i> , 2020 , 56,	13.6	9
1702	Pharmacology of Pulmonary Arterial Hypertension: An Overview of Current and Emerging Therapies. 2020 , 3, 598-612		8
1701	Thoracic Visceral Adipose Tissue Area and Pulmonary Hypertension in Lung Transplant Candidates. The Lung Transplant Body Composition Study. 2020 , 17, 1393-1400		3
1700	Downregulation of PGI pathway in Pulmonary Hypertension Group-III patients. 2020 , 160, 102158		3
1699	Inpatient Initiation of Oral Treprostinil in an Academic Medical System. 2020 , 34, 547-553		1
1698	Platelet glycolytic metabolism correlates with hemodynamic severity in pulmonary arterial hypertension. 2020 , 318, L562-L569		3
1697	Multiscale Modeling Framework of Ventricular-Arterial Bi-directional Interactions in the Cardiopulmonary Circulation. 2020 , 11, 2		11
1696	Skeletal and Respiratory Muscle Dysfunctions in Pulmonary Arterial Hypertension. 2020 , 9,		10
1695	The Right Ventricle-You May Forget it, but It Will Not Forget You. 2020 , 9,		8
1694	Systemic Consequences of Pulmonary Hypertension and Right-Sided Heart Failure. 2020 , 141, 678-693		39
1693	Comprehensive Diagnostic Evaluation of Cardiovascular Physiology in Patients With Pulmonary Vascular Disease: Insights From the PVDOMICS Program. 2020 , 13, e006363		6
1692	Exercise intolerance in heart failure: The important role of pulmonary hypertension. 2020 , 105, 1997-2003		1
1691	Hypochloremia Is a Noninvasive Predictor of Mortality in Pulmonary Arterial Hypertension. 2020 , 9, e015221		7
1690	Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: An Immunological Perspective. 2020 , 9,		19
1689	Multidimensional tracking of phenotypes and organ involvement in a complete nationwide systemic sclerosis cohort. 2020 , 59, 2920-2929		14
1688	Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients. 2020 , 7, 567-576		1
1687	Pulmonary arterial capacitance predicts outcomes in patients with pulmonary hypertension independent of race/ethnicity, sex, and etiology. 2020 , 163, 105891		1
1686	ACVIM consensus statement guidelines for the diagnosis, classification, treatment, and monitoring of pulmonary hypertension in dogs. 2020 , 34, 549-573		62

1685	Pediatric Pulmonary Arterial Hypertension: Evaluation and Treatment. 2020 , 6, 12-28	1
1684	Electrical Stimulation-Guided Approach to Pulmonary Artery Catheter Ablation in Patients with Idiopathic Pulmonary Arterial Hypertension: A Pilot Feasibility Study with a 12-Month Follow-Up. 2020 , 2020, 8919515	8
1683	Obesity Is Associated With Pulmonary Hypertension and Modifies Outcomes. 2020 , 9, e014195	15
1682	Effects of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension on remodeling in right-sided heart. 2020 , 36, 1053-1060	4
1681	Mural Cell SDF1 Signaling Is Associated with the Pathogenesis of Pulmonary Arterial Hypertension. 2020 , 62, 747-759	12
1680	Elevated pulmonary arterial elastance and right ventricular uncoupling are associated with greater mortality in advanced heart failure. 2020 , 39, 657-665	10
1679	Protective Effect of Statins on Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease Patients: A Nationwide Retrospective, Matched Cohort Study. 2020 , 10, 3104	5
1678	Pulmonary Hypertension in Patients Starting Peritoneal Dialysis. 2020 , 51, 254-260	0
1677	Pulmonary Hypertension and Right Ventricular Failure: Lung Transplant Versus Heart-Lung Transplant. 2020 , 38, 269-281	2
1676	Outcomes of Pulmonary Arterial Hypertension Are Improved in a Specialty Care Center. 2020 , 158, 330-340	7
1675	An evidence-based strategy to screen for pulmonary arterial hypertension in systemic sclerosis. 2020 , 50, 1421-1427	3
1674	Anaemia, iron homeostasis and pulmonary hypertension: a review. 2020 , 15, 573-585	13
1673	Loss of family with sequence similarity 13, member A exacerbates pulmonary hypertension through accelerating endothelial-to-mesenchymal transition. 2020 , 15, e0226049	5
1672	Genetic Predisposition to High-Altitude Pulmonary Edema. 2020 , 21, 28-36	9
1671	The challenge of an expanded therapeutic window in pulmonary hypertension. 2020 , 17, 195-197	1
1670	Impact of Nutrition on Pulmonary Arterial Hypertension. 2020 , 12,	9
1669	Pregnancy in a Patient With Tetralogy of Fallot and Borderline Pulmonary Arterial Hypertension. 2020 , 2, 91-95	
1668	Lineage Tracing Reveals the Dynamic Contribution of Pericytes to the Blood Vessel Remodeling in Pulmonary Hypertension. 2020 , 40, 766-782	27

1667	Management of reproductive health in patients with pulmonary hypertension. 2020 , 2, 100087		
1666	Familial pulmonary arterial hypertension by heterozygous loss of function. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	23
1665	Impact of race on survival in pulmonary arterial hypertension: Results from the REVEAL registry. 2020 , 39, 321-330		8
1664	Echocardiography Tips in the Emergency Room. 2020 , 16, 167-175		2
1663	Culture of pulmonary artery endothelial cells from pulmonary artery catheter balloon tips: considerations for use in pulmonary vascular disease. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	5
1662	Chronisch thromboembolische pulmonale Hypertonie. 2020 , 34, 79-86		
1661	Drug Treatment of Pulmonary Hypertension in Children. 2020 , 22, 123-147		7
1660	Pulmonary veno-occlusive disease: a probably underdiagnosed cause of pulmonary hypertension in systemic sclerosis. 2020 , 39, 1687-1691		4
1659	Excitation-contraction coupling and relaxation alteration in right ventricular remodelling caused by pulmonary arterial hypertension. 2020 , 113, 70-84		10
1658	A Man in His 40s With Coronary-to-Pulmonary Artery Collateralizations. 2020 , 5, 356		
1657	Right ventricular dyssynchrony: from load-independent right ventricular function to wall stress in severe pulmonary arterial hypertension. 2020 , 10, 2045894020925759		3
1656	RNA Signaling in Pulmonary Arterial Hypertension-A Double-Stranded Sword. 2020 , 21,		5
1655	Lower Plasma Melatonin Levels Predict Worse Long-Term Survival in Pulmonary Arterial Hypertension. 2020 , 9,		3
1654	Predicting pulmonary hypertension in sarcoidosis; value of PH probability on echocardiography. 2020 , 36, 1497-1505		5
1653	Autopsy in adults with congenital heart disease (ACHD). 2020 , 476, 797-820		4
1652	Molecular Profiling of Vascular Remodeling in Chronic Pulmonary Disease. 2020 , 190, 1382-1396		2
1651	Hereditary hemorrhagic telangiectasia and liver involvement: Vascular liver diseases: position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFEFL), and ERN-rare liver. 2020 , 44, 426-432		2
1650	Risk Stratification of Acute Pulmonary Embolism and Determining the Effect on Chronic Cardiopulmonary Complications: The REACH Study. 2020 , 4, e45-e50		7

1649	Clinical update on pulmonary hypertension. 2020 , 68, 821-827	16
1648	Pulmonary Hypertension and Pregnancy. 2020 , 99-112	0
1647	Chronic lung disease-associated PH: PAH-approved drugs and established universal healthcare insurance in Japan. 2020 , 58, 230-231	
1646	Management of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis. 2020 , 13, 15-29	13
1645	Pulmonary vasodilators can lead to various complications in pulmonary "arterial" hypertension associated with congenital heart disease. 2020 , 35, 1307-1315	1
1644	Supporting the use of sildenafil infusions in paediatric and neonatal intensive care - A compatibility study. 2020 , 151, 153-161	0
1643	POINT: Should the New Definition of PH Be the Clinical Practice Standard? Yes. 2020 , 157, 764-766	2
1642	COUNTERPOINT: Should the New Definition of PH Be the Clinical Practice Standard? No. 2020 , 157, 766-768	2
1641	Methods to improve the yield of right heart catheterization in pulmonary hypertension. 2020 , 2, 100015	2
1640	Pulmonary vascular diseases. 2020 , 4, S2-S5	
1639	Update in Pulmonary Vascular Diseases and Right Ventricular Dysfunction 2019. 2020 , 202, 22-28	3
1638	Exercise right heart catheterization before and after balloon pulmonary angioplasty in inoperable patients with chronic thromboembolic pulmonary hypertension. 2020 , 10, 2045894020917884	3
1637	Significance of Pulmonary Vascular Resistance and Diastolic Pressure Gradient on the New Definition of Combined Post-Capillary Pulmonary Hypertension. 2020 , 61, 301-307	2
1636	Diastolic Pulmonary Artery to Pulmonary Capillary Wedge Pressure Difference: A Predictor of Outcome After Left Ventricular Assist Device Implantation. 2020 , 9, e016110	1
1635	Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic. 2020 , 10, 2045894020920153	32
1634	NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension. 2020 , 20, 85	8
1633	Paeoniflorin Ameliorates Chronic Hypoxia/SU5416-Induced Pulmonary Arterial Hypertension by Inhibiting Endothelial-to-Mesenchymal Transition. 2020 , 14, 1191-1202	11
1632	Hepatopulmonary Syndrome and Portopulmonary Hypertension: Management in Liver Transplantation in the Horizon 2020. 2020 , 52, 1503-1506	3

1631	Impact of concomitant obstructive sleep apnea on pulmonary involvement and main pulmonary artery diameter in adults with scleroderma. 2021 , 25, 135-143		
1630	Clinical Evaluation and Diagnosis of Rheumatic Heart Disease. 2021 , 69-106		
1629	Idiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra. 2021 , 178, 172-186		7
1628	Pulmonary hypertension in Saudi Arabia: First data from the SAUDIPH registry with a focus on pulmonary arterial hypertension. 2021 , 26, 92-101		4
1627	Pulmonary hypertension in chronic obstructive pulmonary disease. 2021 , 178, 132-151		19
1626	Pulmonary hypertension in bronchopulmonary dysplasia. 2021 , 89, 446-455		29
1625	EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multicentre study. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	9
1624	Cardiovascular complications of sickle cell disease. 2021 , 31, 187-193		11
1623	Current and future treatments of pulmonary arterial hypertension. 2021 , 178, 6-30		42
1622	Impairment of right ventricular strain evaluated by cardiovascular magnetic resonance feature tracking in patients with interstitial lung disease. 2021 , 37, 1073-1083		2
1621	Systemic vascular distensibility relates to exercise capacity in connective tissue disease. 2021 , 60, 1429-1434		5
1620	Anticoagulation in Pulmonary Arterial Hypertension: Do We Know the Answer?. 2021 , 46, 100738		3
1619	Altered cardiac repolarisation in highlanders with high-altitude pulmonary hypertension during wakefulness and sleep. 2021 , 30, e13153		
1618	A Fluid Challenge Test for the Diagnosis of Occult Heart Failure. 2021 , 159, 791-797		6
1617	Portopulmonary hypertension: An unfolding story. 2021 , 45, 101492		0
1616	Sleep-related breathing disorders and pulmonary hypertension. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	8
1615	Outcomes of Pulmonary Endarterectomy Operation Concomitant with Cardiac Procedures. 2021 , 69, 279-283		1
1614	Endothelial-to-Mesenchymal Transition in Pulmonary Arterial Hypertension. 2021 , 34, 891-914		12

1613	The evolving role of interventional cardiology in the treatment of pulmonary hypertension. 2021 , 97, E446-E453	1
1612	Editorial commentary: Challenges in the diagnosis and management of pulmonary artery stenosis. 2021 , 31, 185-186	
1611	Macitentan in the treatment of pulmonary arterial hypertension. 2021 , 17, 49-58	3
1610	Renin-Angiotensin-Aldosterone System Inhibitor Use and Mortality in Pulmonary Hypertension: Insights From the Veterans Affairs Clinical Assessment Reporting and Tracking Database. 2021 , 159, 1586-1597	4
1609	Cardiac-MRI Predicts Clinical Worsening and Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. 2021 , 14, 931-942	20
1608	Pulmonary hypertension after pneumonectomy: a preclinical model in rats and human pulmonary endothelial cells. 2021 , 59, 147-154	1
1607	How should a physician approach the pharmacological management of chronic thromboembolic pulmonary hypertension?. 2021 , 22, 557-563	1
1606	Prognostic Value of Change in Cardiac Index After Prostacyclin Initiation in Pediatric Pulmonary Hypertension. 2021 , 42, 116-122	0
1605	Right cardiac involvement in lung diseases: a multimodality approach from diagnosis to prognostication. 2021 , 289, 440-449	2
1604	Characteristics and Long-term Outcomes of Pulmonary Venocclusive Disease Induced by Mitomycin C. 2021 , 159, 1197-1207	5
1603	'Surgery first' if cure is your aim in CTEPH. 2021 , 26, 140-142	1
1602	Targeting Jak-Stat Signaling in Experimental Pulmonary Hypertension. 2021 , 64, 100-114	10
1601	Top End Pulmonary Hypertension Study: Understanding Epidemiology, Therapeutic Gaps and Prognosis in Remote Australian Setting. 2021 , 30, 507-515	0
1600	Associated Pleural and Pericardial Effusions: An Extensive Differential Explored. 2021 , 134, 435-443.e5	0
1599	Riociguat: Clinical research and evolving role in therapy. 2021 , 87, 2645-2662	7
1598	Diagnostic assessment and procedural imaging for transcatheter edge-to-edge tricuspid valve repair: a step-by-step guide. 2021 , 22, 8-10	5
1597	Pulmonary hypertension in connective tissue diseases, new evidence and challenges. 2021 , 51, e13453	9
1596	Management of Pulmonary Arterial Hypertension. 2021 , 15, 2	13

1595	Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand. 2021 , 26, 23-51	9
1594	Prevalence and clinical associations with premature ovarian insufficiency, early menopause, and low ovarian reserve in systemic sclerosis. 2021 , 40, 2267-2275	4
1593	The prevalence and incidence rate of pulmonary arterial hypertension in systemic sclerosis: Systematic review and meta-analysis. 2021 , 20, 102713	10
1592	Correlation Between Doppler Echocardiography and Right Heart Catheterisation-Derived Systolic and Mean Pulmonary Artery Pressures: Determinants of Discrepancies Between the Two Methods. 2021 , 30, 656-664	1
1591	Pulmonary Manifestations of Congenital Heart Disease in Children. 2021 , 68, 25-40	1
1590	Pulmonary Hypertension Due to Left Heart Disease-A Practical Approach to Diagnosis and Management. 2021 , 37, 572-584	4
1589	Portopulmonary Hypertension: Prevalence, Clinical and Hemodynamic Features. 2021 , 46, 100747	7
1588	Pulmonary Vascular Disease Due to Plasma Cell Dyscrasia. 2021 , 5, 210-218	2
1587	Astragaloside IV attenuates inflammatory response mediated by NLRP-3/calpain-1 is involved in the development of pulmonary hypertension. 2021 , 25, 586-590	9
1586	NO-sensitive guanylyl cyclase in the lung. 2020 ,	1
1585	TMEM16A Regulates Pulmonary Arterial Smooth Muscle Cells Proliferation via p38MAPK/ERK Pathway in High Pulmonary Blood Flow-Induced Pulmonary Arterial Hypertension. 2020 , 58, 27-37	3
1584	Pulmonary hypertension with 2020 vision. 2021 , 178, 3-5	
1583	NDUFA4L2 in smooth muscle promotes vascular remodeling in hypoxic pulmonary arterial hypertension. 2021 , 25, 1221-1237	2
1582	Macitentan in infants and children with pulmonary hypertensive vascular disease. Feasibility, tolerability and practical issues - a single-centre experience. 2021 , 11, 2045894020979503	4
1581	Influence of advanced pulmonary vascular remodeling on accuracy of echocardiographic parameters of left ventricular filling pressure. 2021 , 11, 2045894020983723	0
1580	Perillyl alcohol suppresses monocrotaline-induced pulmonary arterial hypertension in rats via anti-remodeling, anti-oxidant, and anti-inflammatory effects. 2021 , 43, 270-280	6
1579	Breathing for Two. 2021 , 384, 61-68	1
1578	AAV1-Mediated shRNA Knockdown of in Rat Bronchus Attenuates Hypoxia-Induced Pulmonary Artery Remodeling. 2021 , 32, 796-805	0

1577	Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry. 2021 , 18, 613-622		4
1576	Relative incidence and predictors of pulmonary arterial hypertension complicating type 2 diabetes: The Fremantle Diabetes Study Phase I. 2021 , 35, 107773		0
1575	Our current understanding of and approach to the management of lung cancer with pulmonary hypertension. 2021 , 15, 373-384		
1574	Reversible pulmonary hypertension associated with multivisceral Whipple's disease. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	
1573	Cancer in Systemic Sclerosis: Analysis of Antibodies Against Components of the Th/To Complex. 2021 , 73, 315-323		7
1572	Targeting transforming growth factor- β receptors in pulmonary hypertension. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	16
1571	Sex Differences in Portopulmonary Hypertension. 2021 , 159, 328-336		2
1570	Tricuspid regurgitant jet velocity and myocardial tissue Doppler parameters predict mortality in a cohort of patients with sickle cell disease spanning from pediatric to adult age groups - revisiting this controversial concept after 16 years of additional evidence. 2021 , 96, 31-39		4
1569	2020 ESC Guidelines for the management of adult congenital heart disease. 2021 , 42, 563-645		290
1568	2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. 2021 , 42, 17-96		264
1567	Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	6
1566	An evaluation of selexipag for the treatment of pulmonary hypertension. 2021 , 22, 29-36		2
1565	MR 4D flow-based mean pulmonary arterial pressure tracking in pulmonary hypertension. 2021 , 31, 1883-1893		4
1564	Management of portopulmonary hypertension: What is more important, PAH severity or liver disease severity?. 2021 , 74, 237-238		
1563	Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease. 2021 , 73, 295-304		10
1562	Nailfold videocapillaroscopy: a novel possible surrogate marker for the evaluation of peripheral microangiopathy in pulmonary arterial hypertension. 2021 , 50, 85-94		4
1561	Computed tomography appearances of the lung parenchyma in pulmonary hypertension. 2021 , 94, 20200830		3
1560	Associated factors of early-onset pulmonary hypertension and clinical difference between early- and late-onset pulmonary hypertension in Thai systemic sclerosis. 2021 , 31, 649-656		1

1559	United States Pulmonary Hypertension Scientific Registry: Baseline Characteristics. 2021 , 159, 311-327	7
1558	Right heart failure in pulmonary hypertension: Diagnosis and new perspectives on vascular and direct right ventricular treatment. 2021 , 178, 90-107	17
1557	Pulmonary Arterial Hypertension in Indonesia: Current Status and Local Application of International Guidelines. 2021 , 16, 23	1
1556	Right Ventricular Response to Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. 2021 , 137-156	
1555	Cardiopulmonary Monitoring of Patients with Pulmonary Hypertension and Right Ventricular Failure. 2021 , 871-903	
1554	Burden of pulmonary arterial hypertension in England: retrospective HES database analysis. 2021 , 15, 1753466621995040	0
1553	Non-Invasive Assessment of Pulmonary Vasculopathy. 2021 , 2, 5-14	
1552	The mechanism of ions in pulmonary hypertension. 2021 , 11, 2045894020987948	2
1551	Hormones, Hemodynamics, and Hepatic Function: Digesting the Intricacies of Sex Differences in Portopulmonary Hypertension. 2021 , 159, 11-13	0
1550	Non-Invasive Assessment of Endothelial Dysfunction in Pulmonary Arterial Hypertension. 2021 , 32, 6-14	1
1549	Chronic thromboembolic pulmonary hypertension: evaluation of V/Q SPECT/CT and V/Q Quotient SPECT findings with postoperative results of pulmonary endarterectomy. 2021 , 42, 369-377	1
1548	Outcome of pulmonary hypertension in pregnancy in contemporary era: A case-based narrative review. 2021 , 7, 89	
1547	Pulmonary Pressures. 2021 , 31-37	
1546	Immuno-Pathogenesis of Respiratory Diseases. 2021 , 1-46	
1545	Targeting smooth muscle cell phenotypic switching in vascular disease. 2021 , 2, 79-94	12
1544	Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleus. 2021 , 117, 2309-2325	10
1543	PM-Scl and Th/To in systemic sclerosis: a comparison of different autoantibody assays. 2021 , 40, 2763-2769	0
1542	Arterial vascular volume changes with haemodynamics in schistosomiasis-associated pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2021 , 57,	13.6 0

- 1541 Congenital extrahepatic portocaval malformation: Rare but potentially treatable cause of pulmonary hypertension. **2021**, 73, 99-103 0
- 1540 Multimodality Imaging in the Evaluation and Treatment of Pulmonary Valve Disorders. **2021**, 23, 1
- 1539 PPAR α increases HUWE1 to attenuate NF- κ B/p65 and sickle cell disease with pulmonary hypertension. **2021**, 5, 399-413 2
- 1538 CardioRheumatology. **2021**, 481-503
- 1537 Improved low-risk criteria scores for combination therapy of sildenafil and generic bosentan in patients with congenital heart disease with severe pulmonary hypertension: A prospective open label study. **2021**, 10, 2048004020982213 1
- 1536 Sex Differences in Pulmonary Arterial Hypertension. **2021**, 197-249 1
- 1535 Pulmonary Hypertension as a Complication of Pediatric Cancer. **2021**, 8, 2333794X211009094
- 1534 Assessment of Right Ventricular Function in Pulmonary Hypertension. **2021**, 195-200
- 1533 Vital capacity and valvular dysfunction could serve as non-invasive predictors to screen for exercise pulmonary hypertension in the elderly based on a new diagnostic score. **2021**, 13, 68-78
- 1532 Rescue balloon pulmonary angioplasty for life-threatening acute pulmonary embolism on chronic thromboembolic pulmonary hypertension patients. **2021**, 33, 101415
- 1531 Pulmonary Hypertension: Transition Challenges in the Current Therapeutic Era. **2021**, 145-165 0
- 1530 Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension. **2021**, 1303, 275-303 4
- 1529 Imaging of pulmonary hypertension in adults: a position paper from the Fleischner Society. *European Respiratory Journal*, **2021**, 57, 13.6 7
- 1528 Clinical characteristics and outcomes in patients with primary Sjogren's syndrome-associated interstitial lung disease. **2021**, 16, 156-164 0
- 1527 Atypical Causes of Severe Pulmonary Hypertension in Infancy. **2021**, 8, 2333794X211001240
- 1526 Mechanosensing and Mechanotransduction in Pulmonary Hypertension. **2021**, 299-318 0
- 1525 Pulmonale Hypertonie. **2021**, 271-279
- 1524 Oxygen-sensitivity and Pulmonary Selectivity of Vasodilators as Potential Drugs for Pulmonary Hypertension. **2021**, 10, 0

- 1523 Sex Differences in Right Ventricular Dysfunction: Insights From the Bench to Bedside. **2020**, 11, 623129 4
- 1522 Long-term outcomes of pregnant women with pulmonary hypertension diagnosed by echocardiography: a retrospective cohort study in a single center from China. **2021**, 11, 2045894020966876 4
- 1521 Evaluation of hemodynamic parameters among patients with myeloproliferative neoplasms and suspected pulmonary hypertension. **2021**, 62, 1458-1465 0
- 1520 DIAGNOSTIC AND PREDICTIVE VALUE OF RIGHT HEART CATHETERIZATION-DERIVED MEASUREMENTS IN PULMONARY HYPERTENSION. **2021**, 74, 546-553 0
- 1519 Great Artery and Vascular Anomalies. **2021**, 525-570
- 1518 Pulmonary Hypertension in Heart Failure. **2021**, 3, 147 0
- 1517 Potential Cellular Targets Associated with the Signaling of the Pulmonary Hypertension. **2021**, 435-445
- 1516 Pulmonary manifestations of systemic lupus erythematosus. **2021**, 521-529
- 1515 Endothelial Dysfunction in Pulmonary Hypertension: Cause or Consequence?. **2021**, 9, 17
- 1514 Medicinal Plants Used in the Treatment of Pulmonary Hypertension. **2021**, 317-339
- 1513 Radiological Findings in Multidetector Computed Tomography (MDCT) of Hereditary and Sporadic Pulmonary Venous Occlusive Disease: Certainties and Uncertainties. **2021**, 11, 2
- 1512 Lung Transplantation for Pulmonary Hypertension. **2021**, 1-12
- 1511 Redox Regulation, Oxidative Stress, and Inflammation in Group 3 Pulmonary Hypertension. **2021**, 1303, 209-241 0
- 1510 Neglected cardiovascular diseases and their significance in the Global North. **2021**, 46, 129-137 0
- 1509 Screening of key biomarkers and immune infiltration in Pulmonary Arterial Hypertension via integrated bioinformatics analysis. **2021**, 12, 2576-2591 6
- 1508 Hypertension pulmonaire. **2021**, 369-376
- 1507 Encyclopedia of Molecular Pharmacology. **2021**, 1-8
- 1506 Acute Right-Heart Failure in Patients with Chronic Precapillary Pulmonary Hypertension. **2021**, 301-316

1505	Impact of the revised hemodynamic definition on the diagnosis of precapillary pulmonary hypertension: a retrospective single-center study in China. 2021 , 11, 1047-1057	1
1504	Acute exacerbation in interstitial lung disease. 2021 , 16, 178-187	1
1503	High Altitude and the Right Ventricle. 2021 , 171-181	
1502	Persistent Pulmonary Hypertension in Corrected Valvular Heart Disease: Hemodynamic Insights and Long-Term Survival. 2021 , 10, e019949	3
1501	The Challenge to Decide between Pulmonary Hypertension Due to Chronic Lung Disease and PAH with Chronic Lung Disease. 2021 , 11,	3
1500	Clinical evaluation of pulmonary hypertension using patient-reported outcomes: a cross-sectional study. 2021 , 21, 48	
1499	Thirty-day hospital readmission in systemic sclerosis associated pulmonary hypertension: A nationwide study. 2021 , 51, 324-330	1
1498	Exercise Right Heart Catheterisation in Cardiovascular Diseases: A Guide to Interpretation and Considerations in the Management of Valvular Heart Disease. 2020 , 16, e01	0
1497	Prevalence and clinical association with calcinosis cutis in early systemic sclerosis. 2021 , 31, 1113-1119	1
1496	mTOR Signaling in Pulmonary Vascular Disease: Pathogenic Role and Therapeutic Target. 2021 , 22,	8
1495	Pulmonary hypertension is an important co-morbidity in developmental lung diseases of infancy: Bronchopulmonary dysplasia and congenital diaphragmatic hernia. 2021 , 56, 670-677	3
1494	Central Role of Dendritic Cells in Pulmonary Arterial Hypertension in Human and Mice. 2021 , 22,	3
1493	The multifaceted problem of pulmonary arterial hypertension in systemic sclerosis. 2021 , 3, e149-e159	4
1492	Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders. 2021 , 18,	7
1491	Metabolism in Pulmonary Hypertension. 2021 , 83, 551-576	13
1490	Determinants and Management of the Post-Pulmonary Embolism Syndrome. 2021 , 42, 299-307	7
1489	Performance Under Pressure: The Relevance of Pulmonary Vascular Response to Exercise Challenge in Scleroderma. 2021 , 159, 481-483	1
1488	Balloon pulmonary angioplasty vs. pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis. 2021 , 26, 897-917	3

1487	Recent advances in the management of pulmonary arterial hypertension: lessons from the upfront combination of ambrisentan and tadalafil. 2021 , 15, 493-504	2
1486	Balloon Pulmonary Angioplasty: State of the Art. 2020 , 16, e02	5
1485	[Differential Diagnosis of Pulmonary Hypertension Using the Example of Collagenosis-associated PAH in the Context of Chronic Lung and Left Heart Disease]. 2021 , 75, 122-137	
1484	New Hemodynamic Insights in Pulmonary Vascular Disease and Heart Failure with Preserved Ejection Fraction. 2021 , 23, 1	
1483	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. 2020 , 177, 106241	4
1482	Kcnk3 dysfunction exaggerates the development of pulmonary hypertension induced by left ventricular pressure overload. 2021 , 117, 2474-2488	4
1481	Evolution of patients with chronic thromboembolic pulmonary hypertension treated by balloon pulmonary angioplasty, according to their anticoagulant regimens. 2021 , 36, 910-915	3
1480	Therapeutic Potential of Regorafenib-A Multikinase Inhibitor in Pulmonary Hypertension. 2021 , 22,	1
1479	A novel non-invasive and echocardiography-derived method for quantification of right ventricular pressure-volume loops. 2021 ,	3
1478	Angiotensin-Converting Enzyme 2 Activator Ameliorates Severe Pulmonary Hypertension in a Rat Model of Left Pneumonectomy Combined With VEGF Inhibition. 2021 , 8, 619133	2
1477	Post-tuberculous lung disease: should we be using Theophylline?. 2021 , 13, 1230-1238	
1476	The predictive value of minute ventilation versus carbon dioxide production in pulmonary hypertension associated with left heart disease. 2021 , 9, 351	1
1475	Update on Perioperative Pediatric Pulmonary Hypertension Management. 2021 ,	1
1474	A novel echocardiographic method for estimation of pulmonary artery wedge pressure and pulmonary vascular resistance. 2021 , 8, 1216-1229	8
1473	Pulmonary vasodilator use in continuous-flow left ventricular assist device management. 2021 , 9, 522	
1472	The clinical characteristics, treatment, and survival of portopulmonary hypertension in Japan. 2021 , 21, 89	1
1471	Understanding right ventricular dyssynchrony: Its myriad determinants and clinical relevance. 2021 , 106, 797-800	
1470	Pulmonary Hypertension Associated With Respiratory Diseases - Which Patients Should Be Treated With Pulmonary Arterial Hypertension-Targeted Therapies?. 2021 , 85, 343-344	

1469	Pulmonary Disease, Pulmonary Hypertension and Atrial Fibrillation. 2021 , 13, 141-153	4
1468	Chronic Thromboembolic Disease and Chronic Thromboembolic Pulmonary Hypertension. 2021 , 42, 81-90	4
1467	Endothelin receptor antagonists for pulmonary arterial hypertension. 2021 , 3, CD004434	1
1466	Epidemiology, Pathogenesis, and Clinical Approach in Group 5 Pulmonary Hypertension. 2020 , 7, 616720	3
1465	The Inflammatory Profile of CTEPH-Derived Endothelial Cells Is a Possible Driver of Disease Progression. 2021 , 10,	3
1464	Molecular and Genetic Profiling for Precision Medicines in Pulmonary Arterial Hypertension. 2021 , 10,	4
1463	Increased Mortality in Patients With Preoperative and Persistent Postoperative Pulmonary Hypertension Undergoing Mitral Valve Surgery for Mitral Regurgitation: A Cohort Study. 2021 , 10, e018394	2
1462	Contemporary Pharmacotherapeutic Approach in Pulmonary Arterial Hypertension. 2021 , 42, 125-131	0
1461	Personalized Medicine for Pulmonary Hypertension:: The Future Management of Pulmonary Hypertension Requires a New Taxonomy. 2021 , 42, 207-216	0
1460	Group 3 Pulmonary Hypertension: A Review of Diagnostics and Clinical Trials. 2021 , 42, 59-70	3
1459	The contemporary pulmonary artery catheter. Part 2: measurements, limitations, and clinical applications. 2021 , 1	3
1458	Association of premature menopause with incident pulmonary hypertension: A cohort study. 2021 , 16, e0247398	3
1457	Long-Chain Acylcarnitines and Monounsaturated Fatty Acids Discriminate Heart Failure Patients According to Pulmonary Hypertension Status. 2021 , 11,	1
1456	Mildly Elevated Pulmonary Arterial Pressure Is Associated With a High Risk of Progression to Pulmonary Hypertension and Increased Mortality: A Systematic Review and Meta-Analysis. 2021 , 10, e018374	4
1455	Kommentar zu den Leitlinien (2020) der European Society of Cardiology zum Management von Erwachsenen mit angeborenem Herzfehler. 2021 , 15, 248-253	2
1454	Impact of the new definition for pulmonary hypertension in patients with lung disease: an analysis of the United Network for Organ Sharing database. 2021 , 11, 2045894021999960	2
1453	Current Drug Treatment Strategies for Atrial Fibrillation and TASK-1 Inhibition as an Emerging Novel Therapy Option. 2021 , 12, 638445	4
1452	MUW researcher of the month. 2021 , 133, 267-268	

1451	Long-Term Outcomes in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta-Analyses of Randomized, Controlled Trials and Observational Registries. 2021 , 73, 837-847	9
1450	Imaging of Pulmonary Hypertension in Adults: A Position Paper from the Fleischner Society. 2021 , 298, 531-549	10
1449	Preclinical Investigation of Trifluoperazine as a Novel Therapeutic Agent for the Treatment of Pulmonary Arterial Hypertension. 2021 , 22,	2
1448	Late non-infectious pulmonary complications. 2021 , 231-240	
1447	An interesting case of progressive dyspnoea and diffuse mediastinal adenopathy in a 25-year-old man. 2021 , 17, 200289	
1446	The role of cardiopulmonary exercise test in identifying pulmonary veno-occlusive disease. <i>European Respiratory Journal</i> , 2021 , 57,	13.6 1
1445	Sex Differences in Ischemic Stroke Outcomes in Patients With Pulmonary Hypertension. 2021 , 10, e019341	2
1444	Combined pre- and post-capillary pulmonary hypertension: The clinical implications for patients with heart failure. 2021 , 16, e0247987	3
1443	Congenital Heart Disease-Associated Pulmonary Hypertension. 2021 , 42, 9-18	3
1442	Combining Data Sets as Well as Therapies Shows Improved Outcome in Connective Tissue Disease-Associated Pulmonary Hypertension. 2021 , 73, 725-727	1
1441	Non-invasive early exclusion of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: the InShape II study. 2021 , 76, 1002-1009	11
1440	Pulmonary hypertension: Spectrum of disease, clinical presentation and treatment outcomes at the main respiratory pulmonary hypertension clinic in KwaZulu-Natal Province, South Africa. 2021 , 27,	0
1439	The isobaric pulmonary arterial compliance in pulmonary hypertension. 2021 , 7,	1
1438	Hemodynamic function of the right ventricular-pulmonary vascular-left atrial unit: normal responses to exercise in healthy adults. 2021 , 320, H923-H941	5
1437	Prognostic Significance of Systemic Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Idiopathic Pulmonary Hypertension. 2021 , 17, 77-93	2
1436	Endothelial Autocrine Signaling through CXCL12/CXCR4/FoxM1 Axis Contributes to Severe Pulmonary Arterial Hypertension. 2021 , 22,	5
1435	[Chronic exposure to altitude. Clinical characteristics and diagnosis]. 2021 , 91, 500-507	
1434	COVID-19: Achieving Maximum Medical Improvement and Assessing Permanent Impairment. 2021 , 26, 3-12	

1433	Preoperative Assessment and Perioperative Management of the Patient with Pulmonary Vascular Disease. 2021 , 42, 133-141	1
1432	Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial. 2021 , 204, 209-221	30
1431	Macrophage-derived PDGF-B induces muscularization in murine and human pulmonary hypertension. 2021 , 6,	9
1430	An endothelial activin A-bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertension. 2021 , 12, 1720	9
1429	Invasive Hemodynamic and Metabolic Evaluation of HFpEF. 2021 , 23, 1	0
1428	RETROSPECTIVE COMPUTER-ASSISTED IMAGE ANALYSIS OF DOPPLER ECHOCARDIOGRAPHY IN PULMONARY HYPERTENSION PATIENTS. 2021 , 21, 2150016	
1427	Pulmonary Arterial Hypertension Secondary to Drugs and Toxins. 2021 , 42, 19-38	3
1426	Autoimmune Polyendocrine Syndrome Complicated by Pulmonary Hypertension. 2021 , 21, 561-565	0
1425	Limited Scleroderma-Induced Pulmonary Arterial Hypertension Resulting in Impaired Postoperative Respiratory Function. 2021 , 13, e13742	1
1424	Hypoxemia during sleep and overnight rostral fluid shift in pulmonary arterial hypertension: a pilot study. 2021 , 11, 2045894021996930	1
1423	Pulmonary Hypertension in Left Heart Disease. 2021 , 42, 39-58	5
1422	NHLBI-CMREF Workshop Report on Pulmonary Vascular Disease Classification: JACC State-of-the-Art Review. 2021 , 77, 2040-2052	6
1421	Revisiting a Distinct Entity in Pulmonary Vascular Disease: Chronic Thromboembolic Pulmonary Hypertension (CTEPH). 2021 , 57,	1
1420	Esclerosis sisthica. 2021 , 13, 1769-1778	
1419	Analysis of the 2020 European Society of Cardiology (ESC) Guidelines for the Management of Adults With Congenital Heart Disease (ACHD). 2021 ,	0
1418	Depression, anxiety and psychological distress in patients with pulmonary hypertension: a mixed-methods study. 2021 , 8,	5
1417	Experimental design of the Effects of Dehydroepiandrosterone in Pulmonary Hypertension (EDIPHY) trial. 2021 , 11, 2045894021989554	0
1416	Characterization of a Cohort of Patients with Chronic Thromboembolic Pulmonary Hypertension from Northeastern Colombia (REHINO Study). 2021 , 1, 105-113	

1415	Pulmonary Hypertension Complicating Pregnancy. 2021 , 10, 71-83	0
1414	Regional Variation in Methamphetamine-associated Pulmonary Arterial Hypertension: Who'd Better Call Saul?. 2021 , 18, 584-585	0
1413	Endothelial Dysfunction and Disruption in Pulmonary Hypertension.	1
1412	P2X7 Receptor-Mediated Inflammation in Cardiovascular Disease. 2021 , 12, 654425	6
1411	Prevalence and Associated Factors of Portopulmonary Hypertension in Patients with Portal Hypertension: A Case-Control Study. 2021 , 2021, 5595614	2
1410	Integrating haemodynamics identifies an extreme pulmonary hypertension phenotype. <i>European Respiratory Journal</i> , 2021 , 58,	13.6 2
1409	JCS/JHFS 2021 Statement on Palliative Care in Cardiovascular Diseases. 2021 , 85, 695-757	5
1408	Incidence, Clinical Correlates, and Outcomes of Pulmonary Hypertension after Kidney Transplantation: Analysis of Linked U.S. Registry and Medicare Billing Claims. 2021 ,	2
1407	Incidence and prognostic significance of pleural effusions in pulmonary arterial hypertension. 2021 , 11, 20458940211012366	0
1406	Protocol: Prospective observational study investigating the prevalence and clinical outcome of portopulmonary hypertension in Japanese patients with chronic liver disease. 2021 , 16, e0249435	
1405	Right ventricular stroke work index by echocardiography in adult patients with pulmonary arterial hypertension. 2021 , 21, 219	
1404	Monotherapy in patients with pulmonary arterial hypertension at four German PH centres. 2021 , 21, 130	0
1403	Mortality, Kidney Failure, and Hospitalization Among Medicare Beneficiaries With CKD and Pulmonary Hypertension. 2021 , 78, 700-708.e1	1
1402	Pulmonary vasodilator treatment in pulmonary hypertension due to left heart or lung disease: time for a high-definition picture?. 2021 , 11, 20458940211018074	
1401	Perioperative management of patients with pulmonary hypertension undergoing non-cardiothoracic, non-obstetric surgery: a systematic review and expert consensus statement. 2021 , 126, 774-790	6
1400	Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management. 2021 , 22, 109	11
1399	Body Habitus Considerations During Right Heart Catheterization. 2021 , 3, 1108-1116	0
1398	Systematic Understanding of Pathophysiological Mechanisms of Oxidative Stress-Related Conditions-Diabetes Mellitus, Cardiovascular Diseases, and Ischemia-Reperfusion Injury. 2021 , 8, 649785	8

1397	Identifying New Targets for Treatment of Pulmonary Hypertension. 2021 , 159, 1326-1327	
1396	Abnormal levels of apolipoprotein A-I in chronic thromboembolic pulmonary hypertension. 2021 , 11, 20458940211010371	2
1395	and in human pulmonary artery hypertension: fruits from weighted gene co-expression network analysis. 2021 , 13, 2242-2254	2
1394	Hemodynamic Characteristics and Outcomes of Pulmonary Hypertension in Patients Undergoing Tricuspid Valve Repair or Replacement. 2021 , 3, 488-497	0
1393	Assessment of right ventricular reserve utilizing exercise provocation in systemic sclerosis. 2021 , 37, 2137-2147	3
1392	Incidence of alveolar capillary dysplasia with misalignment of pulmonary veins in infants with unexplained severe pulmonary hypertension: The roles of clinical, pathological, and genetic testing. 2021 , 155, 105323	1
1391	Pulmonary Hypertension. 2021 , 174, ITC49-ITC64	7
1390	Pulmonary hypertension in dogs: an overview. 2021 , 26, 1-9	
1389	Pulmonary hypertension due to interstitial lung disease or chronic obstructive pulmonary disease: a patient experience study of symptoms and their impact on quality of life. 2021 , 11, 20458940211005641	1
1388	Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs. <i>European Respiratory Journal</i> , 2021 , 58,	13.6 2
1387	Exercise intolerance in pulmonary arterial hypertension: insight into central and peripheral pathophysiological mechanisms. 2021 , 30,	2
1386	Management of Women With Congenital or Inherited Cardiovascular Disease From Pre-Conception Through Pregnancy and Postpartum: JACC Focus Seminar 2/5. 2021 , 77, 1778-1798	13
1385	Chronic Obstructive Pulmonary Disease and the Cardiovascular System: Vascular Repair and Regeneration as a Therapeutic Target. 2021 , 8, 649512	7
1384	EnRank: An Ensemble Method to Detect Pulmonary Hypertension Biomarkers Based on Feature Selection and Machine Learning Models. 2021 , 12, 636429	3
1383	Fasudil Dichloroacetate Alleviates SU5416/Hypoxia-Induced Pulmonary Arterial Hypertension by Ameliorating Dysfunction of Pulmonary Arterial Smooth Muscle Cells. 2021 , 15, 1653-1666	4
1382	Pulmonary arterial hypertension in systemic sclerosis. 2021 , 50, 104062	2
1381	Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE. 2021 , 40, 279-288	3
1380	Optimizing the diagnosis and assessment of chronic thromboembolic pulmonary hypertension with advancing imaging modalities. 2021 , 11, 20458940211007375	3

1379	Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	5
1378	Validity of echocardiographic tricuspid regurgitation gradient to screen for new definition of pulmonary hypertension. 2021 , 34, 100822		3
1377	Long-term tolerability of phosphodiesterase-5 inhibitors in pulmonary hypertension of sickle cell disease. 2021 , 107, 54-62		3
1376	Loss of immune homeostasis in patients with idiopathic pulmonary arterial hypertension. 2021 , 76, 1209-1218		3
1375	Impact of targeted pulmonary arterial hypertension therapy in patients with combined post- and precapillary pulmonary hypertension. 2021 , 235, 74-81		2
1374	Current Perspectives on the Physiological Activities of Fermented Soybean-Derived Cheonggukjang. 2021 , 22,		7
1373	SOX17 Loss-of-Function Mutation Underlying Familial Pulmonary Arterial Hypertension. 2021 , 62, 566-574		6
1372	The Role of JAK/STAT Molecular Pathway in Vascular Remodeling Associated with Pulmonary Hypertension. 2021 , 22,		6
1371	Off-label use of PAH-targeted medications approved for adults and their financial coverage by health insurances are vital for children with pulmonary hypertension. 2021 , 51, e13571		0
1370	Preventing disease progression in Eisenmenger syndrome. 2021 , 19, 501-518		
1369	Adjusting to the New Normal: Echocardiography to Find Pulmonary Hypertension. 2021 , 35, 100867		
1368	Clinical Impact of the New Definition of Precapillary Pulmonary Hypertension. 2021 , 159, 1995-1997		5
1367	Animal models of pulmonary hypertension: Getting to the heart of the problem. 2021 ,		3
1366	Immunomodulation Therapy Using Tolerogenic Macrophages in a Rodent Model of Pulmonary Hypertension. 2021 , 30, 515-525		1
1365	Sickle cell disease related chronic thromboembolic pulmonary hypertension: challenging clinical scenario. 2021 , 1		
1364	Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH. 2021 , 13, 80		11
1363	Nailfold videocapillaroscopic changes in patients with pulmonary arterial hypertension associated with connective tissue diseases. 2021 , 41, 1289-1298		1
1362	Interleukin-17 aggravates right ventricular remodeling via activating STAT3 under both normoxia and hypoxia. 2021 , 21, 249		0

- 1361 The Experience, Prerequisites, and the Barriers in Organizing a Specialized Rehabilitation Program for Patients with Pulmonary Hypertension. **2021**, 100, 949-957
- 1360 Right ventricular pressure-volume loop shape and systolic pressure change in pulmonary hypertension. **2021**, 320, L715-L725 4
- 1359 Eriğin ve Geriatrik Bireylerde Kardiyopulmoner Rehabilitasyon Gerektiren Hastalıklar. 0
- 1358 Disease-specific platelet signaling defects in idiopathic pulmonary arterial hypertension. **2021**, 320, L739-L749 3
- 1357 Guía ESC 2020 para el tratamiento de las cardiopatías congénitas del adulto. **2021**, 74, 436.e1-436.e79 3
- 1356 Development and Validation of Algorithms to Identify Pulmonary Arterial Hypertension in Administrative Data. **2021**, 159, 1986-1994 2
- 1355 PH CARE COVID survey: an international patient survey on the care for pulmonary hypertension patients during the early phase of the COVID-19 pandemic. **2021**, 16, 196 4
- 1354 . **2021**, 13, 33-40 0
- 1353 Anti-tRNA synthetase syndrome interstitial lung disease: A single center experience. **2021**, 106432 0
- 1352 Lung function and stress echocardiography in pulmonary arterial hypertension: a cross-sectional study. **2021**, 139, 505-510
- 1351 The relationship between retinal microcirculation and right heart catheterization and echocardiography findings in patients with idiopathic pulmonary arterial hypertension. **2021**, 28, e12704 2
- 1350 Plasma markers in pulmonary hypertension subgroups correlate with patient survival. **2021**, 22, 137 5
- 1349 Cardiac Magnetic Resonance Imaging Right Ventricular Longitudinal Strain Predicts Mortality in Patients Undergoing TAVI. **2021**, 8, 644500 1
- 1348 Systemic Sclerosis-Associated Pulmonary Hypertension: Spectrum and Impact. **2021**, 11, 6
- 1347 GCN2 Regulates ATF3-p38 MAPK Signaling Transduction in Pulmonary Veno-Occlusive Disease. **2021**, 26, 677-689 2
- 1346 Sex Dimorphism in Pulmonary Hypertension: The Role of the Sex Chromosomes. **2021**, 10, 2
- 1345 Clinical, radiologic and serologic profile of patients with interstitial pneumonia with autoimmune features: a cross-sectional study. **2021**, 1 1
- 1344 Circulating Plasma miRNA and Clinical/Hemodynamic Characteristics Provide Additional Predictive Information About Acute Pulmonary Thromboembolism, Chronic Thromboembolic Pulmonary Hypertension and Idiopathic Pulmonary Hypertension. **2021**, 12, 648769 2

1343	Current Understanding of the Right Ventricle Structure and Function in Pulmonary Arterial Hypertension. 2021 , 12, 641310	3
1342	Osthole improves pulmonary artery hypertension by inducing apoptosis in pulmonary artery smooth muscle cells. 2021 , 73, 1109-1117	0
1341	High Right Ventricular Afterload during Exercise in Patients with Pulmonary Arterial Hypertension. 2021 , 10,	0
1340	Association between pulmonary artery to aorta diameter ratio with pulmonary hypertension and outcomes in diffuse cystic lung diseases. 2021 , 100, e26483	1
1339	ROCK Inhibition as Potential Target for Treatment of Pulmonary Hypertension. 2021 , 10,	6
1338	Serotonin and chronic hypoxic pulmonary hypertension activate a NADPH oxidase 4 and TRPM2 dependent pathway for pulmonary arterial smooth muscle cell proliferation and migration. 2021 , 138, 106860	3
1337	Interstitial lung diseases and pulmonary hypertension. 2021 , 8,	0
1336	Midsystolic Notch and Pulmonary Hypertension: Pathophysiologic Mechanism and Technical Considerations. 2021 , 34, 693-695	0
1335	Fetal Gene Reactivation in Pulmonary Arterial Hypertension: GOOD, BAD, or BOTH?. 2021 , 10,	2
1334	AMPK and Pulmonary Hypertension: Crossroads Between Vasoconstriction and Vascular Remodeling. 2021 , 9, 691585	5
1333	Pulmonary hypertension in interstitial lung disease: screening, diagnosis and treatment. 2021 , 27, 396-404	4
1332	Clinical characteristics and survival of patients with three major connective tissue diseases associated with pulmonary hypertension: A study from China. 2021 , 22, 925	2
1331	Screening for the early detection of pulmonary arterial hypertension in patients with systemic sclerosis: A systematic review and meta-analysis of long-term outcomes. 2021 , 51, 495-512	3
1330	Histopathology of newborn lung disease. 2021 , 287-300	0
1329	Safety and Tolerability of a Rapid Transition From Intravenous Treprostinil to Oral Selexipag in Three Adolescent Patients With Pulmonary Arterial Hypertension. 2021 , 26, 512-516	0
1328	Sarcoidosis associated pulmonary hypertension: an update. 2021 , 27, 285-295	1
1327	The role of imaging in pulmonary hypertension. 2021 , 11, 859-880	1
1326	Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances. 2021 , 203, 1472-1487	13

1325	Anti-inflammatory role and mechanism of microRNA-92b-3p in the progression of hypoxic pulmonary hypertension. 2021 , 119725	0
1324	At a crossroads: coronavirus disease 2019 recovery and the risk of pulmonary vascular disease. 2021 , 27, 342-349	2
1323	Iron deficiency in pulmonary arterial hypertension: perspectives. 2021 , 11, 20458940211021301	0
1322	The Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium Channels. 2021 , 12, 705421	
1321	Epoprostenol for the treatment of pulmonary arterial hypertension. 2021 , 14, 1005-1013	5
1320	2020 KSC/KATRD Guideline for the Diagnosis and Treatment of Pulmonary Hypertension: Executive Summary. 2021 ,	0
1319	Left ventricular global longitudinal strain predicts elevated cardiac pressures and poor clinical outcomes in patients with non-ischemic dilated cardiomyopathy. 2021 , 19, 21	3
1318	Five-year survival after an acute episode of decompensated pulmonary arterial hypertension in the modern management era of right heart failure. <i>European Respiratory Journal</i> , 2021 , 58,	13.6 1
1317	Guía ESC 2020 sobre cardiología del deporte y el ejercicio en pacientes con enfermedad cardiovascular. 2021 , 74, 545.e1-545.e73	2
1316	Pulmonary hypertension in preterm infants. 2021 , 89-103	1
1315	Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry. 2021 , 11, 20458940211020913	3
1314	Risk Factors for Prolonged Mechanical Ventilation After Pulmonary Endarterectomy: 7 Years' Experience From an Experienced Hospital in China. 2021 , 8, 679273	0
1313	Sex-Related Differences in Dynamic Right Ventricular-Pulmonary Vascular Coupling in Heart Failure With Preserved Ejection Fraction. 2021 , 159, 2402-2416	3
1312	Pulmonary hypertension associated with neurofibromatosis type 2. 2021 , 11, 20458940211029550	
1311	Pulmonary Complications in Cystic Fibrosis: Past, Present, and Future: Adult Cystic Fibrosis Series. 2021 , 160, 1232-1240	2
1310	Postpulmonary embolism syndrome. 2021 , 27, 335-341	1
1309	Pulmonary Vascular Resistance Predicts Mortality and Graft Failure in Transplantation Patients With Portopulmonary Hypertension. 2021 , 27, 1811-1823	3
1308	Frataxin deficiency promotes endothelial senescence in pulmonary hypertension. 2021 , 131,	8

1307	▣ Nicotinic acetylcholine receptor mediates right ventricular fibrosis and diastolic dysfunction in pulmonary hypertension. 2021 , 6,	2
1306	With No Lysine Kinase 1 Promotes Right Ventricular Dysfunction Via Glucotoxicity.	
1305	Pediatric Pulmonary Hypertension: Definitions, Mechanisms, Diagnosis, and Treatment. 2021 , 11, 2135-2190	2
1304	Right Ventricle Remodeling Metabolic Signature in Experimental Pulmonary Hypertension Models of Chronic Hypoxia and Monocrotaline Exposure. 2021 , 10,	3
1303	Soluble ST2 and mixed venous oxygen saturation for prediction of mortality in patients with pulmonary hypertension. 2021 , 13, 3478-3488	0
1302	Exercise right ventricular ejection fraction predicts right ventricular contractile reserve. 2021 , 40, 504-512	2
1301	Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast Study. 2021 , 11,	0
1300	Radiofrequency Catheter Ablation of Supraventricular Tachycardia in Patients With Pulmonary Hypertension: Feasibility and Long-Term Outcome. 2021 , 12, 674909	0
1299	Cor pulmonale. 2021 , 13, 2026-2036	1
1298	The Prognostic Value of Cardiac Axis Deviation in Systemic Sclerosis-related Pulmonary Hypertension. 2021 ,	0
1297	Pulmonary Hypertension in Patients with Common Variable Immunodeficiency. 2021 , 41, 1549-1562	2
1296	2020 Chinese expert-based consensus on the diagnosis and treatment of connective tissue disease associated pulmonary arterial hypertension. 2021 , 2, 63-78	
1295	Different cardiovascular and pulmonary phenotypes for single- and double-knock-out mice deficient in BMP9 and BMP10. 2021 ,	7
1294	Screening for Pulmonary Hypertension in Systemic Sclerosis-A Primer for Cardio-Rheumatology Clinics. 2021 , 11,	1
1293	Frataxin and endothelial cell senescence in pulmonary hypertension. 2021 , 131,	2
1292	Intravenous prostanoids in systemic sclerosis-associated pulmonary arterial hypertension: a single centre experience. 2021 ,	1
1291	Recent advancements in pulmonary arterial hypertension and right heart failure research: overview of selected abstracts from ATS2020 and emerging COVID-19 research. 2021 , 11, 20458940211037274	0
1290	French recommendations for the management of systemic sclerosis. 2021 , 16, 322	3

1289	Die idiopathische pulmonale Fibrose jenseits der Lunge: Krankheitsmechanismen verstehen, um Diagnose und Therapie zu verbessern. 1-12	
1288	Angiotensin-Converting Enzyme 2 (ACE2) as a Potential Diagnostic and Prognostic Biomarker for Chronic Inflammatory Lung Diseases. 2021 , 12,	2
1287	Management of Pulmonary Hypertension Due to Chronic Lung Disease. 2021 , 17, 124-133	
1286	Under Pressure: Right Heart Catheterization and Provocative Testing for Diagnosing Pulmonary Hypertension. 2021 , 17, 92-100	0
1285	Inhibitory effects of RAGE-aptamer on development of monocrotaline-induced pulmonary arterial hypertension in rats. 2021 , 78, 12-16	1
1284	Echocardiographic, Biochemical, and Electrocardiographic Correlates Associated With Progressive Pulmonary Arterial Hypertension. 2021 , 8, 705666	1
1283	Manual der Arbeitsgruppe Interventionelle Kardiologie (AGIK) der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e. V. (DGK). 2021 , 15, 370-403	1
1282	Halofuginone, a promising drug for treatment of pulmonary hypertension. 2021 , 178, 3373-3394	6
1281	Favorable Pregnancy Outcomes in Women With Well-Controlled Pulmonary Arterial Hypertension. 2021 , 8, 689764	3
1280	Cardiac Output Determination in Precapillary Pulmonary Hypertension: A Systematic Review. 2021 , 100, 1243-1250	2
1279	The different facets of sickle cell disease-related pulmonary hypertension. 2021 , 27, 319-328	1
1278	ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part I: Epidemiology, assessment of extrapulmonary conditions, candidate evaluation, selection criteria, and pathology statements. 2021 , 40, 1251-1266	1
1277	Impact of the new definition of pulmonary hypertension according to world symposium of pulmonary hypertension 2018 on diagnosis of post-capillary pulmonary hypertension. 2021 , 335, 105-110	4
1276	Risk stratification in patients with residual pulmonary hypertension after pulmonary endarterectomy. 2021 , 334, 116-122	3
1275	Changes in the Pulmonary Artery Wave Reflection in Dogs with Experimentally-Induced Acute Pulmonary Embolism and the Effect of Vasodilator. 2021 , 11,	4
1274	Is pulmonary vascular resistance index better than pulmonary vascular resistance in predicting outcomes in pulmonary arterial hypertension?. 2021 , 40, 614-622	0
1273	Pregnancy and pulmonary arterial hypertension: a case series and literature review. 2021 , 3, 100358	3
1272	BMP9 and BMP10: two close vascular quiescence partners that stand out. 2021 ,	6

1271	Pulmonary Hypertension in 2021: Part I-Definition, Classification, Pathophysiology, and Presentation. 2021,	6
1270	Lung and heart-lung transplantation for children with PAH: Dramatic benefits from the implementation of a high-priority allocation program in France. 2021, 40, 652-661	
1269	Clinical Phenogroups in Heart Failure with Preserved Ejection Fraction. 2021, 17, 483-498	2
1268	Inverse modeling framework for characterizing patient-specific microstructural changes in the pulmonary arteries. 2021, 119, 104448	3
1267	Association between HIV and incident pulmonary hypertension in US Veterans: a retrospective cohort study. 2021, 2, e417-e425	0
1266	Short-Term Impact of Iron Deficiency in Different Subsets of Patients with Precapillary Pulmonary Hypertension from an Eastern European Pulmonary Hypertension Referral Center. 2021, 14, 3355-3366	1
1265	Hypoxia and the integrated stress response promote pulmonary hypertension and preeclampsia: Implications in drug development. 2021, 26, 2754-2773	3
1264	Effectiveness and safety of a simple home-based rehabilitation program in pulmonary arterial hypertension: an interventional pilot study. 2021, 13, 79	3
1263	Ventilatory efficiency in pulmonary vascular diseases. 2021, 30,	4
1262	ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part II: Cardiac, surgical, perioperative, operative, and post-operative challenges and management statements. 2021, 40, 1267-1278	
1261	Shifting gears: the search for group 3 pulmonary hypertension treatment. 2021, 27, 296-302	1
1260	Pulmonary hypertension in systemic sclerosis: diagnosis by systematic screening and prognosis after three years follow-up. 2021, 21, 251	1
1259	Optimal Tricuspid Regurgitation Velocity to Screen for Pulmonary Hypertension in Tertiary Referral Centers. 2021, 160, 2209-2219	0
1258	Pulmonary Hypertension in Patients With Heart Failure With Mid-Range Ejection Fraction. 2021, 8, 694240	0
1257	Acute Hemodynamic Effect of Acetazolamide in Patients With Pulmonary Hypertension Whilst Breathing Normoxic and Hypoxic Gas: A Randomized Cross-Over Trial. 2021, 8, 681473	2
1256	Cardiovascular phenotypes predict clinical outcomes in sickle cell disease: An echocardiography-based cluster analysis. 2021, 96, 1166-1175	1
1255	Use of Handheld Ultrasound to Estimate Right Atrial Pressure in a Pulmonary Hypertension Clinic. 2021,	2
1254	What's new in pulmonary hypertension clinical research: lessons from the best abstracts at the 2020 American Thoracic Society International Conference. 2021, 11, 20458940211040713	0

1253	Impairment of skeletal muscle oxygen extraction and cardiac output are matched in precapillary pulmonary hypertension. 2021 , 7,	
1252	Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. 2021 , 40, 1349-1379	34
1251	Genetic basis of pulmonary arterial hypertension: a prospective study from a highly inbred population. 2021 , 11, 20458940211032057	
1250	A young lady with dyspnoea: Quest for the cause. 2021 ,	
1249	Right Ventricular Function and Its Coupling With Pulmonary Circulation in Precapillary Pulmonary Hypertension: A Three-Dimensional Echocardiographic Study. 2021 , 8, 690606	1
1248	Hospital readmission in systemic sclerosis associated pulmonary hypertension: Results from the PHAROS registry. 2021 ,	0
1247	Arterial load and right ventricular-vascular coupling in pulmonary hypertension. 2021 , 131, 424-433	3
1246	Chronic Thromboembolic Pulmonary Hypertension: A Comprehensive Review and Multidisciplinary Approach to Surgical Treatment. 2021 , 17, e18-e28	2
1245	Evaluation, Diagnosis, and Classification of Pulmonary Hypertension. 2021 , 17, 86-91	1
1244	Circulating Cell Biomarkers in Pulmonary Arterial Hypertension: Relationship with Clinical Heterogeneity and Therapeutic Response. 2021 , 10,	1
1243	Echocardiography in Pulmonary Arterial Hypertension: Comprehensive Evaluation and Technical Considerations. 2021 , 10,	1
1242	Quantification of Arterial and Venous Morphologic Markers in Pulmonary Arterial Hypertension Using CT Imaging. 2021 , 160, 2220-2231	4
1241	Translation, cross-cultural adaptation, reliability, and validity of the Turkish version of the Duke Activity Status Index in patients with pulmonary hypertension. 2021 ,	
1240	Oxygen sensing, mitochondrial biology and experimental therapeutics for pulmonary hypertension and cancer. 2021 , 170, 150-178	10
1239	Impact of the new pulmonary hypertension definition on long-term mortality in patients with severe aortic stenosis undergoing valve replacement. 2021 , 44, 1276-1285	1
1238	Excipient-Induced Pulmonary Vascular Disease: An Underrecognized and Deadly Complication of Opioid Addiction. 2021 , 199, 363-368	0
1237	The Role of Exercise Doppler Echocardiography to Unmask Pulmonary Arterial Hypertension in Selected Patients with Systemic Sclerosis and Equivocal Baseline Echocardiographic Values for Pulmonary Hypertension. 2021 , 11,	3
1236	Performance of the DETECT Algorithm for Pulmonary Hypertension Screening in a Systemic Sclerosis Cohort. 2021 , 73, 1731-1737	5

1235	The direct comparison of inhaled versus intravenous levosimendan in children with pulmonary hypertension undergoing on-cardiopulmonary bypass cardiac surgery: A randomized, controlled, non-inferiority study. 2021 , 71, 110231	3
1234	Characteristics of patients meeting the new definition of pre-capillary pulmonary hypertension (Nice 2018) in a single Japanese pulmonary hypertension center. 2021 , 21, 260	1
1233	Endothelial metabolism in pulmonary vascular homeostasis and acute respiratory distress syndrome. 2021 , 321, L358-L376	1
1232	Novel Therapeutic Targets for the Treatment of Right Ventricular Remodeling: Insights from the Pulmonary Artery Banding Model. 2021 , 18,	1
1231	Inhibition of HDAC1 alleviates monocrotaline-induced pulmonary arterial remodeling through up-regulation of miR-34a. 2021 , 22, 239	1
1230	Lung transplantation for interstitial lung disease. 2021 , 30,	4
1229	[Characteristics of patients with connective tissue disease-associated pulmonary arterial hypertension treated with prostanoids: A multicenter retrospective study]. 2021 , 42, 825-831	
1228	Fluid challenge and balloon occlusion testing in patients with atrial septal defects. 2021 ,	0
1227	Chronic Thromboembolic Pulmonary Hypertension Mimicking Acute Pulmonary Embolism: A Case Report. 2021 , 22, e933031	0
1226	Comment on: Transcriptomic analysis of CFTR-impaired endothelial cells reveals a pro-inflammatory phenotype. <i>European Respiratory Journal</i> , 2021 , 58,	13.6
1225	The Role of Regulatory T Cells in Pulmonary Arterial Hypertension. 2021 , 12, 684657	5
1224	Hemodynamics Prior to Valve Replacement for Severe Aortic Stenosis and Pulmonary Hypertension during Long-Term Follow-Up. 2021 , 10,	0
1223	Serious illness conversations in pulmonary hypertension. 2021 , 11, 20458940211037529	1
1222	Pulmonary hypertension in the child with bronchopulmonary dysplasia. 2021 , 56, 3546-3556	3
1221	Two cases of pregnancy after achieving complete remission of chronic active Epstein-Barr virus infection. 2021 , 47, 4049-4054	0
1220	Update from the World Symposium on Pulmonary Hypertension 2018: does the new hemodynamic definition of pediatric pulmonary hypertension have an impact on treatment strategies?. 2021 , 11, 1048-1051	0
1219	Phenotypic Diversity of Vascular Smooth Muscle Cells in Pulmonary Arterial Hypertension: Implications for Therapy. 2021 ,	4
1218	Topic-Based, Recent Literature Review on Pulmonary Hypertension. 2021 , 96, 3109-3121	1

1217	Medical management of pulmonary arterial hypertension in pregnancy: A single center experience. 2021 , 4, 100145	0
1216	Role of cardiovascular magnetic resonance in pediatric pulmonary hypertension-novel concepts and imaging biomarkers. 2021 , 11, 1057-1069	
1215	Novel Experimental Therapies for Treatment of Pulmonary Arterial Hypertension. 2021 , 13, 817-857	3
1214	Tuberous sclerosis complex for the pulmonologist. 2021 , 30,	2
1213	A multiscale model of vascular function in chronic thromboembolic pulmonary hypertension. 2021 , 321, H318-H338	5
1212	Chronic thromboembolic pulmonary hypertension anno 2021. 2021 , 36, 711-719	1
1211	Pulmonary vascular disease in Fontan circulation-is there a rationale for pulmonary vasodilator therapies?. 2021 , 11, 1111-1121	1
1210	Pulmonary veno-occlusive disease in childhood-a rare disease not to be missed. 2021 , 11, 1070-1079	0
1209	Pulmonale Hypertonie und Rechtsherzinsuffizienz. 2021 , 10, 330-338	
1208	Covid-19-induced pulmonary hypertension in children, and the use of phosphodiesterase-5 inhibitors. 10, 792	
1207	Pulmonary Hypertension in Patients With COPD: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). 2021 , 160, 678-689	12
1206	Hemodynamics for the Heart Failure Clinician: A State-of-the-Art Review. 2021 ,	6
1205	Pulmonary hypertension in patients with chronic myeloid leukemia. 2021 , 100, e26975	2
1204	Assessment of the performance of the Brazilian Portuguese Nottingham Health Profile in adult growth hormone deficiency and pulmonary hypertension. 2020 , 9, 1399	
1203	Transcriptomic profile of cationic channels in human pulmonary arterial hypertension. 2021 , 11, 15829	1
1202	Pharmacological Alteration of Cellular Mechanical Properties in Pulmonary Arterial Smooth Muscle Cells of Idiopathic Pulmonary Arterial Hypertension. 2021 , 12, 231-237	0
1201	Pediatric pulmonary hypertension. 2021 , 11, 1023-1027	
1200	Hemodynamic and prognostic impact of the diastolic pulmonary arterial pressure in children with pulmonary arterial hypertension-a registry-based analysis. 2021 , 11, 1037-1047	2

1199	Inaccuracy of a non-invasive estimation of pulmonary vascular resistance assessed by cardiovascular magnetic resonance in heart failure patients. 2021 , 11, 16597	
1198	Pulmonary hypertension phenotypes in patients with systemic sclerosis. 2021 , 30,	5
1197	Bildgebung bei pulmonaler Hypertonie. 2021 , 18, 307-313	
1196	Chronic thromboembolic pulmonary hypertension: initial experience of patients undergoing pulmonary thromboendarterectomy. 2021 , 40, 741-741	0
1195	Promising therapeutic approaches in pulmonary arterial hypertension. 2021 , 59, 127-139	4
1194	Diagnostic Delays and Characteristics of Pediatric Pulmonary Hypertension Presenting as Syncope. 2021 , 60, 443-446	0
1193	External validation of different clinical and echocardiographic scores to distinguish post- from precapillary pulmonary hypertension. 2021 , 38, 1558-1566	
1192	Targeting JP2: A New Treatment for Pulmonary Hypertension. 2021 , 2021, 2003446	1
1191	Chest high-resolution computed tomography in patients with connective tissue disease: pulmonary conditions beyond "the usual suspects". 2021 ,	1
1190	Soluble Receptor for Advanced Glycation End Products (sRAGE) Is a Sensitive Biomarker in Human Pulmonary Arterial Hypertension. 2021 , 22,	1
1189	Association between Leflunomide and Pulmonary Hypertension. 2021 , 18, 1306-1315	0
1188	A guide to echocardiographic assessment in children and adolescents with pulmonary hypertension. 2021 , 11, 1160-1177	0
1187	Chronic Thromboembolic Pulmonary Hypertension: the Bedside. 2021 , 23, 147	1
1186	Role of the Immune System Elements in Pulmonary Arterial Hypertension. 2021 , 10,	3
1185	The definition of pulmonary hypertension: history, practical implications and current controversies.. 2021 , 17, 210076	1
1184	SPECT imaging of pulmonary vascular disease in bleomycin-induced lung fibrosis using a vascular endothelium tracer. 2021 , 22, 240	
1183	Balloon pulmonary angioplasty protocol in a Portuguese pulmonary hypertension expert center. 2021 , 40, 653-665	3
1182	The relationship of ocular parameters with clinical parameters and disease-related quality of life in patients with systemic sclerosis: A cross-sectional study. 2021 , 24, 1308-1316	

- 1181 Balloon pulmonary angioplasty protocol in a Portuguese pulmonary hypertension expert center. **2021**, 40, 653-665
- 1180 Impaired pulmonary vasomotor control in exercising swine with multiple comorbidities. **2021**, 116, 51 1
- 1179 Effect of pulsatile stretch on unfolded protein response in a new model of the pulmonary hypertensive vascular wall. **2021**, 27, 101080
- 1178 The effects of pulmonary hypertension on skeletal muscle oxygen pressures in contracting rat spinotrapezius muscle. **2021**, 106, 2070-2082 1
- 1177 Echocardiographic Assessment of Pulmonary Hypertension. **2021**, 992-1010
- 1176 Clinical Presentation and Treatment of High-Risk Sarcoidosis. **2021**, 18, 1935-1947 2
- 1175 Advances in the management of pulmonary arterial hypertension. **2021**, 69, 1270-1280 4
- 1174 Dor torçica em doente com hipertensã arterial pulmonar. **2021**, 41, 73-73
- 1173 Acid-sensing ion channel 1 contributes to pulmonary arterial smooth muscle cell depolarization following hypoxic pulmonary hypertension. **2021**, 599, 4749-4762 4
- 1172 An Autopsy Case of Pulmonary Veno-Occlusive Disease Complicated with Chronic Obstructive Pulmonary Disease and Severe Pulmonary Hypertension. **2021**, 62, 1186-1190
- 1171 Prevalence, Incidence and Associates of Pulmonary Hypertension Complicating Type 2 Diabetes: Insights from the Fremantle Diabetes Study Phase 2 and National Echocardiographic Database of Australia. **2021**, 10, 0
- 1170 Special considerations for pulmonary rehabilitation in conditions other than COPD. **2021**, 145-164 2
- 1169 Ventricular-vascular coupling is predictive of adverse clinical outcome in paediatric pulmonary arterial hypertension. **2021**, 8, 1
- 1168 Sex Differences, Estrogen Metabolism and Signaling in the Development of Pulmonary Arterial Hypertension. **2021**, 8, 719058 3
- 1167 Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A prospective French multicenter cohort. **2021**, 40, 1009-1018 1
- 1166 Advanced airway management and respiratory care in decompensated pulmonary hypertension. **2021**, 1, 2
- 1165 NT-proBNP, hs-cTnT, and CRP predict the risk of cardiopulmonary outcomes in systemic sclerosis: Findings from the Canadian Scleroderma Research Group.. **2022**, 7, 62-70 2
- 1164 Overexpression of Msx1 in Mouse Lung Leads to Loss of Pulmonary Vessels Following Vascular Hypoxic Injury. **2021**, 10,

1163	Clinical features and survival in Takayasu's arteritis-associated pulmonary hypertension: a nationwide study. 2021 , 42, 4298-4305	5
1162	Epigenetic Regulation by in Cardiopulmonary Progenitor Cells Is Required to Prevent Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease. 2021 , 144, 1042-1058	3
1161	Recent trends of NF- κ B decoy oligodeoxynucleotide-based nanotherapeutics in lung diseases. 2021 , 337, 629-644	7
1160	How We Would Treat Our Own Pulmonary Hypertension if We Needed to Undergo Cardiac Surgery. 2021 ,	0
1159	Severe Pulmonary Hypertension: An Important Sequel After Severe Post-Acute COVID-19 Pneumonia. 2021 , 47, 101004	5
1158	Clinical impact of new diagnostic criteria for postcapillary pulmonary hypertension. 2021 , 339, 166	
1157	Takayasu arteritis-associated pulmonary hypertension. 2021 , 42, 4306-4308	3
1156	Cardiovascular events in perimembranous ventricular septal defect with left ventricular volume overload: a French prospective cohort study (FRANCISCO). 2021 , 31, 1557-1562	
1155	Critical Role of Caveolin-1 Loss/Dysfunction in Pulmonary Hypertension. 2021 , 9,	0
1154	Accuracy and diagnostic performance of doppler echocardiography to estimate mean pulmonary artery pressure in heart failure. 2021 , 38, 1624-1631	
1153	Innovative Anti-Inflammatory and Pro-resolving Strategies for Pulmonary Hypertension: High Blood Pressure Research Council of Australia Award 2019. 2021 , 78, 1168-1184	1
1152	Myeloid cell-specific deletion of inducible nitric oxide synthase protects against smoke-induced pulmonary hypertension in mice. <i>European Respiratory Journal</i> , 2021 ,	13.6 0
1151	Echocardiography Monitoring of Pulmonary Hypertension after Pediatric Hematopoietic Stem Cell Transplantation: Pediatric Pulmonary Arterial Hypertension and Pulmonary Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation. 2021 , 27, 786.e1-786.e8	1
1150	Reasons for refusing parenteral therapy: a qualitative study of patients with pulmonary arterial hypertension.. 2021 , 11, 20458940211046761	
1149	Low-Dose Dobutamine Stress Echocardiography for the Early Detection of Pulmonary Arterial Hypertension in Selected Patients with Systemic Sclerosis Whose Resting Echocardiography Is Non-Diagnostic for Pulmonary Hypertension. 2021 , 10,	0
1148	Uptake and Patient Perspectives on Additional Testing for Novel Disease-Associated Genes: Lessons from a PAH Cohort. 2021 , 12,	
1147	Physical Examination for the Detection of Pulmonary Hypertension: A Systematic Review. 2021 , 13, e18020	
1146	Positionspapier Schlafmedizin in der Kardiologie Update 2021. 2021 , 15, 429-461	2

1145	Sex Differences and the Role of Sex Hormones in Pulmonary Hypertension. 2021 , 42, 457-465	3
1144	Pulmonary arterial hypertension in pediatric patients undergoing high-dose carboplatin/thiotepa and stem cell transplant. 2021 , 11, 20458940211050469	1
1143	Impact of pulmonary hypertension in patients with acute exacerbation of chronic obstructive pulmonary disease and its effect on healthcare utilization. 2021 , 11, 20458940211046838	0
1142	Right Ventricular Shape Feature Quantification for Evaluation of Pulmonary Hypertension: Feasibility and Preliminary Associations With Clinical Outcome Submitted for Publication. 2022 , 144,	0
1141	Pulmonary arterial hypertension (PAH) from autopsy study: T-cells, B-cells and mastocytes detection as morphological evidence of immunologically mediated pathogenesis. 2021 , 225, 153552	4
1140	Potassium (K) channels in the pulmonary vasculature: Implications in pulmonary hypertension Physiological, pathophysiological and pharmacological regulation. 2021 , 225, 107835	8
1139	Role of echocardiography in evaluating patients with pulmonary hypertension secondary to congenital heart diseases in economically developing countries. 2021 , 101449	
1138	Computational simulation-derived hemodynamic and biomechanical properties of the pulmonary arterial tree early in the course of ventricular septal defects. 2021 , 20, 2471-2489	1
1137	Pulmonary arterial hypertension: promising advances and remaining challenges. 2021 , 69, 1268-1269	
1136	A case of pulmonary arterial hypertension with V/Q SPECT/CT that showed localized uptake of 99mTc just below the pleura and a unique distribution. 2021 , 9, e0847	
1135	Pulmonary hypertension associated with busulfan. 2021 , 11, 20458940211030170	1
1134	Mouse model of experimental pulmonary hypertension: Lung angiogram and right heart catheterization. 2021 , 11, 20458940211041512	2
1133	Fatal Excipients: An Autopsy Case Series of Excipient Lung Disease. 2021 ,	1
1132	Derivation and characterisation of endothelial cells from patients with chronic thromboembolic pulmonary hypertension. 2021 , 11, 18797	2
1131	Impact of Three Different Algorithms for the Screening of SSc-PAH and Comparison with the Decisions of a Multidisciplinary Team. 2021 , 11,	0
1130	Use of Epoprostenol in the Treatment of Pulmonary Arterial Hypertension. 2021 , 13, e18191	0
1129	Diagnostic test accuracy of artificial intelligence analysis of cross-sectional imaging in pulmonary hypertension: a systematic literature review. 2021 , 94, 20210332	0
1128	Adenylate Kinase 4-A Key Regulator of Proliferation and Metabolic Shift in Human Pulmonary Arterial Smooth Muscle Cells via Akt and HIF-1 β Signaling Pathways. 2021 , 22,	2

- 1127 Multimodal Approach of Isolated Pulmonary Vasculitis: A Single-Institution Experience. **2021**,
- 1126 Novel molecular insights and public omics data in pulmonary hypertension. **2021**, 1867, 166200 2
- 1125 Diagnostic value of cardiac natriuretic peptide on pulmonary hypertension in systemic sclerosis: A systematic review and meta-analysis. **2021**, 89, 105287 2
- 1124 Hipertensi3 pulmonar. **2021**, 13, 2359-2370
- 1123 Pulmonary hypertension: A rare but severe complication of common variable immunodeficiency. **2021**, 127, 512-513
- 1122 Mildly elevated pulmonary artery systolic pressure on echocardiography: bridging the gap in current guidelines. **2021**, 9, 1185-1191 2
- 1121 Novel Pyrazolo[3,4-b] Pyridine Derivative (HLQ2g) Attenuates Hypoxic Pulmonary Hypertension via Restoring cGKI Expression and BMP Signaling Pathway. **2021**, 12, 691405 0
- 1120 Distinct time courses and mechanics of right ventricular hypertrophy and diastolic stiffening in a male rat model of pulmonary arterial hypertension. **2021**, 321, H702-H715 1
- 1119 Cardiac acoustic biomarkers as surrogate markers to diagnose the phenotypes of pulmonary hypertension: an exploratory study. **2021**, 1 0
- 1118 Identification of novel metabolic signatures potentially involved in the pathogenesis of COPD associated pulmonary hypertension. **2021**, 17, 94 1
- 1117 Hemopexin dosing improves cardiopulmonary dysfunction in murine sickle cell disease. **2021**, 175, 95-107 1
- 1116 The association between sleep-related breathing disorders and pre-capillary pulmonary hypertension: A chicken and egg question. **2021**, 80, 100835 0
- 1115 Inflammatory markers in Eisenmenger syndrome and their association with clinical outcomes. A cross-sectional comparative study. **2021**, 342, 34-38 0
- 1114 Regulatory effects of HIF-1 β and HO-1 in hypoxia-induced proliferation of pulmonary arterial smooth muscle cells in yak. **2021**, 87, 110140 2
- 1113 Vasodilator use in precapillary pulmonary hypertension with end stage kidney disease: A single center experience. **2021**, 188, 106596 0
- 1112 The Pulmonary Circulation and the Right Ventricle in ARDS. **2022**, 746-762
- 1111 Diseases Associated with Group 5 Pulmonary Hypertension. **2022**, 723-732
- 1110 The Physiology of Interstitial Lung Disease. **2022**, 10-22

1109 Hemodynamic Study. **2022**, 201-216

1108 Group 2 Pulmonary Hypertension: Clinical Features and Treatment. **2022**, 665-677

1107 Cardiopulmonary Exercise Testing in Pulmonary Vascular Disease. **2022**, 582-596

1106 Group 3 PH: Clinical Features and Treatment. **2022**, 678-690

1105 Group 1 Clinical Features and Treatment. **2022**, 616-632

1104 Pulmonary Hypertension in Children: A Global View. **2022**, 733-745

1103 Classification of Pulmonary Vascular Disease. **2022**, 560-566

1102 Heart Failure and Pulmonary Hypertension. **2022**, 217-255

1101 Cardiac Catheterization in Pulmonary Hypertension. **2022**, 605-615

1100 Clinical Features of Pulmonary Hypertension and Right Heart Failure. **2022**, 552-559

1099 Physiology of the Normal Pulmonary Circulation. **2022**, 486-505

1098 Lung Transplantation for Pulmonary Hypertension. **2022**, 650-660

1097 An Introduction to Advanced Lung Disease. **2021**, 11-25

1096 Intercellular Communication by Vascular Endothelial Cell-Derived Extracellular Vesicles and Their MicroRNAs in Respiratory Diseases. **2020**, 7, 619697

6

1095 Cardiopulmonary Function Abnormalities in Cohort of Adults following Bronchopulmonary Dysplasia as Preterm Infants. **2021**,

1094 Systemic Sclerosis: Current State and Survival After Lung Transplantation. **2021**, 13, e12797

1093 Evolving Schema for Employing Network Biology Approaches to Understand Pulmonary Hypertension. **2021**, 1303, 57-69

1092 Carfilzomib-induced pulmonary hypertension with associated right ventricular dysfunction: A case report. **2021**, 9, 2050313X21994031

3

1091	Endothelial cells in the pathogenesis of pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	30
1090	Peripheral microangiopathy in precapillary pulmonary hypertension: a nailfold video capillaroscopy prospective study. 2021 , 22, 27		8
1089	Optimism for Interstitial Lung Disease-Associated Pulmonary Hypertension?. 2021 , 384, 376-377		3
1088	Proteomic analysis of pulmonary arterial hypertension. 2021 , 12, 20406223211047304		0
1087	State-of-the-art MR Imaging for Thoracic Diseases. 2021 ,		2
1086	Idiopathic Pulmonary Arterial Hypertension in the Pediatric Age Group. 2021 , 1-24		
1085	Systemic and pulmonary hypertension and sleep. 2021 ,		
1084	Statins for the Treatment of Pulmonary Hypertension in Patients with Chronic Obstructive Pulmonary Disease. 2020 , 11, 613761		1
1083	Pulmonary Arterial Hypertension. 2021 , 223-234		
1082	Extracellular matrix degradation pathways and fatty acid metabolism regulate distinct pulmonary vascular cell types in pulmonary arterial hypertension. 2021 , 11, 2045894021996190		2
1081	Predicting mortality during long-term follow-up in pulmonary arterial hypertension. 2021 , 7,		3
1080	Bioinformatic exploration of the immune related molecular mechanism underlying pulmonary arterial hypertension. 2021 , 12, 3137-3147		2
1079	Lung transplantation for pulmonary hypertension.. 2021 , 13, 6708-6716		0
1078	Echocardiography of the Right Heart. 2021 , 103-115		
1077	Pulmonary Embolism. 2021 , 205-266		
1076	Mechanisms of Pulmonary Hypertension in Acute Respiratory Distress Syndrome (ARDS). 2020 , 7, 624093		5
1075	Serum and pulmonary uric acid in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	6
1074	Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. 2021 , 384, 325-334		74

1073	Haemodynamic effects and potential clinical implications of inhaled nitric oxide during right heart catheterization in heart transplant candidates. 2020 , 7, 673-681	5
1072	Pulmonary Hypertension Associated with Chronic Lung Diseases: Treatment Considerations. 2020 , 79-96	1
1071	Pulmonary Veno-occlusive Disease and Pulmonary Capillary Hemangiomatosis. 2020 , 89-108	1
1070	Pulmonary arterial hypertension specific therapy: The old and the new. 2020 , 214, 107576	16
1069	[Familial pulmonary veno-occlusive disease with a composite biallelic heterozygous EIF2AK4 mutation]. 2020 , 37, 823-828	0
1068	Why, Whom, and How to Screen for Chronic Thromboembolic Pulmonary Hypertension after Acute Pulmonary Embolism. 2021 , 47, 692-701	5
1067	Exercise training decreases oxidative stress in skeletal muscle of rats with pulmonary arterial hypertension. 2020 , 1-9	1
1066	Combination therapy with pulmonary arterial hypertension targeted drugs and immunosuppression can be a useful strategy for sarcoidosis-associated pulmonary hypertension: a case report. 2021 , 5, ytaa454	2
1065	Oxygen and pulmonary arterial hypertension: effects, mechanisms, and therapeutic benefits. 2021 , 28, 127-136	2
1064	Pulmonary Artery Denervation as an Innovative Treatment for Pulmonary Hypertension With and Without Heart Failure. 2021 , 29, 89-95	0
1063	Pulmonary Hypertension in Pregnancy. 2020 , 63, 868-877	1
1062	Long-term Outcomes and Survival in Moderate-severe Portopulmonary Hypertension After Liver Transplant. 2021 , 105, 346-353	6
1061	Clinical Outcomes After Liver Transplantation in Patients With Portopulmonary Hypertension. 2021 , 105, 2283-2290	7
1060	Rare variant analysis of 4,241 pulmonary arterial hypertension cases from an international consortium implicate FBLN2, PDGFD and rare de novo variants in PAH.	4
1059	Novel risk genes and mechanisms implicated by exome sequencing of 2,572 individuals with pulmonary arterial hypertension.	2
1058	The application of big data to cardiovascular disease: paths to precision medicine. 2020 , 130, 29-38	34
1057	Virtual echocardiography screening tool to differentiate hemodynamic profiles in pulmonary hypertension. 2020 , 10, 2045894020950225	4
1056	Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort. <i>European Respiratory Journal</i> , 2021 , 57,	13.6 12

1055	ERS statement on chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	70
1054	Emerging role of cardiovascular magnetic resonance imaging in the management of pulmonary hypertension. 2020 , 29,		10
1053	Social deprivation in Scottish populations with pulmonary hypertension secondary to connective tissue disease and chronic thromboembolic disease. 2020 , 6,		1
1052	Adaptation and validation of the quality of life assessment of the Cambridge pulmonary hypertension outcome review (CAMPHOR) for Brazil. 2020 , 4, 43		5
1051	Viral hepatitis and interstitial lung diseases: can HRCT assess their relation and characterize its pattern?. 2020 , 51,		1
1050	The 6th World Symposium on Pulmonary Hypertension: what's old is new. 2019 , 8,		49
1049	The role of pulmonary arterial hypertension-targeted therapy in systemic sclerosis. 2019 , 8,		3
1048	Unusually Rapid Development of Pulmonary Hypertension and Right Ventricular Failure after COVID-19 Pneumonia. 2020 , 7, 001784		7
1047	Ten-year outcome of chronic thromboembolic pulmonary hypertension patients in a tertiary center. 2020 , 23, 105-109		3
1046	Targeting epigenetic mechanisms as an emerging therapeutic strategy in pulmonary hypertension disease. 2020 , 2, R17-R34		12
1045	Pulmonary Hypertension in Heart Failure Patients. 2020 , 6, e05		2
1044	Acute vasoreactivity testing predicts outcome of idiopathic pulmonary arterial hypertension patients with a negative acute response. 2020 , 8, 1650		1
1043	Modern Right Heart Catheterization: Beyond Simple Hemodynamics. 2020 , 19, 6-15		7
1042	App-Based Versus Standard Six-Minute Walk Test in Pulmonary Hypertension: Mixed Methods Study. 2021 , 9, e22748		2
1041	Liver disease and heart failure. 2020 , 62, 26-37		4
1040	Pulmonary Arterial Hypertension in Connective Tissue Disorders: The emerging role of screening and early diagnosis. A position paper for Greek Rheumatologists. 2019 , 30, 90-93		3
1039	Endothelial to Mesenchymal Transition in Pulmonary Vascular Diseases. 2020 , 8,		6
1038	Echocardiography for the Assessment of Pulmonary Hypertension and Congenital Heart Disease in the Young. 2020 , 11,		1

1037	Customized Massive Parallel Sequencing Panel for Diagnosis of Pulmonary Arterial Hypertension. 2020 , 11,	10
1036	Total, Bioavailable, and Free Vitamin D Levels and Their Prognostic Value in Pulmonary Arterial Hypertension. 2020 , 9,	11
1035	EURASIAN CLINICAL GUIDELINES ON DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION. 2020 , 78-122	29
1034	Clinical Updates on the Diagnosis and Management of Chronic Thromboembolic Pulmonary Hypertension. 2020 , 49, 320-330	1
1033	Pulmonary hypertension in patients with Philadelphia-negative myeloproliferative neoplasms: a single-center retrospective analysis of 225 patients. 2020 , 55, 77-84	2
1032	Screening for pulmonary arterial hypertension in systemic sclerosis: Now or never!. 2020 , 7, S187-S192	1
1031	Chronic thromboembolic pulmonary hypertension: the magic of pathophysiology.. 2022 , 11, 106-119	3
1030	Pulmonary rehabilitation for COPD: A narrative review and call for further implementation in Saudi Arabia. 2021 , 16, 299-305	3
1029	Preprocedural frailty is strongly associated with symptoms after balloon pulmonary angioplasty.. 2022 , 4, 45-51	
1028	High-intensity interval training and pulmonary hemodynamics in COPD with hypoxemia. 2021 , 8, 1984642	0
1027	Residual pulmonary hypertension after pulmonary thromboendarterectomy: incidence, pathogenesis and therapeutic options.. 2022 , 11, 163-165	1
1026	Clinical and physiological characteristics of, medically treated, chronic thromboembolic pulmonary hypertension patients in Saudi Arabia: A single center experience. 2021 , 16, 347-353	
1025	Detection of patients with chronic thromboembolic pulmonary hypertension by volumetric iodine quantification in the lung-a case control study.. 2022 , 12, 1121-1129	2
1024	Noninvasive prediction of pulmonary hemodynamics in chronic thromboembolic pulmonary hypertension by electrocardiogram-gated computed tomography. 2021 , 8, 100384	0
1023	Evidence base for specific pulmonary vasodilators in adults with congenital heart disease. 2021 , 93, 1106-1116	1
1022	Temporal trends in pulmonary arterial hypertension: Results from the COMPERA registry. <i>European Respiratory Journal</i> , 2021 ,	13.6 6
1021	An Overview of miRNAs Involved in PASM C Phenotypic Switching in Pulmonary Hypertension. 2021 , 2021, 5765029	1
1020	Update on the Treatment of Pulmonary Arterial Hypertension. 2021 , 117, 750-764	0

1019	Murine models of sickle cell disease and beta-thalassemia demonstrate pulmonary hypertension with distinctive features. 2021 , 11, 20458940211055996	2
1018	Tricuspid Annular Systolic Velocity to Left Ventricular Outflow Velocity Time Integral Ratio: Proof of Concept Utility Analysis. 2021 , 13, e18860	0
1017	Early combination of pulmonary vasodilators prevents chronic kidney disease progression in connective tissue disease-associated pulmonary hypertension. 2021 , 24, 1419-1426	
1016	Sex Differences in Pulmonary Hypertension. 2021 , 2,	0
1015	Schistosome-Associated Pulmonary Arterial Hypertension: A Review Emphasizing Pathogenesis. 2021 , 8, 724254	1
1014	Matrix Metalloproteinase 8 in Pulmonary Hypertension: The Sheep in the Wolf's Skin?. 2021 ,	1
1013	Dominating Cause of Pulmonary Hypertension May Change Over Time-Diagnostic and Therapeutic Considerations in a Patient with Pulmonary Hypertension Due to Rheumatoid Arthritis with Lung Involvement. 2021 , 11,	0
1012	Clinical application of pulmonary vascular resistance in patients with pulmonary arterial hypertension. 2021 , 16, 311	2
1011	Impaired endothelium-dependent and endothelium-independent systemic vasodilatory reserve in pulmonary hypertension regardless the clinical group: A generalized dysfunction beyond the pulmonary arteries?. 2021 , 25, 733-740	
1010	Hepatopulmonary Syndrome and Portopulmonary Hypertension: Pulmonary Vascular Complications of Liver Disease. 2021 , 11, 1-22	1
1009	Novel Prognostic Predictor for Primary Pulmonary Hypertension: Focus on Blood Urea Nitrogen. 2021 , 8, 724179	2
1008	Evaluation of Pulmonary Hypertension Using 4D Flow MRI. 2021 ,	1
1007	Pulmonary hypertension in pregnancy-the Anesthesiologist's perspective. 2021 , 5, 100234	0
1006	Computational repurposing of therapeutic small molecules from cancer to pulmonary hypertension. 2021 , 7, eabh3794	7
1005	A computational model of contributors to pulmonary hypertensive disease: impacts of whole lung and focal disease distributions. 2021 , 11, 20458940211056527	0
1004	Role of the Purinergic P2Y2 Receptor in Pulmonary Hypertension. 2021 , 18,	0
1003	Vasodilator therapy for pulmonary hypertension in children: a national study of patient characteristics and current treatment strategies.. 2021 , 11, 20458940211057891	0
1002	Considerations for inotrope and vasopressor use in critically ill patients with pulmonary arterial hypertension. 2021 , 79,	

1001	The Right Ventricular-Pulmonary Arterial Coupling and Diastolic Function Response to Therapy in Pulmonary Arterial Hypertension. 2021,	0
1000	Cardiovascular Diseases That Have Emerged From the Darkness. 2021, 10, e021095	3
999	Liver abnormalities in pulmonary arterial hypertension. 2021, 11, 20458940211054304	1
998	[Functional characterization of patients with isolated post-capillary or combined post-capillary and pre-capillary pulmonary hypertension]. 2021, 146, e88-e94	0
997	Effects of Adding Respiratory Training to Osteopathic Manipulative Treatment on Exhaled Nitric Oxide Level and Cardiopulmonary Function in Patients With Pulmonary Arterial Hypertension. 2021,	
996	Biomarkers of Pulmonary Hypertension Are Altered in Children with Down Syndrome and Pulmonary Hypertension. 2021,	1
995	Incidence and predictors of chronic thromboembolic pulmonary hypertension following acute pulmonary embolism: An echocardiography guided approach. 2021, 73, 746-750	1
994	Endothelial upregulation of mechanosensitive channel Piezo1 in pulmonary hypertension. 2021, 321, C1010-C1027	3
993	Comprensi3 actual de los biomarcadores circulantes en la hipertensi3 pulmonar debida a enfermedad de ventr3culo izquierdo. 1-9	
992	Evidence supporting a role for circulating macrophages in the regression of vascular remodeling following sub-chronic exposure to hemoglobin plus hypoxia. 2021, 11, 20458940211056806	1
991	Treatment of pulmonary hypertension associated with COPD: a systematic review.. 2022, 8,	1
990	Case report: Stepwise transition from subcutaneous treprostinil to epoprostenol in high-risk pulmonary arterial hypertension. 2021, 5, ytaa578	2
989	Exercise-induced changes of vital signs in adults with sickle cell disease. 2021, 96, 1630-1638	0
988	[Targeting activin receptor IIA ligands for the treatment of pulmonary arterial hypertension]. 2021, 37, 839-843	
987	Pulmonary arterial hypertension: An overview. 2021, 51, 37-43	
986	Pulmonary Hypertension in General Cardiology Practice. 2019, 113, 419-428	2
985	Chronic Lung Pathologies That Require Repair and Regeneration. 2019, 1-12	0
984	Pulmonary hypertension. 2019, 628-636	

- 983 Pediatric Pulmonary Hypertension and Relevant Experimental Animal Models: Pulmonary Arterial Hypertension, Bronchopulmonary Dysplasia and Congenital Diaphragmatic Hernia. **2019**, 35, 99-111
- 982 Perioperative anesthetic considerations in patients with pulmonary hypertension undergoing non-cardiac and non-obstetric surgeries. **2019**, 2, 31-39 1
- 981 Tools of the Trade: How Do You Perform and Interpret an Exercise Test?. **2019**, 18, 47-55
- 980 Anesthetic management during bronchoscopy of patients with pulmonary hypertension. **2019**, 7, 355 0
- 979 Current Clinical Management and Basic Research in Pediatric Pulmonary Hypertension. **2019**, 35, 136-152
- 978 Pulmonary Hypertension and Mortality in Patients Awaiting Kidney Transplant: Cause for Concern and Potential Opportunity. **2020**, 104, 2001-2002
- 977 Pulmonary Hypertension Due to Left Heart Disease—Combine or Not Combined? DPG In or Out? A Practical Approach to the Patient With Suspected Left Heart Disease. **2019**, 18, 87-91 1
- 976 Loss of family with sequence similarity 13, member A exacerbates pulmonary hypertension through accelerating endothelial-to-mesenchymal transition.
- 975 Multimodality Imaging of Pulmonary Hypertension. **2019**, 18, 115-125
- 974 Interstitial pneumonia with autoimmune features. **2019**, 140-152
- 973 What Echocardiography Can Reliably Tell Us About Our Pulmonary Hypertension Patients. **2019**, 18, 110-114 1
- 972 Ask the Expert: Radiographic Signs and Patterns of Pulmonary Hypertension: A Pictorial Essay. **2019**, 18, 141-151 0
- 971 Pulmonary hypertension in patients with sarcoidosis: A single-center experience. **2021**, 25, 36-41 1
- 970 Echocardiography in the ICU. **2020**, 1-24
- 969 [Protective role of myelocytic nitric oxide synthases in pulmonary hypertension due to lung diseases and/or hypoxia]. **2020**, 155, 69-73
- 968 4D Flow MR Imaging for Pulmonary Hypertension. **2020**, 40, 1-6
- 967 Role of echocardiography in screening for portopulmonary hypertension in liver transplant candidates: a meta-analysis. **2020**, 8, e9243 0
- 966 Soluble Guanylate Cyclase Stimulators for Chronic Thromboembolic Pulmonary Hypertension Patients Treatment: New Data. **2020**, 16, 317-323 0

- 965 Türkiye'de tersiyer bir merkezde sistemik skleroz hastalarında pulmoner hipertansiyon taraması- kesitsel orjinal çalışmada.
- 964 The cardiovascular system in idiopathic pulmonary fibrosis. **2020**, 198-211
- 963 Cardiovascular implications of pulmonary hypertension due to chronic respiratory diseases. **2020**, 167-183
- 962 Predictors of Long-term Outcomes in Patients With Connective Tissue Disease Associated With Pulmonary Arterial Hypertension. **2021**, 27, e371-e377 1
- 961 Multifactorial Pulmonary Hypertension in Systemic Sclerosis. **2020**, 12, e9144
- 960 Dasatinib-Induced Pulmonary Arterial Hypertension. **2020**, 28, e695-e696 0
- 959 Combined Emphysema and Interstitial Lung Disease as a Rare Presentation of Pulmonary Involvement in a Patient with Chronic Visceral Acid Sphingomyelinase Deficiency (Niemann-Pick Disease Type B). **2020**, 21, e923394
- 958 Anesthetic and Circulatory Management of Patients with Pulmonary Hypertension. **2020**, 40, 520-526
- 957 Editorial: Pulmonary Hypertension in the Modern Era: Science and Clinical Practice. **2021**, 8, 785181
- 956 Supra-systemic pulmonary hypertension after complicated percutaneous mitral balloon valvuloplasty: a case report and review of literature. **2021**, 21, 258
- 955 Cold exposure aggravates pulmonary arterial hypertension through increased miR-146a-5p, miR-155-5p and cytokines TNF- α , IL-1 β and IL-6. **2021**, 287, 120091 6
- 954 Full recovery of right ventricular systolic function in children undergoing bilateral lung transplantation for severe PAH.. **2021**, 0
- 953 Heart Failure with Preserved Ejection Fraction and Cardiomyopathy: an Under-recognized Complication of Systemic Sclerosis. **2021**, 23, 1
- 952 Cardiovascular Events, Sleep Apnoea, and Pulmonary Hypertension in Primary Sjögren's Syndrome: Data from the French Health Insurance Database. **2021**, 10, 0
- 951 Pulmonary hypertension in children with chronic bronchopulmonary pathology: a pulmonologist's perspective to the problem. **2021**, 300-309
- 950 Prevalence of Micronutrient Deficiencies and Relationship with Clinical and Patient-Related Outcomes in Pulmonary Hypertension Types I and IV. **2021**, 13, 1
- 949 Dapagliflozin has No Protective Effect on Experimental Pulmonary Arterial Hypertension and Pulmonary Trunk Banding Rat Models. **2021**, 12, 756226 2
- 948 Beyond Scleroderma: Pulmonary Arterial Hypertension in Patients with Other Connective Tissue Diseases. **2020**, 51-60

- 947 Pulmonary Hemodynamics and Outcome in a Large Cohort of Patients with Sinus Venosus Septal Defect. **2020**, 15, 69-78
- 946 Clinical Outcomes of Myocarditis after Moderate-Dose Steroid Therapy in Systemic Sclerosis: A Pilot Study. **2020**, 2020, 8884442 3
- 945 Exercise Training for Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. **2021**, 23, 442-454
- 944 Occult pulmonary arterial hypertension in patients with previous pulmonary tuberculosis. **2020**, 26, 1
- 943 Imaging of Pulmonary Hypertension in Congenital Heart Disease. **2021**, 499-514
- 942 Peut-on mesurer de façon fiable les pressions pulmonaires en Écho-Doppler ?. **2020**, 2020, 3-9
- 941 Selexipag for the treatment of pulmonary arterial hypertension. **2021**, 15, 583-595 1
- 940 Assessment of the performance of the Brazilian Portuguese Nottingham Health Profile in adult growth hormone deficiency and pulmonary hypertension. **2020**, 9, 1399
- 939 Pulmonary arterial hypertension associated with congenital heart disease: classification and pathophysiology. **2020**, 4, 1
- 938 Feasibility and safety of a telemetric pulmonary artery pressure monitoring system in acute and chronic porcine models of pulmonary hypertension.
- 937 The investigation and diagnosis of pulmonary hypertension in adults with congenital heart disease. **2020**, 4, 1
- 936 Astragaloside IV blocks monocrotaline-induced pulmonary arterial hypertension by improving inflammation and pulmonary artery remodeling. **2021**, 47, 595-606 4
- 935 Critical Neonatal Congenital Heart Disease – A Rare Complication after Successful Surgical Correction. **2020**, 6, 104-108 2
- 934 Thrombotic Lesion of the Pulmonary Vessels in Patients with Pulmonary Embolism. **2020**, 16, 1002-1008
- 933 Pulmonary hemodynamics and remodeling of the right heart in patients with COPD depending on the risk group, the direction of drug correction. **2020**, 30, 756-763 0
- 932 Clinical and functional recovery in a patient with pulmonary hypertension after bariatric surgery. **2021**, 38, 571-573 1
- 931 Epidemiology and Diagnosis of Chronic Thromboembolic Pulmonary Hypertension. **2020**, 181-202
- 930 Epidemiology of Pediatric Pulmonary Hypertension. **2020**, 1-17

- 929 The diagnostic challenge in pulmonary tumour embolism in cancer: a case report and literature review. **2020**, 24, 258-262
- 928 Exercise Pulmonary Hypertension. **2020**, 1-27
- 927 How did the updated hemodynamic definitions affect the frequency of pulmonary hypertension in patients with systemic sclerosis?. **2021**, 25, 30-35
- 926 Pulmonary Hypertension in Sickle Cell Disease: Current Controversies and Clinical Practices. **2020**, 123-134 1
- 925 Controversies in the Management of Pulmonary Hypertension in the Setting of Lung Disease. **2020**, 109-122
- 924 Isolated Postcapillary and Combined Pre- and Postcapillary Pulmonary Hypertension. **2020**, 61-70
- 923 THE DIFFICULTIES IN THE DIAGNOSIS OF PULMONARY HYPERTENSION ASSOCIATED WITH CHRONIC LUNG DISEASE. **2020**, 73, 1853-1860
- 922 Echocardiographic Screening Methods for Pulmonary Hypertension: A Practical Review. **2020**, 28, 1-9 0
- 921 Current Approach to Chronic Thromboembolic Disease Without Pulmonary Hypertension. **2020**, 71-87
- 920 Pulmonary Hypertension in Chronic Kidney Disease and End-Stage Renal Disease. **2020**, 173-194 1
- 919 Management of Pulmonary Hypertension in the Hospital Setting. **2020**, 155-170
- 918 [Management of right ventricular failure in pulmonary vascular diseases]. **2020**, 37, 171-179 0
- 917 An Infantile Case of Pulmonary Veno-Occlusive Disease Confirmed by Autopsy. **2020**, 36, 65-71
- 916 Perioperative Management of Pulmonary Hypertension. a Review. **2021**, 7, 83-96 0
- 915 External validation of a refined 4-strata risk assessment score from the French pulmonary hypertension Registry. *European Respiratory Journal*, **2021**, 13.6 4
- 914 Sex and gender in pulmonary arterial hypertension. **2021**, 30, 2
- 913 Comparison Of Chest And Wrist Based Actigraphy In Pulmonary Arterial Hypertension. 0
- 912 Response. **2021**, 160, e541

- 911 The roles of immune system and autoimmunity in pulmonary arterial hypertension: A Review. **2021**, 102094 1
- 910 A 24-Year-Old Woman With Dyspnea, Chest Pain, and Dry Cough. **2021**, 160, e503-e506
- 909 The physiologic basis of pulmonary arterial hypertension. *European Respiratory Journal*, **2021**, 13.6 5
- 908 The Impact of Clinical Treatment Plan of the New Definition of Precapillary Pulmonary Hypertension. **2021**, 160, e540-e541
- 907 Risk of Pulmonary Arterial Hypertension During Qing-Dai Use for the Treatment of Ulcerative Colitis. **2020**, 84, 1235-1236 1
- 906 [The place of riociguat in the treatment of patients with pulmonary arterial hypertension associated with systemic connective tissue diseases]. **2020**, 60, 92-101
- 905 Plexiform Lesions in Pulmonary Arterial Hypertension: Are we Getting Closer to Manage with More Patience and Rigor?. **2020**, 115, 491-492 1
- 904 Optimal Cut-Off of Tricuspid Regurgitation Velocity According to the New Definition of Pulmonary Hypertension - Its Use in Predicting Pulmonary Hypertension. **2020**, 2, 625-629 0
- 903 Update on pediatric pulmonary arterial hypertension. **2021**, 36, 67-79 3
- 902 Pulmonary thromboendarterectomy in Portugal: Initial experience. **2020**, 39, 505-512
- 901 [Management of pulmonary arteriovenous malformation with pulmonary hypertension]. **2020**, 37, 671-676
- 900 Donor-recipient predicted heart mass ratio and right ventricular-pulmonary arterial coupling in heart transplant. **2021**, 59, 847-854 2
- 899 Top End Pulmonary Hypertension Study: Understanding Epidemiology, Therapeutic Gaps and Prognosis in Remote Australian Setting.
- 898 Pulmonary hypertension in hereditary haemorrhagic telangiectasia is associated with multiple clinical conditions. **2021**, 7,
- 897 Cardiac catheterization in pulmonary hypertension: doing it right, with a catheter on the left. **2020**, 10, 1718-1724 1
- 896 Approach to a patient with pulmonary hypertension. **2019**, 16, 478-481 1
- 895 SPECT and PET imaging of adrenomedullin receptors: a promising strategy for studying pulmonary vascular diseases. **2019**, 9, 203-215 1
- 894 Cancer and pulmonary hypertension: Learning lessons and real-life interplay. **2020**, 2020, e202010 1

- 893 Pulmonary vascular disease in Africa: Lessons from registries. **2020**, 2020, e202002
- 892 Pulmonary hypertension: From an orphan disease to a global epidemic. **2020**, 2020, e202005 3
- 891 The haemodynamic assessment of patients with pulmonary arterial hypertension. **2020**, 2020, e202004
- 890 Chronic thromboembolic pulmonary hypertension - still evolving. **2020**, 2020, e202011 1
- 889 Getting to the bottom of right heart failure. **2020**, 10, 1517-1521
- 888 Comparison of efficacy between sequential ventilation and conventional invasive mechanical ventilation in the treatment of pulmonary hypertension complicated with respiratory failure. **2020**, 10, 231-239
- 887 Management of Pulmonary Arterial Hypertension Patients with World Health Organization Functional Class II. **2020**, 36, 583-587
- 886 A Veteran Presenting With Chronic Progressive Dyspnea on Exertion. **2020**, 37, 522-526
- 885 miR-320-3p regulates the proliferation, migration and apoptosis of hypoxia-induced pulmonary arterial smooth muscle cells via KLF5 and HIF1 β . **2021**, 13, 2283-2295 1
- 884 Partial closure with a self-made fenestrated device of secundum atrial septal defect with severe pulmonary artery hypertension in adults. **2021**, 18, 498-504
- 883 Management of intrapulmonary hemorrhage in patients undergoing pulmonary thrombo-endarterectomy. **2021**, 24, 384-388 0
- 882 Pulmonary Arterial Hypertension in Patients Infected with the Human Immunodeficiency Virus. **2022**, 40, 45-54 1
- 881 Pulmonary Hypertension Associated with Connective Tissue Disease. **2022**, 40, 29-43 1
- 880 Update on Medical Management of Pulmonary Arterial Hypertension. **2022**, 40, 13-27 1
- 879 Management of Pulmonary Hypertension in the Pediatric Patient. **2022**, 40, 115-127 2
- 878 Pulmonary Hypertension in Adults with Congenital Heart Disease. **2022**, 40, 55-67 0
- 877 Surgical Management of Chronic Thromboembolic Pulmonary Hypertension. **2022**, 40, 89-101
- 876 Left Heart Disease-Related Pulmonary Hypertension. **2022**, 40, 69-76 3

- 875 Interventional Management of Chronic Thromboembolic Pulmonary Hypertension. **2022**, 40, 103-114
- 874 Pulmonary Hypertension. **2022**, 40, xi-xii
- 873 Progress in Pulmonary Rehabilitation. **2021**, 58, 1106-1112
- 872 Chronic thromboembolic pulmonary hypertension: Initial experience of patients undergoing pulmonary thromboendarterectomy. **2021**, 40, 741-752 0
- 871 Kardiale Beteiligung bei Sarkoidose. **2022**, 1-14
- 870 Incidence and outcomes of COVID-19 in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: data from the Hellenic pulmOnary hyPertension rEgistry (HOPE). **2021**, 1
- 869 Pharmacology and pharmacovigilance of protein kinase inhibitors.. **2021**, 1
- 868 Factors associated with portopulmonary hypertension. **2021**, 51, 1179-1180
- 867 Predictive value of chest HRCT for survival in idiopathic pulmonary arterial hypertension. **2021**, 22, 293
- 866 PATET ratio by Doppler echocardiography: noninvasive detection of pediatric pulmonary arterial hypertension. **2021**,
- 865 Selexipag and the Pulmonary Hypertension Continuum. **2021**, 1
- 864 Comparison of Dasatinib- and Imatinib-Related Cardiotoxic Adverse Events in Japanese Patients With Chronic Myeloid Leukemia and Gastrointestinal Stromal Tumor.. **2022**, 4, 1-8 0
- 863 Estimates of Prevalence of Pulmonary Hypertension according to Different International Definitions. **2021**, 2021, 1385322
- 862 Expanding the Evidence of a Semi-Dominant Inheritance in Associated with Pulmonary Arterial Hypertension. **2021**, 10, 2
- 861 Neutrophil-Lymphocyte Ratio as an Independent Predictor of Survival in Pulmonary Arterial Hypertension: An Exploratory Study.. **2022**, 4, 357-363 0
- 860 A Systematic Evaluation of Quality, Accuracy, and Reliability of Internet Websites about Pulmonary Arterial Hypertension. **2021**, 1
- 859 The clinical characteristics of patients with pulmonary hypertension combined with obstructive sleep apnoea. **2021**, 21, 378 0
- 858 Prognostic impact of hypochromic erythrocytes in patients with pulmonary arterial hypertension. **2021**, 22, 288 0

857	Pulmonary arterial hypertension and CFTR: the paradox of going forward by tacking sideways!. <i>European Respiratory Journal</i> , 2021 , 58,	13.6
856	Chronic Thromboembolic Pulmonary Hypertension (CTEPH). 2022 , 235-247	
855	Patient-Specific Computational Analysis of Hemodynamics in Adult Pulmonary Hypertension. 2021 , 49, 3465	0
854	Screening for portopulmonary hypertension using computed tomography-based measurements of the main pulmonary artery and ascending aorta diameters in patients with portal hypertension. 2021 ,	0
853	Comparison of Repetitive Cardiac Output Measurements at Rest and End-Exercise by Direct Fick Using Pulse Oximetry vs. Blood Gases in Patients With Pulmonary Hypertension. 2021 , 8, 776956	1
852	Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone. 2021 ,	0
851	Interplay of sex hormones and long-term right ventricular adaptation in a Dutch PAH-cohort.. 2021 ,	0
850	Role of Store-Operated Ca Entry in the Pulmonary Vascular Remodeling Occurring in Pulmonary Arterial Hypertension.. 2021 , 11,	1
849	The role of immune cells in pulmonary hypertension: Focusing on macrophages. 2021 , 83, 153-153	2
848	Visualizing Pulmonary Vascular Disease With CT Scanning. 2021 , 160, 1998-1999	1
847	k-t accelerated multi-VENC 4D flow MRI improves vortex assessment in pulmonary hypertension. 2021 , 145, 110035	1
846	A Wrinkle in Time: Circadian biology in pulmonary vascular health and disease. 2021 ,	1
845	Protective effects of progesterone on pulmonary artery smooth muscle cells stimulated with Interleukin 6 via blocking the shuttling and transcriptional function of STAT3. 2021 , 102, 108379	
844	Lowering Tricuspid Regurgitant Velocity Threshold to Identify a Mean Pulmonary Artery Pressure ≥ 20 mm Hg: Is It Time to Release the Hounds?. 2021 , 160, 2000-2002	
843	Pulmonary Hypertension. 2021 ,	
842	Encyclopedia of Molecular Pharmacology. 2021 , 1328-1336	
841	Prevalence and etiologies of pulmonary hypertension at Somalia-Turkey Training and Research Hospital in Mogadishu.. 2021 , 40, 215	2
840	Effect of pulmonary artery catheter balloon inflation on pulmonary hemodynamics.. 2022 , 12, 37-41	

- 839 Pulmonary hypertension in India: Need for organized approach.. **2022**, 39, 3-4
- 838 Chronic Daily House Dust Mite Exposure in Mice is an Effective Model to Quantify the Effect of Pharmacologic Agents on Discrete Stages of Artery Remodeling in Pulmonary Hypertension.. **2022**, 12, e4273
- 837 Sleep architecture in patients with interstitial lung disease with and without pulmonary hypertension.. **2022**, 1 1
- 836 Interplay Between Thyroid Hormone Status and Pulmonary Hypertension in Graves' Disease: Relevance of the Assessment in Thyrotoxic and Euthyroid Patients.. **2021**, 12, 780397
- 835 The haemodynamic assessment of patients with pulmonary arterial hypertension. **2020**, 2020, e202004 0
- 834 Pulmonary hypertension: From an orphan disease to a global epidemic. **2020**, 2020, e202005 4
- 833 Cancer and pulmonary hypertension: Learning lessons and real-life interplay. **2020**, 2020, e202010 1
- 832 Chronic thromboembolic pulmonary hypertension is still evolving. **2020**, 2020, e202011 1
- 831 Pulmonary vascular disease in Africa: Lessons from registries. **2020**, 2020, e202002
- 830 Getting to the bottom of right heart failure. **2020**, 10, 1517-1521
- 829 A Veteran Presenting With Chronic Progressive Dyspnea on Exertion. **2020**, 37, 522-526
- 828 2020 Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. **2022**, 26, 4683 9
- 827 [Triple combination therapy with macitentan, riociguat, and selexipag in a patient with idiopathic pulmonary arterial hypertension (functional class III)]. **2021**, 61, 104-107
- 826 Can serum 8-hydroxy-2'-deoxyguanosine levels reflect the severity of pulmonary arterial hypertension?. **2021**, 67, 1437-1442 1
- 825 Circulating Interleukin-7 in Human Pulmonary Arterial Hypertension.. **2021**, 8, 794549
- 824 A case of hepatic abscess - the penny dropped!. **2021**, 51, 71-72
- 823 The Roles of S100A4 and the EGF/EGFR Signaling Axis in Pulmonary Hypertension with Right Ventricular Hypertrophy.. **2022**, 11, 1
- 822 Pulmonary vascular distensibility with passive leg raise is comparable to exercise and predictive of clinical outcomes in pulmonary hypertension.. **2022**, 12, e12029 2

821	RAS protein activator like 2 promotes the proliferation and migration of pulmonary artery smooth muscle cell through AKT/mammalian target of Rapamycin complex 1 pathway in pulmonary hypertension.. 2022 ,	1
820	Epigenetic Mechanisms as Emerging Therapeutic Targets and Microfluidic Chips Application in Pulmonary Arterial Hypertension.. 2022 , 10,	1
819	Anesthesia in Children With Pulmonary Hypertension: Clinically Significant Serious Adverse Events Associated With Cardiac Catheterization and Noncardiac Procedures.. 2022 ,	0
818	The Right Heart. 2022 , 161-177	
817	MicroRNA-325-3p Targets Human Epididymis Protein 4 to Relieve Right Ventricular Fibrosis in Rats with Pulmonary Arterial Hypertension.. 2022 , 2022, 4382999	1
816	Physiological aspects of cardiopulmonary dysanapsis on exercise in adults born preterm.. 2021 ,	1
815	Clinical insights into pulmonary hypertension in chronic obstructive pulmonary disease.. 2022 , 12, e12006	0
814	Effect of pulmonary hypertension on 5-year outcome of kidney transplantation.. 2022 , 12, e12010	1
813	Stem Cell and Exosome Therapy in Pulmonary Hypertension.. 2022 , 52, 110-122	1
812	Treatment of Portopulmonary Hypertension (PoPH): A Review. 2022 , 100071	
811	RNA Modification Signature of Peripheral Blood as a Potential Diagnostic Marker for Pulmonary Hypertension.. 2022 , HYPERTENSIONAHA12118724	0
810	N7-methylguanosine modification of lncRNAs in a rat model of hypoxic pulmonary hypertension: a comprehensive analysis.. 2022 , 23, 33	0
809	Histologic and proteomic remodeling of the pulmonary veins and arteries in a porcine model of chronic pulmonary venous hypertension.. 2022 ,	0
808	Relationship between Dasatinib-induced Pulmonary Hypertension and Drug Dose.. 2022 ,	0
807	Is derived vectorcardiography a potential screening tool for pulmonary hypertension?. 2021 , 70, 79-83	0
806	Ventricular mass discriminates pulmonary arterial hypertension as redefined at the Sixth World Symposium on Pulmonary Hypertension.. 2022 , 12, e12005	
805	Pulmonale Hypertonie. 2022 , 419-438	
804	Inflammatory Glycoprotein 130 Signaling Links Changes in Microtubules and Junctophilin-2 to Altered Mitochondrial Metabolism and Right Ventricular Contractility.. 2021 , CIRCHEARTFAILURE121008574	1

803	Simulation of Cardiac Flow under the Septal Defect Based on Lattice Boltzmann Method.. 2022 , 24,	
802	Comparing Diagnosis and Treatment of Pulmonary Hypertension Patients at a Pulmonary Hypertension Center versus Community Centers.. 2022 , 10,	0
801	Utility of Automated Cardiac Chamber Volumetry by Non-Gated CT Pulmonary Angiography for Detection of Pulmonary Hypertension Using the 2018 Updated Hemodynamic Definition.. 2022 ,	
800	hsa_circWDR37_016 Regulates Hypoxia-Induced Proliferation of Pulmonary Arterial Smooth Muscle Cells.. 2022 , 2022, 7292034	1
799	A Clinical Approach to Multimodality Imaging in Pulmonary Hypertension.. 2021 , 8, 794706	1
798	Disease characteristics and clinical outcome over two decades from the Swiss pulmonary hypertension registry.. 2022 , 12, e12001	0
797	Hemodynamic profiles in a series of patients undergoing right heart catheterization. Experience in one center of Medellin, Colombia.. 2022 , 92, 53-59	
796	E-REVEAL Lite 2.0 scoring for early prediction of disease progression in pulmonary arterial hypertension.. 2022 , 12, e12026	1
795	Prevalence, incidence, and survival of pulmonary arterial hypertension: A systematic review for the global burden of disease 2020 study.. 2022 , 12, e12020	1
794	Hemodynamic Evaluation of the Right Heart-Pulmonary Circulation Unit in Patients Candidate to Transjugular Intrahepatic Portosystemic Shunt.. 2022 , 11,	
793	Prevalence of Sarcoidosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis.. 2021 , 8, 809594	0
792	Surgical management of giant pulmonary artery aneurysms in patients with severe pulmonary arterial hypertension.. 2022 ,	1
791	Clinical impact of pulmonary hypertension on the outcomes of acute myocardial infarction patients with or without chronic obstructive pulmonary disease.. 2022 , 101, e28627	
790	Epidemiology and outcomes of pulmonary hypertension in the cardiac intensive care unit.. 2022 ,	0
789	Using health administrative data to identify patients with pulmonary hypertension: A single center, proof of concept validation study in Ontario, Canada.. 2022 , 12, e12040	
788	Caspase-4/11-Mediated Pulmonary Artery Endothelial Cell Pyroptosis Contributes to Pulmonary Arterial Hypertension.. 2022 , HYPERTENSIONAHA12117868	3
787	Pulsatile pulmonary artery pressure in a large animal model of chronic thromboembolic pulmonary hypertension: Similarities and differences with human data.. 2022 , 12, e12017	
786	Cardiac geometry, function and mechanics in left ventricular non-compaction cardiomyopathy with preserved ejection fraction.. 2022 , 1	1

785	Left atrial ablation for the management of atrial tachyarrhythmias in patients with pulmonary hypertension: A case series.. 2022 , 8, 275-279		
784	Pulmonary Hypertension in Pregnancy: A Positive Outcome with a Multidisciplinary Team and Individualized Treatment Plan.. 2022 ,		
783	Long-Term Outcomes in Adult Patients With Pulmonary Hypertension After Percutaneous Closure of Atrial Septal Defects.. 2021 , CIRCINTERVENTIONS121011110		1
782	Haemoptysis in Pulmonary Arterial Hypertension Associated with Congenital Heart Disease: Insights on Pathophysiology, Diagnosis and Management.. 2022 , 11,		1
781	Dasatinib-induced Pulmonary Hypertension.. 2022 ,		
780	Inhibiting Pyruvate Kinase Muscle Isoform 2 Regresses Group 2 Pulmonary Hypertension Induced by Supra-coronary Aortic Banding.. 2022 , e13764		1
779	Critical care management of the patient with pulmonary hypertension.. 2021 ,		0
778	Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality.. 2022 ,		9
777	Echocardiographic probability of pulmonary hypertension: a validation study.. <i>European Respiratory Journal</i> , 2022 ,	13.6	4
776	Smooth muscle Rac1 contributes to pulmonary hypertension.. 2022 ,		1
775	Determinants of altered left ventricular suction in pre-capillary pulmonary hypertension.. 2022 ,		
774	Chronic Thromboembolic Pulmonary Hypertension: An Update.. 2022 , 12,		4
773	The substitution of SERCA2 redox cysteine 674 promotes pulmonary vascular remodeling by activating IRE1 α XBP1s pathway. 2022 ,		1
772	Proteomics discovery of pulmonary hypertension biomarkers: Insulin-like growth factor binding proteins are associated with disease severity.. 2022 , 12, e12039		0
771	An emerging strategy for targeted therapy of pulmonary arterial hypertension: Vasodilation plus vascular remodeling inhibition.. 2022 ,		0
770	Different cytokine patterns in BMPR2-mutation positive patients and pulmonary arterial hypertension patients without mutations and their influence on survival.. 2022 ,		1
769	Numerical predictions of shear stress and cyclic stretch in pulmonary hypertension due to left heart failure.. 2022 , 21, 363		2
768	Mending the MELD: An in-depth review of the past, present, and future portopulmonary hypertension MELD exception.. 2022 ,		0

767	Progression of pulmonary veno-occlusive disease without pulmonary hypertension.. 2022 , 12, e12046	0
766	Chronic thromboembolic pulmonary hypertension: a review of risk factors, management and current challenges.. 2022 ,	0
765	Outcome of Surgery for Chronic Thromboembolic Pulmonary Disease without Pulmonary Hypertension.. 2022 ,	0
764	Prevalence of musculoskeletal pain and its impact on quality of life and functional exercise capacity in patients with pulmonary arterial hypertension.. 2022 , 193, 106759	0
763	Treating Inflammation Associated with Pulmonary Hypertension: An Overview of the Literature.. 2022 , 15, 1075-1083	0
762	The impact of sex chromosomes in the sexual dimorphism of pulmonary arterial hypertension.. 2022 ,	0
761	Mitochondrial Metabolism, Redox, and Calcium Homeostasis in Pulmonary Arterial Hypertension.. 2022 , 10,	5
760	Prevalence of moderate to severe lower urinary tract symptoms in systemic sclerosis.. 2022 ,	
759	Magnetic resonance imaging in pulmonary hypertension: an overview of current applications and future perspectives.. 2022 , 152, w30055	1
758	Pulmonary Hypertension in Interstitial Lung Disease.. 2022 ,	
757	Two Siblings With Peripheral Pulmonary Arterial Stenosis: Pulmonary Angiography of Advanced and Early Stages.. 2022 , 161, e75-e80	1
756	A case report of a 37-year-old woman with pulmonary arterial hypertension first presented during her 3rd pregnancy and favourable long-term vasoreactive response.. 2022 , 6, ytac031	
755	Metabolic profile in endothelial cells of chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension.. 2022 , 12, 2283	0
754	The Impact of Breathing Hypoxic Gas and Oxygen on Pulmonary Hemodynamics in Patients With Pulmonary Hypertension.. 2022 , 9, 791423	1
753	The Different Effects of Direct Bilirubin on Portopulmonary Hypertension and Idiopathic Pulmonary Arterial Hypertension. 2022 , 2022, 1-10	0
752	Diastolic Dysfunction Is Unmasked on Exercise in Patients With Asymptomatic, Severe Aortic Stenosis: An Invasive Hemodynamic Study.. 2022 , CIRCHEARTFAILURE121009253	0
751	Effect of mode of intraoperative support on primary graft dysfunction after lung transplant.. 2022 ,	2
750	Advances in treatment of chronic thromboembolic pulmonary hypertension.. 2022 , 212, 30-37	1

749	IL-33/ST2 receptor-dependent signaling in the development of pulmonary hypertension in Sugen/hypoxia mice.. 2022 , 10, e15185	1
748	The Role of Thyroid Disorders, Obesity, Diabetes Mellitus and Estrogen Exposure as Potential Modifiers for Pulmonary Hypertension.. 2022 , 11,	0
747	[44/f-Dyspnea and fatigue : Preparation for the medical specialist examination: part 103].. 2022 , 63, 15-20	
746	[Involvement of the Piezo1 and TRPV4 stretch-activated channels in pulmonary hypertension].. 2022 ,	0
745	POINT: Did the World Symposium on Pulmonary Hypertension Get It Right in Redefining Abnormal Pulmonary Arterial Pressure? Yes.. 2022 , 161, 311-312	0
744	COUNTERPOINT: Did the World Symposium on Pulmonary Hypertension Get It Right in Redefining Abnormal Pulmonary Arterial Pressure? No.. 2022 , 161, 313-315	0
743	Rebuttal From Dr Kovacs.. 2022 , 161, 315-316	
742	Cytokine signatures differentiate systemic sclerosis patients at high versus low risk for pulmonary arterial hypertension.. 2022 , 24, 39	1
741	Influence of Upright Versus Supine Position on Resting and Exercise Hemodynamics in Patients Assessed for Pulmonary Hypertension.. 2022 , 11, e023839	0
740	A review of genetically-driven rodent models of pulmonary hypertension.. 2022 , 144, 106970	0
739	A Meta-analysis of the efficacy of pulmonary artery denervation in the treatment of pulmonary hypertension.. 2022 , 53, 42-50	0
738	Clinical Relevance of Right Atrial Functional Response to Treatment in Pulmonary Arterial Hypertension.. 2021 , 8, 775039	1
737	Pulmonary Arterial Hypertension.. 2021 , 385, 2361-2376	27
736	Hypertension pulmonaire. 2021 , 202-206	
735	1,8-Cineole Ameliorates Right Ventricle Dysfunction Associated with Pulmonary Arterial Hypertension by Restoring Connexin 43 and Mitochondrial Homeostasis.	
734	OUP accepted manuscript.	6
733	Cell-to-Cell Crosstalk: A New Insight into Pulmonary Hypertension.. 2022 , 1	0
732	Compensatory roles of Protein Related to DAN and Cerberus (PRDC) decrease in pulmonary arterial hypertension.. 2022 , 18, 2372-2391	

731	Acute and Chronic Lung Disease from Recreational Inhalants. 2022 , 149-177	
730	Clinical Application of 4D Flow MR Imaging to Pulmonary Hypertension.. 2022 , 21,	2
729	The Effects of Ginsenoside Compound K on Pulmonary Arterial Hypertension Rats: Suppression of Vascular Remodeling and Inhibiting NF- κ B/NLRP3 Inflammasome Signalling.	
728	Pulmonary Hypertension and Air Pollution. 2022 , 179-186	
727	Presentation of Congenital Portosystemic Shunts in Children.. 2022 , 9,	1
726	Cardiac disease in pregnancy. 2022 ,	0
725	Metabolism, Mitochondrial Dysfunction, and Redox Homeostasis in Pulmonary Hypertension.. 2022 , 11,	2
724	High prevalence of occult left ventricular diastolic dysfunction detected by exercise stress test in systemic sclerosis.. 2022 , 12, 2423	1
723	Puerarin-V prevents the progression of hypoxia- and monocrotaline-induced pulmonary hypertension in rodent models.. 2022 ,	2
722	Spectral Detector CT-Derived Pulmonary Perfusion Maps and Pulmonary Parenchyma Characteristics for the Semiautomated Classification of Pulmonary Hypertension.. 2022 , 9, 835732	0
721	Human Immune Deficiency Virus-Associated Pulmonary Arterial Hypertension: A Report from the Pulmonary Hypertension Association Registry.. 2022 ,	2
720	SUR1 as a New Therapeutic Target for Pulmonary Arterial Hypertension.. 2022 ,	1
719	Molecular hydrogen is a promising therapeutic agent for pulmonary disease.. 2022 , 23, 102-122	2
718	Dysregulated Immunity in Pulmonary Hypertension: From Companion to Composer.. 2022 , 13, 819145	1
717	Screening Strategies for Pulmonary Hypertension in Patients with Interstitial Lung Disease: A Multidisciplinary Delphi Study.. 2022 ,	2
716	ERS statement on chronic thromboembolic pulmonary hypertension. 2022 , 32, 13-52	
715	Riociguat in Patients with CTEPH and Advanced Age and/or Comorbidities.. 2022 , 11,	1
714	Description of damage in different clusters of patients with antiphospholipid syndrome.. 2022 , 9612033221079781	

713	Endothelial Senescence: A New Age in Pulmonary Hypertension.. 2022 , 130, 928-941	2
712	Serum markers of cardiac complications in a systemic sclerosis cohort.. 2022 , 12, 4661	0
711	Hereditary haemorrhagic telangiectasia with atrial septal defect and pulmonary hypertension during advanced pregnancy: a case report and literature review.. 2022 , 50, 3000605221085427	
710	Lung-Kidney Interactions and Their Role in Chronic Kidney Disease-Associated Pulmonary Diseases.. 2022 ,	0
709	Connexins may play a critical role in cigarette smoke-induced pulmonary hypertension.. 2022 ,	
708	Finding Pulmonary Arterial Hypertension-Switching to Offense to Mitigate Disease Burden.. 2022 ,	2
707	[French practical guidelines for the diagnosis and management of IPF - '2021 update, short version].. 2022 ,	1
706	Pregnancy in Congenital Heart Disease, Complicated by Pulmonary Arterial Hypertension-A Challenging Issue for the Pregnant Woman, the Foetus, and Healthcare Professionals.. 2022 , 58,	0
705	Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension.. 2022 , 12, 5289	0
704	Experimental animal models of pulmonary hypertension: Development and challenges.. 2022 ,	1
703	MRI Feature Tracking Strain in Pulmonary Hypertension: Utility of Combined Left Atrial Volumetric and Deformation Assessment in Distinguishing Post- From Pre-capillary Physiology.. 2022 , 9, 787656	
702	Cardiac complications of Sickle Cell Disease in pediatric patients: A case report and contemporary literature review. 2022 , 101517	
701	sPAP/PAAT Ratio as a New Index of Pulmonary Vascular Load: A Study in Normal Subjects and Ssc Patients with and without PH.. 2022 , 29, 134-142	
700	Resting heart rate as a preoperative predictor of postoperative atrial fibrillation after pulmonary thromboendarterectomy.. 2022 ,	1
699	Metabolomics-based mechanism exploration of pulmonary arterial hypertension pathogenesis: novel lessons from explanted human lungs.. 2022 ,	0
698	Management and prognosis of HIV-associated pulmonary arterial hypertension: 20 years of evidence from the REHAP registry.. 2022 ,	0
697	The Role of Glutamine and Glutaminase in Pulmonary Hypertension.. 2022 , 9, 838657	1
696	Lung Ventilation/Perfusion Scintigraphy for the Screening of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Which Criteria to Use?. 2022 , 9, 851935	0

695	Insights on the Gut-Mesentery-Lung Axis in Pulmonary Arterial Hypertension: A Poorly Investigated Crossroad.. 2022 , ATVBAHA121316236	0
694	Prediction of peak oxygen uptake from 6-minute walk test in pulmonary hypertension. 00664-2021	1
693	Pulmonary arterial hypertension in hereditary hemorrhagic telangiectasia associated with ACVRL1 mutation: a case report.. 2022 , 16, 99	0
692	Multifactorial pulmonary hypertension in infantile scimitar syndrome.. 2022 ,	0
691	Development and evaluation of a predictive algorithm for unsatisfactory response among patients with pulmonary arterial hypertension using health insurance claims data.. 2022 , 1-33	0
690	Recommended Reading from the University of Oklahoma Pulmonary and Critical Care Medicine Fellows.. 2022 ,	
689	Clinical Features and Outcomes in Adults With Childhood Repair of Partial Atrioventricular Septal Defect. 2022 , 1, 100007	1
688	The right ventricle under pressure: Anatomy and imaging in sickness and health.. 2022 ,	
687	Progressive dyspnoea in a patient with idiopathic non-cirrhotic portal hypertension.. 2022 , 18, 210168	
686	Dual-energy CT lung perfusion characteristics in pulmonary arterial hypertension (PAH) and pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis (PVOD/PCH): preliminary experience in 63 patients.. 2022 , 1	1
685	An Overview of Different Techniques for Improving the Treatment of Pulmonary Hypertension Secondary in Systemic Sclerosis Patients.. 2022 , 12,	4
684	Increased risk of mortality in systemic sclerosis-associated pulmonary hypertension: a systemic review and meta-analysis.. 2022 , 62, 10	0
683	Eurasian clinical guidelines for cardiovascular complications of cancer treatments: diagnosis, prevention and treatment (2022). 2022 , 6-79	2
682	Value of Cardiopulmonary Exercise Testing in Prognostic Assessment of Patients with Interstitial Lung Diseases.. 2022 , 11,	
681	Pulmonary arterial hypertension.. 2022 ,	1
680	Sarcoidosis-associated pulmonary hypertension. 2022 , 234-255	
679	Therapeutic alternatives in chronic thromboembolic pulmonary hypertension: from pulmonary endarterectomy to balloon pulmonary angioplasty to medical therapy. State of the art from a multidisciplinary team.. 2022 , 11, 120-127	1
678	Diagnostic accuracy of automated 3D volumetry of cardiac chambers by CT pulmonary angiography for identification of pulmonary hypertension due to left heart disease.. 2022 , 1	

- 677 CONTRIBUTION OF STIM-ACTIVATED TRPC-ORAI CHANNELS IN PULMONARY HYPERTENSION INDUCED BY CHRONIC SUSTAINED AND INTERMITTENT HYPOXIA.. **2022**, 0
- 676 Pulmonary Arterial Hypertension and Consecutive Right Heart Failure Lead to Liver Fibrosis.. **2022**, 9, 862330 1
- 675 Portopulmonary hypertension: Current developments and future perspectives. **2022**, 6, 10-20 0
- 674 Advances in the diagnosis and treatment of sickle cell disease.. **2022**, 15, 20 4
- 673 Prevalence and haemodynamic profiles of pulmonary hypertension in cardiac amyloidosis.. **2022**, 9, 0
- 672 Melatonin Attenuates Dasatinib-Aggravated Hypoxic Pulmonary Hypertension via Inhibiting Pulmonary Vascular Remodeling.. **2022**, 9, 790921 0
- 671 Secreted Protein Acidic and Rich in Cysteine, a Novel Regulator of Vascular Cell Function in Pulmonary Hypertension.. **2022**, 2
- 670 The Association of N-Terminal Pro-Brain Natriuretic Peptide With Time to Clinical Worsening in Hispanic Patients With Pulmonary Arterial Hypertension.. **2022**, 13, 73-80
- 669 Pulmonary hypertension among maintenance hemodialysis patients in Somalia: a hospital-based observational study.. **2022**, 74, 24
- 668 A Novel Factor in Determining the Risk of Ischemic Cerebrovascular Events in Patients with Atrial Fibrillation: Pulmonary Hypertension.. **2022**, 31, 106387
- 667 Pulmonary Hypertension in Pregnancy: Challenges and Solutions.. **2022**, 15, 33-41
- 666 Rationale and design of a screening study to detect schistosomiasis-associated pulmonary hypertension in Ethiopia and Zambia.. **2022**, 12, e12072
- 665 Impact of Esophageal Pressure Measurement on Pulmonary Hypertension Diagnosis in Obese Patients.. **2022**, 0
- 664 Post-tuberculosis pulmonary hypertension: a case of global disparity in health care.. **2022**, 10, e476 1
- 663 Causes and outcomes of ICU hospitalisations in patients with pulmonary arterial hypertension.. **2022**, 8, 0
- 662 CRISPR-mediated Bmpr2 point mutation exacerbates late pulmonary vasculopathy and reduces survival in rats with experimental pulmonary hypertension.. **2022**, 23, 87 0
- 661 BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI in patients with pulmonary arterial hypertension.. **2022**, 12, e12063 1
- 660 [Pulmonary Hypertension and Polycythemia vera].. **2022**, 0

659	Calpain-1 mediates vascular remodelling and fibrosis via HIF-1 α in hypoxia-induced pulmonary hypertension.. 2022 ,	1
658	The Glycobiology of Pulmonary Arterial Hypertension.. 2022 , 12,	2
657	Mechanisms of Pulmonary Vascular Dysfunction in Pulmonary Hypertension and Implications for Novel Therapies.. 2022 ,	1
656	Practical considerations in the management of inhaled prostacyclin therapy for pulmonary hypertension associated with interstitial lung disease (WHO group 3).. 2022 , 196, 106806	
655	Automated vortical blood flow-based estimation of mean pulmonary arterial pressure from 4D flow MRI.. 2022 ,	0
654	Therapeutic potential of carbon monoxide in hypertension-induced vascular smooth muscle cell damage revisited: From physiology and pharmacology.. 2022 , 199, 115008	0
653	Exercise-induced pulmonary hypertension in HFpEF and HFrEF: Different pathophysiologic mechanism behind similar functional impairment.. 2022 , 106978	2
652	Maternal and fetal outcomes in pregnant women with pulmonary hypertension: The impact of left heart disease. 2022 , 8, 100354	
651	Pulmonary hypertension is associated with an increased incidence of cancer diagnoses.	
650	Pulmonale Hypertonie: Differenzialdiagnostik und therapeutische Konsequenzen. 2021 , 17, 317-333	
649	Perioperative approach to precapillary pulmonary hypertension in non-cardiac non-obstetric surgery.. 2021 , 30,	0
648	Nestin-Expressing Cells in the Lung: The Bad and the Good Parts.. 2021 , 10,	1
647	Smouldering fire or conflagration? An illustrated update on the concept of inflammation in pulmonary arterial hypertension.. 2021 , 30,	1
646	Hospital costs of Balloon Pulmonary Angioplasty (BPA) procedure and management for CTEPH patients: An observational study based on the French national hospital discharge database (PMSI). 2021 , 16, e0260483	0
645	Ca ²⁺ Mediates HIF-dependent Upregulation of Aquaporin 1 in Pulmonary Arterial Smooth Muscle Cells.	
644	A Stepwise Guide to the Diagnosis and Treatment of Heart Failure with Preserved Ejection Fraction.. 2021 ,	0
643	Chronic thromboembolic pulmonary hypertension: anticoagulation and beyond. 2021 , 2021, 478-484	
642	Jugular venous ultrasound predicts outcomes in pulmonary hypertension outpatients. <i>European Respiratory Journal</i> , 2021 ,	13.6

641	Severity of precapillary pulmonary hypertension: Predictive factor.. 2021 ,	
640	Diagnosis of pulmonary hypertension associated with congenital heart disease. Part 1. Definition, classification and initial examination of patients. 2021 , 66, 28-37	1
639	Predictors of survival in portopulmonary hypertension: a 20-year experience.. 2021 , 34,	0
638	Secondary left heart failure occurred during VA-ECMO assistance for severe residual pulmonary hypertension after pulmonary endarterectomy: a case report.. 2021 , 21, 317	1
637	Genomics of Pulmonary Hypertension. 2021 , 20, 142-149	
636	New Insights into Pulmonary Hypertension: A Role for Connexin-Mediated Signalling.. 2021 , 23,	2
635	Exercise tolerance in pulmonary hypertension.. 2021 , 58, 388-388	
634	Vascular Remodeling in Pulmonary Arterial Hypertension: The Potential Involvement of Innate and Adaptive Immunity.. 2021 , 8, 806899	5
633	Risk Factors of Pulmonary Hypertension in Patients on Hemodialysis: A Single Center Study.. 2021 , 14, 487-494	
632	Spectrum of interstitial lung diseases and their association with pulmonary hypertension. 2021 ,	0
631	The clinical features of pulmonary artery involvement in Takayasu arteritis and its relationship with ischemic heart diseases and infection. 2021 , 23, 293	0
630	Association of Genes of the NO Pathway with Altitude Disease and Hypoxic Pulmonary Hypertension.. 2021 , 10,	1
629	Senescence Alterations in Pulmonary Hypertension.. 2021 , 10,	1
628	Histological Justification for the Need of Radiofrequency Ablation of Pulmonary Arteries in Patients with High-Grade Secondary Pulmonary Hypertension.. 2021 , 13, 56-62	
627	Some take-home messages from the 9th International Meeting on Pulmonary Rare Diseases and Orphan Drugs.. 2021 , 30,	
626	Secular and Regional Trends among Pulmonary Arterial Hypertension Clinical Trial Participants.. 2021 ,	0
625	Carbon Monoxide Diffusion Capacity as a Severity Marker in Pulmonary Hypertension.. 2021 , 11,	1
624	An Acute Hyperoxia Test Predicts Survival in Children with Pulmonary Hypertension Living at High Altitude.. 2021 , 22, 395-405	

623	Upregulation of Aquaporin 1 Mediates Increased Migration and Proliferation in Pulmonary Vascular Cells From the Rat SU5416/Hypoxia Model of Pulmonary Hypertension.. 2021 , 12, 763444	1
622	Pulmonary Hypertension (Adult). 2022 , 275-281	
621	Pulmonary arterial load and ventricular-arterial coupling in pulmonary hypertension. 2022 , 899-915	
620	Essential Therapy for Heart Failure with Preserved Ejection Fraction in 2022. 2022 , 2, 55-63	
619	Therapeutic approaches to improve pulmonary arterial load and right ventricular-pulmonary arterial coupling. 2022 , 935-958	
618	Obesity and its Influence on the Development of Pulmonary Hypertension.	
617	Dysregulation of the Nitric Oxide/Dimethylarginine Pathway in Hypoxic Pulmonary Vasoconstriction-Molecular Mechanisms and Clinical Significance.. 2022 , 9, 835481	1
616	Efficacy of intermittent inhaled iloprost in inoperable chronic thromboembolic pulmonary hypertension. 2022 , 32, 53-61	
615	Identifying Patients with Group 3 Pulmonary Hypertension Associated with COPD or ILD Using an Administrative Claims Database.. 2022 ,	0
614	Dan-Shen-Yin Granules Prevent Hypoxia-Induced Pulmonary Hypertension STAT3/HIF-1 α /VEGF and FAK/AKT Signaling Pathways.. 2022 , 13, 844400	2
613	Reviewing the suitability of mitochondrial transplantation as therapeutic approach for pulmonary hypertension in the era of personalised medicine.. 2022 ,	0
612	Anesthetic management of cesarean delivery of parturient with systemic lupus erythematosus associated with pulmonary arterial hypertension - A case report -.	
611	An evolutionary machine learning for pulmonary hypertension animal model from arterial blood gas analysis. 2022 , 105529	1
610	Is it Still 'Idiopathic'?: Features of Autoimmunity in IPAH.. 2022 ,	
609	Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.. 2022 , 327, 1379-1391	9
608	Der Rechtsherzkatheter - Schritt f#252;r Schritt. 2022 , 76,	
607	Distinguishing exercise intolerance in early-stage pulmonary hypertension with invasive exercise hemodynamics: Rest V _E /VCO and ETCO identify pulmonary vascular disease.. 2022 ,	0
606	Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT).. 2022 , 12, e12083	

- 605 The CTEPH Trajectories Study: Assessment of Follow-up after Acute Pulmonary Embolism to Identify Missed Opportunities for CTEPH Diagnosis.. **2022**,
- 604 Biventricular Myocardial Strain Analysis in Patients with Pulmonary Arterial Hypertension Using Cardiac Magnetic Resonance Tissue-Tracking Technology.. **2022**, 11,
- 603 Comorbidities of sarcoidosis.. **2022**, 54, 1014-1035 0
- 602 Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.. **2022**, 1 2
- 601 The fate of haemodialysis vascular access after kidney transplantation: why ligation should not be systematically performed.. **2022**,
- 600 When Pulmonary Hypertension Complicates Heart Failure.. **2022**, 40, 191-198 0
- 599 Data_Sheet_1.pdf. **2020**,
- 598 Data_Sheet_1.docx. **2020**,
- 597 Over one-third of Th/To antibody positive scleroderma patients develop pulmonary hypertension in long-term follow-up.. **2022**, 1
- 596 Novel Pharmacological Targets for Pulmonary Arterial Hypertension. **2021**, 11, 2297-2349 1
- 595 CAQ Corner: Cardiovascular and Pulmonary Evaluation of Liver Transplant Candidates: What you need to know for the board exam.. **2022**,
- 594 Accelerating the Availability of Medications to Pediatric Patients by Optimizing the Use of Extrapolation of Efficacy.. **2022**, 1 0
- 593 Drugs of Misuse: Focus on Vascular Dysfunction.. **2022**, 0
- 592 The treatment strategy of connective tissue disease associated pulmonary arterial hypertension: Evolving into the future.. **2022**, 108192 1
- 591 Chronic obstructive pulmonary disease and atherosclerosis: common mechanisms and novel therapeutics.. **2022**, 136, 405-423 1
- 590 Prognostic Power of Pulmonary Arterial Compliance Is Boosted by a Hemodynamic Unloading Test With Glyceryl Trinitrate in Heart Failure Patients With Post-capillary Pulmonary Hypertension.. **2022**, 9, 838898
- 589 Management of intrapulmonary hemorrhage in patients undergoing pulmonary thrombo-endarterectomy. **2021**, 24, 384 0
- 588 Pneumologie. **2022**, 465-540

- 587 Modelling Pulmonary Arterial Hypertension: Clinical Concepts, Engineering Applications and an Integrated Medico-engineering Approach. **2022**, 169-187
- 586 Survival and Left Ventricular Dysfunction Post Lung Transplantation for Pulmonary Arterial Hypertension.
- 585 Chloride Channels in the Lung: Challenges and Perspectives for Viral Infections, Pulmonary Arterial Hypertension, and Cystic Fibrosis.
- 584 Correlation of Hemodynamic and Respiratory Parameters in Invasive Cardiopulmonary Exercise Testing (iCPET). **2022**, 12, 655 1
- 583 Leflunomide-induced pulmonary arterial hypertension: Case report and review of literature. **2022**, 0
- 582 Effect of Ground-Based Walk Training in Pulmonary Hypertension.. **2022**, 1
- 581 Differentiating pulmonary hypertension associated with protein kinase inhibitors. **2022**, 12,
- 580 Noninvasive diagnosis of pulmonary hypertension with hyperpolarised Xe magnetic resonance imaging and spectroscopy.. **2022**, 8,
- 579 Recognizing Pulmonary Hypertension Following Pulmonary Thromboendarterectomy A Practical Guide for Clinicians. 1
- 578 Diagnostic value of miRNA expression and right ventricular echocardiographic functional parameters for chronic thromboembolic pulmonary hypertension with right ventricular dysfunction and injury.. **2022**, 22, 171 1
- 577 Pulmonary hypertension in pregnancy and its effects on the fetus.. **2022**, 101348
- 576 Mesenchymal Stem Cell-Derived Nanovesicles as a Credible Agent for Therapy of Pulmonary Hypertension.. **2022**, 0
- 575 Detection of pulmonary hypertension with six training strategies based on deep learning technology. 0
- 574 Risk assessment tools for survival prognosis: An era of new surrogacy endpoints for clinical outcome measurement in pulmonary arterial hypertension clinical trials?. **2022**, 81, 100893
- 573 COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study.. **2022**, 0
- 572 Phenotyping exercise limitation of patients with Interstitial Fibrosing Lung Disease: the importance of exercise hemodynamics.. **2022**,
- 571 Gastric antral vascular ectasia in systemic sclerosis: a study of its epidemiology, disease characteristics and impact on survival.. **2022**, 24, 103 0
- 570 Right Ventricle to Pulmonary Artery Coupling Predicts the Risk Stratification in Patients With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. **2022**, 9, 0

- 569 Management of Liver Decompensation in Advanced Liver Disease (Renal Impairment, Liver Failure, Adrenal Insufficiency, Cardiopulmonary Complications).. **2022**, 1 0
- 568 Real World Treatment Patterns, Healthcare Resource Utilization, and Cost Among Adults with Pulmonary Arterial Hypertension in The United States.
- 567 A cardiac arrest case due to left coronary artery compression in congenital heart disease-associated pulmonary arterial hypertension. **2022**,
- 566 A Network Approach to Find the "Right" Way.. **2022**, 161, 1138-1139
- 565 Association of Right Ventricular Afterload with Atrial Fibrillation Risk in Older Adults: The Atherosclerosis Risk in Communities Study.. **2022**, 0
- 564 Right Heart Catheterization and Pulmonary Hemodynamics. **2022**, 503-511
- 563 Non-Invasive Cardiac Output Determination Using Magnetic Resonance Imaging and Thermodilution in Pulmonary Hypertension. **2022**, 11, 2717 0
- 562 Comprehensive review on novel targets and emerging therapeutic modalities for pulmonary arterial Hypertension.. **2022**, 621, 121792 1
- 561 Immunity and Inflammation in Pulmonary Arterial Hypertension: From Pathophysiology Mechanisms to Treatment Perspective.. **2022**, 106238 1
- 560 Predicting Group II pulmonary hypertension: diagnostic accuracy of the H2FPEF and OPTICS scores in Scotland.. **2022**, 9, 0
- 559 The Latest in Animal Models of Pulmonary Hypertension and Right Ventricular Failure.. **2022**, 130, 1466-1486 2
- 558 Harnessing Big Data to Advance Treatment and Understanding of Pulmonary Hypertension.. **2022**, 130, 1423-1444 3
- 557 Introduction to Review Series on Pulmonary Vascular Disease and Right Ventricular Heart Failure.. **2022**, 130, 1362-1364 0
- 556 New Mutations and Pathogenesis of Pulmonary Hypertension: Progress and Puzzles in Disease Pathogenesis.. **2022**, 130, 1365-1381 3
- 555 Group 3 Pulmonary Hypertension: From Bench to Bedside.. **2022**, 130, 1404-1422 1
- 554 EGR1 Is Implicated in Right Ventricular Cardiac Remodeling Associated with Pulmonary Hypertension. **2022**, 11, 677 1
- 553 Novel Approaches to Imaging the Pulmonary Vasculature and Right Heart.. **2022**, 130, 1445-1465 2
- 552 Understanding the Pathobiology of Pulmonary Hypertension Due to Left Heart Disease.. **2022**, 130, 1382-1403 1

- 551 Prevalence and Clinical Features of Portopulmonary Hypertension in Patients With Hepatic Cirrhosis: An Echocardiographic Study. **2022**,
- 550 Soluble Guanylate Cyclase Stimulators (Riociguat) in Pulmonary Hypertension: Data from Real-Life Clinical Practice in a 3-Year Follow-Up.. **2022**,
- 549 Endothelin and the Cardiovascular System: The Long Journey and Where We Are Going. **2022**, 11, 759 1
- 548 The Long March to a Cure for Pulmonary Hypertension. **2022**, 2, 215-217
- 547 Inherited Thrombophilia in Chinese CTEPH Patients. **2022**, 2, 256-257
- 546 Pulmonary Hypertension Caused by Fibrosing Mediastinitis. **2022**, 2, 218-234 1
- 545 Portopulmonary hypertension: a patient with shortness of breath.. **2022**, 15, 0
- 544 Calcium Sensing Receptor Variants Increase Pulmonary Hypertension Susceptibility.. **2022**, 101161HYPERTENSIONAHA 1
- 543 Evolving Concepts in Endothelial Pathobiology of Pulmonary Arterial Hypertension.. **2022**, 101161HYPERTENSIONAHA 1
- 542 ERS International Congress 2021: highlights from the Pulmonary Vascular Diseases Assembly. **2022**, 8, 00665-2021 0
- 541 Association of residual pulmonary hypertension with survival after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. **2022**, 12, 1
- 540 Diagnostic Performance of Pulsed Doppler Ultrasound of the Common Femoral Vein to Detect Elevated Right Atrial Pressure in Pulmonary Hypertension.
- 539 USP11 promotes endothelial apoptosis-resistance in pulmonary hypertension by deubiquitinating HINT3.
- 538 Beneficial Effects of Pulmonary Vasodilators on Pre-Capillary Pulmonary Hypertension in Patients with Chronic Kidney Disease on Hemodialysis. **2022**, 12, 780
- 537 A case of severe cancer-related pulmonary hypertension; An unexpected resolution. **2022**, 101671 0
- 536 AMPK Activation Protects Against Pulmonary Hypertension in Rats and Relaxes Isolated Human Pulmonary Artery.
- 535 Progress in Pulmonary Vein Stenosis: Lessons from Success in Treating Pulmonary Arterial Hypertension. **2022**, 9, 799
- 534 Decrease in Tripartite Motif Containing 24 suppresses hypoxia-induced proliferation and migration of pulmonary arterial smooth muscle cells via the AKT/mammalian target of rapamycin complex 1 pathway. **2022**, 13, 13596-13606

533	Pulmonary Vasculature Responsiveness to Phosphodiesterase-5A Inhibition in Heart Failure With Reduced Ejection Fraction: Possible Role of Plasma Potassium. 2022 , 9,		
532	PPAR γ /ETV2 Axis Regulates Endothelial-to-Mesenchymal Transition in Pulmonary Hypertension.		
531	Description of Two New Cases of AQP1 Related Pulmonary Arterial Hypertension and Review of the Literature. 2022 , 13, 927		1
530	An algorithm to identify cases of pulmonary arterial hypertension from the electronic medical record. 2022 , 23,		0
529	A Novel Speckle-Tracking Echocardiography Derived Parameter That Predicts Clinical Worsening in Children with Pulmonary Arterial Hypertension. 2022 , 12, 5494		0
528	Duration of regional cerebral oxygen saturation under 40% is a risk factor for neurological injury following pulmonary thromboendarterectomy: A prospective observational study.		0
527	Case Report: Successful Concomitant Pulmonary Thromboendarterectomy and Carotid Endarterectomy. 2022 , 9,		
526	Right ventricular function across the spectrum of health and disease. <i>heartjnl-2021-320526</i>		0
525	An Update on Advancements and Challenges in Inhalational Drug Delivery for Pulmonary Arterial Hypertension. 2022 , 27, 3490		0
524	An emerging phenotype of pulmonary arterial hypertension patients carrying SOX17 variants. <i>European Respiratory Journal</i> , 2200656	13.6	1
523	Pulmonary hypertension reported with immune checkpoint inhibitors: a pharmacovigilance study.		
522	Chronic Thromboembolic Pulmonary Hypertension.		0
521	Current Status and Barriers in Pulmonary Hypertension Care Delivery in India: A Qualitative Analysis.		
520	Erythrocytes are altered in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2200506	13.6	
519	Lung transplantation in HIV-positive patients: a european retrospective cohort study. <i>European Respiratory Journal</i> , 2200189	13.6	0
518	Regulatory T Cell-Related Gene Indicators in Pulmonary Hypertension. 13,		
517	The Role of EBP50 in Regulating Endothelial-To-Mesenchymal Transition in Pulmonary Hypertension.		
516	Implications of Hydrogen Sulfide in Development of Pulmonary Hypertension. 2022 , 12, 772		0

- 515 Risk stratification in patients with pulmonary arterial hypertension at the time of listing for lung transplantation. **2022,** ○
- 514 AMPK and the Challenge of Treating Hypoxic Pulmonary Hypertension. **2022, 23, 6205** ○
- 513 Advances in the Study of Inhaled Formulations for the Treatment of Pulmonary Arterial Hypertension. **2022, 2022, 1-5** ○
- 512 A Brief Review on Gender Differences in Mexican-Mestizo Patients with Pulmonary Arterial Hypertension (PAH) at a Tertiary-Level Hospital.. **2022, 47, 101275** ○
- 511 Portopulmonary Hypertension: A Review of the Current Literature. **2022,** ○
- 510 SUMOylation in peripheral tissues under low perfusion-related pathological states. ○
- 509 Devemos Considerar a Estimulaçã da Guanilil Ciclase Solúvel como Benéfica para o Tratamento da Hipertensã Pulmonar PréCapilar?. **2022, 118, 1067-1068** ○
- 508 Noninvasive Estimation of Mean Pulmonary Artery Pressure Using MRI, Computer Models, and Machine Learning. **2022, 14-27** ○
- 507 Intelligent Systems and Smart Devices for the Continuous Monitoring of Cardiac Hemodynamics. **2022, 489-500** ○
- 506 Pulmonary Veno-occlusive Disease that Developed Following Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia: A Case Report. **2022,** ○
- 505 THE ROLE OF EXERCISE RIGHT HEART CATHETERIZATION TO GUIDE PULMONARY HYPERTENSION THERAPY IN OLDER ADULTS. ○
- 504 Outcomes of cirrhotic patients with pre-capillary pulmonary hypertension and pulmonary vascular resistance between 2 and 3 Wood Units. *European Respiratory Journal*, 2200107 13.6 ○
- 503 Pregnancy in Pulmonary Arterial Hypertension: A Multidisciplinary Approach. **2022, 9, 196** 1
- 502 Peripheral Blood T Cells of Patients with IPAH Have a Reduced Cytokine-Producing Capacity. **2022, 23, 6508** ○
- 501 Deep Learning for Detection of Exercise-Induced Pulmonary Hypertension Using Chest X-Ray Images. 9, ○
- 500 ISHLT CONSENSUS STATEMENT: Peri-operative Management of Patients with Pulmonary Hypertension and Right Heart Failure Undergoing Surgery. **2022,** ○
- 499 Potential Role of Cellular Senescence in Pulmonary Arterial Hypertension. ○
- 498 Outcomes for Children With Pulmonary Hypertension Undergoing Tracheostomy Placement: A Multi-Institutional Analysis. Publish Ahead of Print, ○

- 497 SIRT 1 Activator Loaded Inhaled Antiangiogenic Liposomal Formulation Development for Pulmonary Hypertension. **2022**, 23, 0
- 496 Platelet-leukocyte aggregate formation and inflammation in patients with pulmonary arterial hypertension and CTEPH. 1-9
- 495 Sleep-Disordered Breathing in Adults with Precapillary Pulmonary Hypertension: Prevalence and Predictors of Nocturnal Hypoxemia. 0
- 494 Defining minimal detectable difference in echocardiographic measures of right ventricular function in systemic sclerosis. **2022**, 24, 0
- 493 Pulmonary arterial hypertension. **2022**, 158, 622-629 0
- 492 Iron deficiency and pulmonary arterial hypertension.
- 491 The Potential Application and Promising Role of Targeted Therapy in Pulmonary Arterial Hypertension. **2022**, 10, 1415 1
- 490 Cine magnetic resonance imaging detects shorter cardiac rest periods in postcapillary pulmonary hypertension. 0
- 489 Gaps of evidence in pulmonary arterial hypertension. **2022**,
- 488 Oxidative Stress and Antioxidative Therapy in Pulmonary Arterial Hypertension. **2022**, 27, 3724 4
- 487 Normalization of Four Different Types of Pulmonary Hypertension After Atrial Septal Defect Closure. 9,
- 486 Clinico-pathological phenotypes of Systemic Sclerosis associated myopathy: analysis of a multicenter large cohort. 0
- 485 A Nomogram for Predicting the Risk of Pulmonary Hypertension for Patients with Chronic Obstructive Pulmonary Disease. Volume 15, 5751-5762 0
- 484 Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique Actualisation 2021. Version intégrale. **2022**,
- 483 Cysteine and glycine-rich protein 2 promotes hypoxic pulmonary vascular smooth muscle cell proliferation through the Wnt3/catenin/lymphoid enhancer-binding factor 1 pathway. 0
- 482 Percutaneous Treatments for Pulmonary Hypertension. **2022**, 11, 293-305
- 481 Senescence in pulmonary arterial hypertension: is there a link?. **2022**, 28, 303-306
- 480 TPN171H alleviates pulmonary hypertension via inhibiting inflammation in hypoxia and monocrotaline-induced rats. **2022**, 145, 107017 0

- 479 Porto-pulmonary arterial hypertension: Translation of pathophysiological concepts to the bedside. **2022**, 145, 107022 ○
- 478 Inhibition of IP3R3 attenuates endothelial to mesenchymal transition induced by TGF- β through restoring mitochondrial function. **2022**, 619, 144-150 1
- 477 Out to the tissues. **2022**, 89-98
- 476 Identification of autophagy-related biomarkers in patients with pulmonary arterial hypertension based on bioinformatics analysis. **2022**, 17, 1148-1157 ○
- 475 Plasma level of antimony correlates with pulmonary arterial hypertension severity. **2022**, 3, 100080 1
- 474 Role of Heparanase in Pulmonary Arterial Hypertension.
- 473 Management of Patients with Advanced Heart Failure According to Hemodynamic Parameters. **2022**, 2, 234-236
- 472 Invasive Cardiopulmonary Hemodynamic Assessment in Patients with Advanced Heart Failure: How to Interpret?. **2022**, 2, 165-172
- 471 Research Status of Pulmonary Hypertension in Plateau Area. **2022**, 12, 6033-6038
- 470 Evaluation of Lung Glucose Uptake with Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/CT in Patients with Pulmonary Arterial Hypertension and Pulmonary Hypertension Due to Left Heart Disease. **2022**,
- 469 An Energy-Efficient Bridge-to-Digital Converter for Implantable Pressure Monitoring Systems. **2022**, 1-10 ○
- 468 Chronic Thromboembolic Pulmonary Hypertension and Chronic Thromboembolic Pulmonary Disease (CTEPD): Clinical and Interventional Perspective. **2022**, 123-130
- 467 Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. **2022**, 1 1
- 466 Contribution of Fatty Acid Oxidation to the Pathogenesis of Pulmonary Hypertension. ○
- 465 Cardiac Effort to Compare Clinic and Remote 6-Minute Walk Testing in PAH. **2022**,
- 464 Mon sommeil, mon coeur, mes vaisseaux. **2022**, 14, 1S86-1S92
- 463 Inhibitors of Mitochondrial Dynamics Mediated by Dynamin-Related Protein 1 in Pulmonary Arterial Hypertension. 10, ○
- 462 A Multimodal Prediction Model for Diagnosing Pulmonary Hypertension in Systemic Sclerosis. ○

- 461 Integrative Proteomic and Phosphoproteomic Analyses of Hypoxia-Treated Pulmonary Artery Smooth Muscle Cells. **2022**, 10, 23 ○
- 460 Perinatal Hypoxia Aggravates Occlusive Pulmonary Vasculopathy In SU5416/Hypoxia-Treated Rats Later In Life. ○
- 459 Pulmonary Hypertension in Remote and Disadvantaged Population: Overcoming Unique Challenges for Improved Outcomes. ○
- 458 Nouveaux regards sur la sarcoïdose. **2022**, 14, 1S115-1S117 ○
- 457 Incidence and outcomes of pulmonary hypertension in the Ireland. **2022**, 9, e001272 ○
- 456 Heterogeneity of Group 2 Innate Lymphoid Cells Defines Their Pleiotropic Roles in Cancer, Obesity, and Cardiovascular Diseases. 13, ○
- 455 The clinical characteristics and outcomes of patients with pulmonary hypertension in association with hyperthyroid state: A systematic review. **2022**, 101, e29832 ○
- 454 The effect of exercise training and physiotherapy on left and right heart function in heart failure with preserved ejection fraction: a systematic literature review. ○
- 453 Exercise Rehabilitation Training in Patients with Pulmonary Hypertension: A Review. **2022**, ○
- 452 Unique Pulmonary Hypertension in Young Children: A Case Series Study. **2022**, 9, 1064 1
- 451 Update in approaches to pulmonary hypertension because of left heart disease. Publish Ahead of Print, ○
- 450 Emerging phenotypes of pulmonary hypertension associated with COPD a field guide. Publish Ahead of Print, ○
- 449 Post-Pulmonary Embolism Syndrome and Functional Outcomes after Acute Pulmonary Embolism. ○
- 448 Quantitative Assessment of Regional Pulmonary Transit Times in Pulmonary Hypertension. ○
- 447 Association of Left Ventricular Diastolic Function with Coronary Artery Calcium Score: A Project Baseline Health Study. **2022**, ○
- 446 Salt-inducible kinases: new players in pulmonary arterial hypertension?. **2022**, ○
- 445 Pulmonary veno-occlusive disease associated with long-term occupational exposure to chemical solvents and pesticides. A case report. **2022**, 100943 ○
- 444 Methamphetamine-associated pulmonary arterial hypertension. Publish Ahead of Print, ○

443	Hemodynamic Responses to Provocative Maneuvers during Right Heart Catheterization.		
442	Are you coupled? Hemodynamic phenotyping in pulmonary hypertension.		0
441	Multimodal Strategies for the Diagnosis and Management of Refractory Congestion. An Integrated Cardiorenal Approach. 13,		0
440	Editorial for Quantitative Assessment of Regional Pulmonary Transit Times in Pulmonary Hypertension		
439	Quantitative CT Evaluation of Small Pulmonary Vessels Has Functional and Prognostic Value in Pulmonary Hypertension.		
438	An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers. 9,		3
437	COMPERA 2.0 risk stratification in medically-managed chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2200313	13.6	0
436	Cross-cultural validation of the Chinese version of the EmPHasis-10 questionnaire in connective tissue disease patients with pulmonary arterial hypertension and its relationship with risk stratification. 2022 , 22,		
435	Recent advances in the management of pulmonary hypertension with interstitial lung disease. 2022 , 31, 210220		2
434	Elucidating the Clinical Implications and Pathophysiology of Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Call to Action: A Science Advisory From the American Heart Association.		1
433	Development of an Electronic Frailty Index for Predicting Mortality and Complications Analysis in Pulmonary Hypertension Using Random Survival Forest Model. 9,		0
432	Clinical Characteristics and Outcomes in Pulmonary Manifestations of Systemic Sclerosis: Contribution from Pulmonary Hypertension and Interstitial Lung Disease Severity.		
431	Cardiac risk stratification of the liver transplant candidate: A comprehensive review. 2022 , 12, 142-156		0
430	Molecular genetics of pulmonary hypertension in children. 2022 , 75, 101936		
429	Induction of GLI1 by miR-27b-3p/FBXW7/KLF5 pathway contributes to pulmonary arterial hypertension. 2022 , 171, 16-29		1
428	Prognostic Implications of the Novel Pulmonary Hypertension Definition in Patients with Aortic Stenosis after Transcatheter Valve Replacement. 2022 , 11, 4279		
427	Srolo Bzhtang reduces inflammation and vascular remodeling via suppression of the MAPK/NF- κ B signaling pathway in rats with pulmonary arterial hypertension. 2022 , 115572		0
426	Pulmonary artery enlargement: an independent risk factor for mortality in hospitalized COVID-19 patients. 2022 ,		

- 425 Prognostic meaning of right ventricular function and output reserve in patients with systemic sclerosis. **2022**, 24, 0
- 424 Chloride channels in the lung: Challenges and perspectives for viral infections, pulmonary arterial hypertension, and chystic fibrosis. **2022**, 108249 0
- 423 Prevalence and clinical associations with primary hypogonadism in male systemic sclerosis. 239719832211120
- 422 First Genotype-Phenotype Study in TBX4 Syndrome: Gain-of-Function Mutations Causative for Lung Disease. 0
- 421 Clinician's Corner: Counseling Patients with Pulmonary Vascular Disease Traveling to High Altitude. 0
- 420 Is Pulmonary Artery Pulsatility Index (PAPi) a Predictor of Outcome after Pulmonary Endarterectomy?. **2022**, 11, 4353 0
- 419 Endothelial Bone Morphogenetic Protein Signaling in Pulmonary Arterial Hypertension. **2022**,
- 418 Case 2-2022: An Adolescent Male in Cardiac Arrest 3 Days After Liver Transplantation for End-Stage Liver Disease. Publish Ahead of Print, 0
- 417 Pulmonary Vascular Research Institute GoDeep: A meta-registry merging deep phenotyping data from international PH reference centers. **2022**, 12, 0
- 416 Soluble markers of B cell activation suggest a role of B cells in the pathogenesis of systemic sclerosis-associated pulmonary arterial hypertension. 13, 1
- 415 Dual-energy CT lung perfusion in systemic sclerosis: preliminary experience in 101 patients.
- 414 Imaging Advances in Chronic Thromboembolic Pulmonary Hypertension. **2022**,
- 413 Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative Group 3 pulmonary hypertension. **2022**, 12, 2
- 412 Elucidating tricuspid Doppler signal interpolation and its implication for assessing pulmonary hypertension. **2022**, 12,
- 411 Altered Lung Microbiome and Metabolome Profile in Children With Pulmonary Arterial Hypertension Associated With Congenital Heart Disease. 9, 0
- 410 Piezo1 Channel Activation Reverses Pulmonary Artery Vasoconstriction in an Early Rat Model of Pulmonary Hypertension: The Role of Ca²⁺ Influx and Akt-eNOS Pathway. **2022**, 11, 2349 0
- 409 A systematic review of clinical study evidence for pulmonary vasodilator therapy following surgery with cardiopulmonary bypass in children with CHD. 1-18
- 408 Kynurenine metabolites predict survival in pulmonary arterial hypertension: A role for IL-6/IL-6Rβ **2022**, 12, 0

- 407 Factors determining change in treatment for ambulatory children with pulmonary arterial hypertension: Implications for monitoring. **2022**, 12,
- 406 Clinical Characteristics and Transplant-Free Survival Across the Spectrum of Pulmonary Vascular Disease. **2022**, 80, 697-718 1
- 405 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. 2200879 18
- 404 French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis - 2021 update. Full-length version. **2022**, 100948
- 403 Unbowed, unbent, unbroken: predicting pulmonary hypertension using echocardiography. **2022**, 60, 2200481
- 402 Right ventricular-pulmonary arterial coupling and its relationship to exercise haemodynamics in a continuum of patients with pulmonary vascular disease due to chronic thromboembolism. 2200450 0
- 401 Astragaloside IV in Hypoxic Pulmonary Hypertension: an In Vivo and In Vitro Experiments. 1
- 400 Pulmonary Hypertension in Children with Down Syndrome: Results from the Pediatric Pulmonary Hypertension Network Registry. **2022**,
- 399 CD39 in the development and progression of pulmonary arterial hypertension.
- 398 Considerations when Selecting Patient-Reported Outcome Measures for Assessment of Health-Related Quality of Life in Patients with Pulmonary Hypertension: A Narrative Review. **2022**,
- 397 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. 58
- 396 Pregnancy Considerations in the Multidisciplinary Care of Patients with Pulmonary Arterial Hypertension. **2022**, 9, 260
- 395 Microvasculopathy Evaluated by Dual-Energy Computed Tomography in Patients with Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension. **2022**, 12, 1232
- 394 Long-Term Study on Therapeutic Strategy for Treatment of Eisenmenger Syndrome Patients: A Case Series Study. **2022**, 9, 1217
- 393 Effects of remote haemodynamic-guided heart failure management in patients with different subtypes of pulmonary hypertension: Insights from the MEMS-HF study. 3
- 392 Lung transplantation for interstitial lung disease in idiopathic inflammatory myositis: A cohort study. 0
- 391 Pulmonary Hypertension Definition, Classification and Epidemiology in Asia. **2022**, 0
- 390 Imaging in Pulmonary Vascular Disease—Understanding Right Ventricle-Pulmonary Artery Coupling. 1-26

- 389 Frequency and Predictors for Chronic Thromboembolic Pulmonary Hypertension after a first Unprovoked Pulmonary Embolism: results from PADIS studies. ○
- 388 Diversity of hemodynamic types in connective tissue disease associated pulmonary hypertension: more than a subgroup of pulmonary arterial hypertension. **2022**, 22,
- 387 Impact of borderline pulmonary hypertension due to left heart failure on mortality in a multicenter registry study: A 3-year survivorship analysis. 9,
- 386 Drug Interactions Associated With Therapies for Pulmonary Arterial Hypertension. 875512252211140 ○
- 385 Comparison between thermodilution and Fick methods for resting and exercise-induced cardiac output measurement in patients with chronic dyspnea. ○
- 384 ER-stress-induced secretion of circulating glucose-regulated protein 78kDa (GRP78) ameliorates pulmonary artery smooth muscle cell remodelling. ○
- 383 Vasoreactive phenotype in children with pulmonary arterial hypertension and syncope. 00223-2022
- 382 Dihydroartemisinin Attenuates Hypoxic Pulmonary Hypertension via the Downregulation of miR-335 Targeting Vangl2. **2022**, 41, 750-767 2
- 381 An explorative metabolomic analysis of the endothelium in pulmonary hypertension. **2022**, 12, ○
- 380 Balloon pulmonary angioplasty versus riociguat in inoperable chronic thromboembolic pulmonary hypertension (MR BPA): an open-label, randomised controlled trial. **2022**, 4
- 379 Targeted therapies in patients with pulmonary arterial hypertension due to congenital heart disease. **2022**, 20,
- 378 Veno-Arterial Extracorporeal Membrane Oxygenation Rescue in a Patient With Pulmonary Hypertension Presenting for Revision Total Hip Arthroplasty: A Case Report and Narrative Review. **2022**,
- 377 Chronic Thromboembolic Pulmonary Hypertension: An Observational Study. **2022**, 58, 1094 ○
- 376 Indications for Lung Transplantation and Patient Selection. **2022**, 55, 255-264
- 375 Chitinase 3-like-1 contributes to the development of pulmonary vascular remodeling in pulmonary hypertension. ○
- 374 Right Heart Catheterization (RHC): A comprehensive review of provocation tests and hepatic hemodynamics in patients with pulmonary hypertension (PH).. **2022**, 101351 ○
- 373 Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension: Focus on Phosphodiesterase Inhibitors. **2022**, 15, 1024
- 372 Outcomes and Prognostic Factors of Pulmonary Hypertension Patients Undergoing Emergent Endotracheal Intubation. 088506662211188

- 371 Development and Validation of a Nomogram for Predicting Obstructive Sleep Apnea in Patients with Pulmonary Arterial Hypertension. Volume 14, 1375-1386
- 370 Diagnosis & management of pulmonary hypertension in congenital diaphragmatic hernia. **2022**, 101383
- 369 Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial. 1
- 368 Cardiac remodelling in the highest city in the world: Effects of altitude and chronic mountain sickness. 1
- 367 Survival and left ventricular dysfunction post lung transplantation for pulmonary arterial hypertension. **2022**, 72, 154120
- 366 Portopulmonary Hypertension Practice Patterns after Liver Transplantation. 0
- 365 Role of left atrial hypertension in pulmonary hypertension associated with bronchopulmonary dysplasia. 10, 0
- 364 Molecular Pathways in Pulmonary Arterial Hypertension. **2022**, 23, 10001 1
- 363 Interventionelle Behandlungsverfahren der pulmonalen Hypertension im Kindesalter. 0
- 362 Safety, Tolerability, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder for Pulmonary Hypertension: A Phase 1, Randomized, Double-Blind, Single- and Multiple-Dose Study. 0
- 361 Why Multitarget Vasodilatory (Endo)cannabinoids Are Not Effective as Antihypertensive Compounds after Chronic Administration: Comparison of Their Effects on Systemic and Pulmonary Hypertension. **2022**, 15, 1119 0
- 360 Pulmonary vascular disease and exercise hemodynamics in chronic liver disease. **2022**, 202, 106987 0
- 359 Pulmonary hypertension mortality trends in United States 1999-2019. **2022**, 75, 47-52 0
- 358 Overview of the cardiovascular effects of environmental metals: New preclinical and clinical insights. **2022**, 454, 116247 0
- 357 Endobronchial Gene Delivery for Pulmonary Hypertension in a Large Animal Model. **2022**, 279-289 0
- 356 18 β -glycyrrhetic acid ameliorates endoplasmic reticulum stress-induced inflammation in pulmonary arterial hypertension through PERK/eIF2 α /NF- κ B signaling. **2022**, 65, 187 0
- 355 Intra-Airway Gene Delivery for Pulmonary Hypertension in Rodent Models. **2022**, 263-278 0
- 354 Postpulmonary Embolism Follow-Up and Epidemiology of Chronic Thromboembolic Pulmonary Hypertension. **2022**, 21, 60-65 0

- 353 Association between income and likelihood of right heart catheterization in individuals with pulmonary hypertension: A US claims database analysis. **2022**, 12, ○
- 352 Medical Management of Chronic Thromboembolic Pulmonary Hypertension. **2022**, 21, 88-92 ○
- 351 Comparison of obstructive sleep apnoea prevalence and severity across WHO pulmonary hypertension groups. **2022**, 9, e001304 ○
- 350 Novel predictor of pulmonary arterial hypertension: Monocyte to HDL cholesterol ratio. **2022**, 101, e29973 ○
- 349 Skeletal Muscle Blood Flow during Exercise is Reduced in a Rat Model of Pulmonary Hypertension. ○
- 348 Utilidad de la ergoespirometría en el diagnóstico precoz de hipertensión pulmonar en pacientes con esclerodermia. **2022**, ○
- 347 Pharmacoeconomic justification of the choice of specific therapy schemes for the treatment of adult patients with pulmonary arterial hypertension. **2022**, 31-41 ○
- 346 Risk factors for portopulmonary hypertension in patients with cirrhosis: A prospective, multicenter study. ○
- 345 Unknown atrial septal defect was diagnosed during the course of treatment for portopulmonary hypertension: A case report. **2022**, ○
- 344 Persistence of Pulmonary Hypertension in Patients undergoing Ventricular Assist Devices and Orthotopic Heart Transplantation. ○
- 343 Baseline Sex Differences in Pulmonary Arterial Hypertension Randomized Clinical Trials. ○
- 342 Covid-19-induced pulmonary hypertension in children, and the use of phosphodiesterase-5 inhibitors. 10, 792 ○
- 341 Selection and management considerations to enhance outcomes in patients supported by left ventricular assist devices. **2022**, 37, 502-510 ○
- 340 Effects of the peripheral CB1 receptor antagonist JD5037 in mono and polytherapy with the AMPK activator metformin in a monocrotaline-induced rat model of pulmonary hypertension. 13, ○
- 339 Mitochondrial Regulation of the Hypoxia-Inducible Factor in the Development of Pulmonary Hypertension. **2022**, 11, 5219 ○
- 338 Clinical characteristics and outcomes of Group 3 and Group 4 Pulmonary Hypertension. ○
- 337 JCS 2022 Guideline on Management and Re-Interventional Therapy in Patients With Congenital Heart Disease Long-Term After Initial Repair. **2022**, 86, 1591-1690 ○
- 336 Pulmonary Hypertension in Scleroderma—Evaluation and Management. **2022**, 101468 ○

335	International consensus statement on obstructive sleep apnea.	0
334	Potassium Channels as Therapeutic Targets in Pulmonary Arterial Hypertension. 2022 , 12, 1341	1
333	Low Pulmonary Artery Pulsatility Index by Echocardiography is Associated with Increased Mortality in Pulmonary Hypertension. 2022 ,	0
332	Clinical Characteristics of Patients Undergoing Right Heart Catheterizations in Community Hospitals. 2022 , 11,	1
331	Analysis of communal Pathogenesis and Immune Infiltration Characteristics Between Psoriasis and Pulmonary Arterial Hypertension.	0
330	Role of the electrocardiogram in the risk stratification of pulmonary hypertension. heartjnl-2022-321475	0
329	Renal Replacement Therapy in Patients With Acute Decompensated Pulmonary Hypertension Admitted to the Intensive Care Unit. 2022 ,	0
328	Dynamic prediction of pulmonary hypertension in systemic sclerosis using landmark analysis.	0
327	Predicting the response to pulmonary vasodilator therapy in systemic sclerosis with pulmonary hypertension by using quantitative chest CT.	0
326	Right Heart Function in Cardiorenal Syndrome.	0
325	Focus on long non-coding RNA MALAT1: Insights into acute and chronic lung diseases. 13,	1
324	Data-driven computational models of ventricular-arterial hemodynamics in pediatric pulmonary arterial hypertension. 13,	0
323	Correlation between Pulmonary Artery Pressure and Vortex Duration Determined by 4D Flow MRI in Main Pulmonary Artery in Patients with Suspicion of Chronic Thromboembolic Pulmonary Hypertension (CTEPH). 2022 , 11, 5237	0
322	Incidental finding of elevated pulmonary arterial pressures during liver transplantation and postoperative pulmonary complications. 2022 , 22,	0
321	Management of the Critically Ill Patient with Pulmonary Arterial Hypertension and Right Heart Failure. 2022 , 43, 425-439	0
320	The role of p53 in the alternation of vascular functions. 13,	1
319	Optical coherence tomography assessment of pulmonary vascular remodeling in advanced heart failure. The OCTOPUS-CHF study. 2022 ,	0
318	Survival and prognostic factors from a multicentre large cohort of unselected Italian systemic sclerosis patients.	0

- 317 Exercise metabolomics in pulmonary arterial hypertension: Where pulmonary vascular metabolism meets exercise physiology. 13, 1
- 316 Management of Idiopathic Pulmonary Arterial Hypertension in a Patient in Trinidad: A Case Report. **2022**, 0
- 315 A Right Heart Catheterization for the Diagnosis of Pulmonary Hypertension. **2022**, 162, 511-513 0
- 314 Improved Survival for Patients with Systemic Sclerosis-associated Pulmonary Arterial Hypertension: The Johns Hopkins Registry. 2
- 313 Der Rechtsherzkatheter - Schritt fñ Schritt. **2022**, 18, 225-232 0
- 312 Hospital outcomes for patients with pulmonary arterial hypertension in sepsis and septic shock. **2022**, 22, 0
- 311 Balloon Pulmonary Angioplasty in the Management of Chronic Thromboembolic Pulmonary Hypertension. **2022**, 42, 1881-1896 0
- 310 Clinical Management and Outcomes of Patients With Portopulmonary Hypertension Enrolled in the Japanese Multicenter Registry. **2022**, 0
- 309 Highlights del 55º Congreso SEPAR. **2022**, 100216 0
- 308 Intraoperative Changes and Prognostic Implications of Pulmonary Hypertension in Hypertrophic Obstructive Cardiomyopathy Patients Undergoing Surgical Septal Myectomy. **2022**, 0
- 307 Smooth muscle Acid-sensing ion channel 1a as a therapeutic target to reverse hypoxic pulmonary hypertension. 9, 1
- 306 Psychometric properties of the sit-to-stand test for patients with pulmonary hypertension: A systematic review protocol. **2022**, 17, e0275646 0
- 305 Priorities for pulmonary hypertension research: a James Lind Alliance priority setting partnership. **2022**, 0
- 304 Pulmonary hypertension: Linking inflammation and pulmonary arterial stiffening. 13, 1
- 303 Current status of pulmonary artery denervation. 9, 0
- 302 Pulmonary hypertension is associated with poor cardiovascular and hematologic outcomes in patients with myeloproliferative neoplasms and cardiovascular disease. 0
- 301 Lycopene Ameliorates Hypoxic Pulmonary Hypertension via Suppression of Oxidative Stress. **2022**, 2022, 1-24 0
- 300 Liver Transplant Outcomes in Patients With Postcapillary Pulmonary Hypertension. **2022**, 8, e1372 0

- 299 MR Imaging for the Evaluation of Diffuse Lung Disease. **2022**, 60, 1021-1032 ○
- 298 Mosaic Attenuation Pattern. **2022**, 60, 963-978 ○
- 297 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction. **2022**, 40, 533-540 ○
- 296 7. State of the Art Pulmonary Hypertension Treatment. **2021**, 110, 1951-1957 ○
- 295 Cardiopulmonary Stability on a Patient with Hip Fracture and Severe Pulmonary Hypertension, Anesthetized with Lumbar-Sacral Plexus Block and Non-Invasive Ventilation: Case Report. **2022**, 12, 301-314 ○
- 294 Porto-Pulmonary Hypertension in Extrahepatic Portal Vein Obstruction. **2022**, 393-396 ○
- 293 Pulmonary Arterial Hypertension in an Infant. **2022**, 389-392 ○
- 292 Real-world evidence of subcutaneous treprostinil use in pulmonary arterial hypertension in Argentina. **2022**, 16, 175346662211327 ○
- 291 Reply to: Effect of Covid-19 Infection in Pulmonary Hypertension. ○
- 290 Cathepsin S Inhibition Suppresses Experimental Systemic Lupus Erythematosus-Associated Pulmonary Arterial Remodeling. **2022**, 23, 12316 ○
- 289 76-Year-Old Woman With Hemoptysis. **2022**, ○
- 288 SLEEP DISORDERS IN ELDERLY POPULATION SUFFERING FROM TB AND RESPIRATORY DISEASES. **2022**, 1 ○
- 287 Vasoreactivity testing in pulmonary hypertension associated with congenital heart disease. **2022**, 58-64 ○
- 286 Diagnostic and prognostic value of ventilatory power in pulmonary hypertension. **2022**, 23, ○
- 285 Evaluating Riociguat in the Treatment of Pulmonary Arterial Hypertension: A Real-World Perspective. Volume 18, 823-832 ○
- 284 Strategizing Drug Therapies in Pulmonary Hypertension for Improved Outcomes. **2022**, 15, 1242 2
- 283 Mild pulmonary hemodynamic alterations in patients with systemic sclerosis: relevance of the new 2022 ESC/ERS definition of pulmonary hypertension and impact on mortality. **2022**, 23, ○
- 282 Pulmonary hypertension due to high cardiac output. **2022**, 107034 ○

- 281 Cardiovascular Magnetic Resonance Imaging Patterns in Rare Cardiovascular Diseases. **2022**, 11, 6403 ○
- 280 Effect of Covid-19 Infection in Pulmonary Hypertension. ○
- 279 A century of exercise physiology: lung fluid balance during and following exercise. ○
- 278 Lungengefäßbeteiligung bei Lebererkrankungen. ○
- 277 Sarcoidosis-associated pulmonary hypertension and its treatment strategy. **2022**, 42, 24-28 ○
- 276 Prognostic Role of Pulmonary Hemodynamics Before Transcatheter Aortic Valve Replacement among Patients With Severe Aortic Stenosis. **2022**, ○
- 275 Sex-specific differences in sleep-disordered breathing and nocturnal hypoxemia in chronic thromboembolic pulmonary hypertension and chronic thromboembolic pulmonary disease. 9, ○
- 274 Prevalence and clinical association of sarcopenia among Thai patients with systemic sclerosis. **2022**, 12, ○
- 273 Computed Tomography as an additional method in the diagnosis of pulmonary hypertension: a prospective study. **2022**, 13, 51-57 ○
- 272 Funktionelle Charakterisierung von Patienten mit isoliert postkapillärer oder kombiniert post- und präkapillärer pulmonaler Hypertonie. **2022**, 76, 689-696 ○
- 271 Improving Pulmonary hypertension Screening by Echocardiography: IMPULSE. **2022**, 9, ○
- 270 Evidence of Advanced Pulmonary Vascular Remodeling in Obstructive Hypertrophic Cardiomyopathy with Pulmonary Hypertension. **2022**, 2
- 269 Congenital Absence of the Portal Vein as a Rare Cause of Portopulmonary Hypertension: A Case Study Series. **2022**, 58, 1484 ○
- 268 An Overview of Solid Organ Transplantation in Patients With Sickle Cell Disease. Publish Ahead of Print, ○
- 267 Development and validation of machine learning for early mortality in systemic sclerosis. **2022**, 12, ○
- 266 Bioinformatics Analysis of Common Genetic and Molecular Traits and Association of Portal Hypertension with Pulmonary Hypertension. **2022**, 2022, 1-12 1
- 265 Recent Advances in the Treatment of Pulmonary Arterial Hypertension. **2022**, 15, 1277 3
- 264 2022 Brazilian Thoracic Association recommendations for long-term home oxygen therapy. e20220179 ○

263	Chronic Thromboembolic Pulmonary Disease and Chronic Thromboembolic Pulmonary Hypertension.	0
262	Portopulmonary Hypertension. 2022,	0
261	Proximal interruption of the pulmonary artery: A review of radiological findings. 10,	0
260	Operability of atrial septal defect with borderline pulmonary vascular resistance index: A study in developing country. 9,	0
259	MKI67 as a potential diagnostic biomarker in pulmonary hypertension. 10,	0
258	Physiopathologie et traitement de l'hypertension artérielle pulmonaire*. 2022,	0
257	Impact of pulmonary hypertension on lung cancer management. 2022, 82, 100964	0
256	Pulmonary arterial hypertension in pregnancy. 2022,	0
255	The comorbidity burden and disease phenotype in pre-capillary pulmonary hypertension: The contributing role of obstructive sleep apnea. 2022,	0
254	Oxidative stress in patients with pulmonary hypertension. 2022, 6, 100053	0
253	Iron metabolism disorder regulated by BMP signaling in hypoxic pulmonary hypertension. 2023, 1869, 166589	0
252	Pulmonary hypertension and associated outcomes in noncardiac surgery: A systematic review and meta-analysis. 2023, 58, 21-27	0
251	SIRT6 inhibits hypoxia-induced pulmonary arterial smooth muscle cells proliferation via HIF-1 α /PDK4 signaling. 2022, 121192	0
250	Echo-Based Hemodynamics to Help Guide Care in Cardiogenic Shock: a Review.	0
249	Cardiopulmonary bypass and cardiac surgery associated pulmonary hypertension: The need for proactivity and reactivity.	0
248	Impacto de la nueva definición hemodinámica de la hipertensión pulmonar. 2022,	0
247	Risk stratification in adult and pediatric pulmonary arterial hypertension: A systematic review. 9,	1
246	Feline pulmonary hypertension: are we overlooking an important comorbidity?. 1098612X2211272	0

- 245 Circulating Markers of Inflammation and Angiogenesis and Clinical Outcomes Across Subtypes of Pulmonary Arterial Hypertension. **2022**, ○
- 244 Influence of Iron Deficiency on Clinical and Haemodynamic Parameters in Pulmonary Arterial Hypertension Cohorts. **2022**, ○
- 243 Agranulocytosis in systemic lupus erythematosus: A case report. **2022**, 10, ○
- 242 Temporal Trends in Portopulmonary Hypertension Model for End-stage Liver Disease Exceptions and Outcomes. **2022**, 8, e1410 ○
- 241 Nouvelles définitions et classification de l'hypertension pulmonaire. **2022**, ○
- 240 Respiratory Microbiome Profile of Pediatric Pulmonary Hypertension Patients Associated With Congenital Heart Disease. ○
- 239 Acquired von Willebrand syndrome (AVWS) type 2, characterized by decreased high molecular weight multimers, is common in children with severe pulmonary hypertension (PH). 10, ○
- 238 Periostin overexpression in scleroderma cardiac tissue and its utility as a marker for disease complications. **2022**, 24, ○
- 237 Quantitative evaluation of pulmonary hypertension using 4D flow MRI: a retrospective study. ○
- 236 Pulmonary hypertension associated with cardiopulmonary bypass and cardiac surgery. ○
- 235 PAH-specific therapy for pulmonary hypertension and interstitial lung disease: A systemic review and meta-analysis. 9, ○
- 234 Management of pregnant patients with pulmonary arterial hypertension. 9, ○
- 233 Clinical Presentations and Multimodal Imaging Diagnosis in Chronic Thromboembolic Pulmonary Hypertension. **2022**, 11, 6678 ○
- 232 The Cardiopulmonary Complications of Sickle Cell Disease. **2022**, 36, 1217-1237 ○
- 231 Association of Pulmonary Hypertension and Monoclonal Gammopathy of Undetermined Significance. **2022**, 2022, 1-8 ○
- 230 PULMONARY ARTERIAL HYPERTENSION INCIDENCE IN LATVIA IN 2019. ○
- 229 Pulmonary hypertension in connective tissue diseases: epidemiology, pathogenesis, and treatment. ○
- 228 Unusual Forms of Pulmonary Hypertension. **2023**, 19, 25-33 ○

- 227 Struggling Between Liver Transplantation and Portopulmonary Hypertension. **2023**, 19, 55-65 ○
- 226 Does pulmonary hypertension affect early-term outcomes of off-pump coronary artery bypass surgery?. **2022**, 68, 1747-1752 ○
- 225 Pregnancy and Pulmonary Hypertension. **2023**, 19, 75-87 ○
- 224 Effects of an inhaled soluble guanylate cyclase (sGC) stimulator MK-5475 in pulmonary arterial hypertension (PAH). **2023**, 206, 107065 ○
- 223 Mildly Elevated Pulmonary Hypertension. **2023**, 19, 1-9 ○
- 222 Pulmonary Arterial Hypertension in Connective Tissue Diseases Beyond Systemic Sclerosis. **2023**, 19, 45-54 ○
- 221 Cardiopulmonary Exercise Testing in Pulmonary Arterial Hypertension. **2023**, 19, 35-43 ○
- 220 Sex- and Gender-Related Aspects in Pulmonary Hypertension. **2023**, 19, 11-24 ○
- 219 Multidisciplinary Approach to Chronic Thromboembolic Pulmonary Hypertension: Role of Radiologists. **2023**, 43, ○
- 218 Efficacy and safety of non-prostanoid prostacyclin receptor agonist for pulmonary hypertension: A meta-analysis. **2023**, 78, 102182 ○
- 217 Long-term Outcomes and Predictors of Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Endarterectomy. **2022**, 28, 107602962211408 ○
- 216 Comparison of intravenous sildenafil with inhaled nitric oxide for acute vasodilator testing in pulmonary arterial hypertension. **2022**, 12, ○
- 215 Hypoxia-induced pulmonary hypertension upregulates eNOS and TGF- β contributing to sex-linked differences in BMPR2 +/R899X mutant mice. **2022**, 12, ○
- 214 Schistosomiasis-Associated Pulmonary Arterial Hypertension. **2022**, 21, 109-114 ○
- 213 Efficacy and safety of oral pulmonary vasodilators in pulmonary veno-occlusive disease. **2022**, 12, ○
- 212 Portopulmonary Hypertension: A Review. **2022**, 21, 123-129 ○
- 211 Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative Group 3 Pulmonary Hypertension. **2022**, 12, ○
- 210 Human Immunodeficiency Virus-Associated Pulmonary Arterial Hypertension. **2022**, 21, 115-122 ○

- 209 Adaptive versus maladaptive right ventricular remodelling. 0
- 208 Hipertensi3 pulmonar. **2022**, 13, 3979-3989 0
- 207 Characteristics of Patients With Pulmonary Arterial Hypertension in a Pulmonary Hypertension Association-Accredited Comprehensive Care Center: A Contrast in Features When Compared With US National Registry Data. **2022**, 0
- 206 Comparison of hypoxia-induced pulmonary hypertension rat models caused by different hypoxia protocols. 1-11 0
- 205 Novel hub genes associated with pulmonary artery remodeling in pulmonary hypertension. 9, 0
- 204 Protocolo diagn3stico y terap3utico del tromboembolismo cr3nico. **2022**, 13, 4026-4031 0
- 203 Identification of Pulmonary Hypertension Animal Models Using a New Evolutionary Machine Learning Framework Based on Blood Routine Indicators. 0
- 202 ACR Appropriateness Criteria3 Suspected Pulmonary Hypertension: 2022 Update. **2022**, 19, S502-S512 0
- 201 Pulmonary Hypertension. 0
- 200 A signal recognition particle-related joint model of LASSO regression, SVM-RFE and artificial neural network for the diagnosis of systemic sclerosis-associated pulmonary hypertension. 13, 0
- 199 Cardiology Assessment of Patients Undergoing Evaluation for Orthotopic Liver Transplantation. **2022**, 100528 0
- 198 Pathophysiology and Pathogenic Mechanisms of Pulmonary Hypertension: Role of Membrane Receptors, Ion Channels and Ca²⁺ Signaling. 1
- 197 Pulmonary hypertension in the primary care setting. **2022**, 33, 11-18 0
- 196 Genes in pediatric pulmonary arterial hypertension and the most promising BMPR2 gene therapy. 13, 0
- 195 Chronic Thromboembolic Pulmonary Hypertension Due to a Rare Anterior Mediastinal Venous Malformation. **2022**, 0
- 194 From acute SARS-CoV-2 infection to pulmonary hypertension. 13, 1
- 193 Evaluaci3n mediante OCT del remodelado vascular pulmonar en insuficiencia cardiaca avanzada. Estudio OCTOPUS-CHF. **2022**, 0
- 192 Esclerodermia sist3mica: epidemiolog3a, fisiopatolog3a y cl3nica. **2022**, 55, 1-27 0

- 191 Clot-regression effects of rivaroxaban in venous thromboembolism treatment in cancer patients—prospective interventional study. **2022**, 12, 0
- 190 Disruption of GCN2 Pathway Aggravates Vascular and Parenchymal Remodeling During Pulmonary Fibrosis. 1
- 189 Associations of right ventricular pulsatile load and cardiac power output to clinical outcomes in heart failure: Difference from systemic circulation. **2022**, 0
- 188 Impact of diastolic pulmonary gradient and pulmonary artery pulse index on outcomes in heart transplant patients—Results from the Eurotransplant database. 9, 0
- 187 The problem of pulmonary arterial hypertension in end-stage renal disease: can peritoneal dialysis be the solution. **2022**, 23, 0
- 186 Current understanding of the role of sleep-disordered breathing in pediatric pulmonary hypertension. **2022**, 101609 0
- 185 Anomalies cardiaques associées à l'hyperthyroïdie : Étude clinique, structurelle et rythmique. **2022**, 0
- 184 Advances in targeted therapy for pulmonary arterial hypertension in children. 0
- 183 The Therapeutic Strategies Targeting Mitochondrial Metabolism in Cardiovascular Disease. **2022**, 14, 2760 0
- 182 Clinical characteristics and risk factors of chronic obstructive pulmonary disease complicated with pulmonary hypertension at different altitudes. 0
- 181 Association of Pulmonary Artery Pressure Change With Post-Lung Transplantation Survival. **2022**, 2, 819-828 0
- 180 Lipidomic Profile Analysis of Lung Tissues Revealed Lipointoxication in Pulmonary Veno-Occlusive Disease. **2022**, 12, 1878 1
- 179 Vascular pathobiology of pulmonary hypertension. **2022**, 0
- 178 Novel and emerging therapies in pulmonary arterial hypertension. 2, 0
- 177 Case report: Rescue treatment with add-on selexipag in a preterm infant with suprasystemic pulmonary hypertension, pulmonary capillary hemangiomatosis, and isolated pulmonary vein stenosis. 9, 0
- 176 The Patient with Congenital Heart Disease in Ambulatory Surgery. **2022**, 0
- 175 Diagnosing Pulmonary Arterial Hypertension Requires an Invasive Right Heart Catheterization. **2022**, 100552 0
- 174 Catheterization of pulmonary and carotid arteries for concurrent measurement of mean pulmonary arterial (mPAP) and systemic arterial pressure (mSAP) in PAH rats. 0

- 173 Diagnosis and management of pulmonary arterial hypertension. **2022**, 18, 220168 ○
- 172 Thirty-year trends and outcome of isolated versus combined group 2 pulmonary hypertension after cardiac transplantation. 9, ○
- 171 Mitochondrial dysfunction in pulmonary arterial hypertension. 13, ○
- 170 Alleviating experimental pulmonary hypertension via co-delivering FoxO1 stimulus and apoptosis activator to hyperproliferating pulmonary arteries. **2022**, 1 ○
- 169 Acute Vasoreactivity Testing and Outcomes in Pulmonary Arterial Hypertension: A Call for Increased Testing. **2022**, ○
- 168 Esclerodermia sistémica: tratamiento. **2022**, 55, 1-11 ○
- 167 Safety and efficacy of RT234 vardenafil inhalation powder on exercise parameters in pulmonary arterial hypertension: phase II, dose-escalation study design. **2022**, 23, ○
- 166 Riociguat real-world use in patients with chronic thromboembolic pulmonary hypertension: a retrospective, observational cohort study in France. **2022**, 100987 ○
- 165 Acute Vasoreactivity Testing During Right Heart Catheterization in Chronic Thromboembolic Pulmonary Hypertension: Results from the Pulmonary Vascular Disease Phenomics Study. ○
- 164 Pulmonary hypertension with a precapillary component in heart failure with preserved ejection fraction. heartjnl-2022-321565 ○
- 163 Diagnosing heart failure with preserved ejection fraction with pulmonary vascular disease. heartjnl-2022-321984 ○
- 162 Pulmonary Hypertension Association's 2022 International Conference Scientific Sessions Overview. ○
- 161 Risk factors for portopulmonary hypertension in patients with cirrhosis: a prospective, multicenter study. ○
- 160 Cytokines as Prognostic Biomarkers in Pulmonary Arterial Hypertension. 2201232 ○
- 159 Cardiac geometry, as assessed by cardiac magnetic resonance, can differentiate subtypes of chronic thromboembolic pulmonary vascular disease. 9, ○
- 158 Peripheral Vascular Ageing in Pulmonary Arterial Hypertension as Assessed by Common Carotid Artery Intima Thickness and Intima/Media Thickness Ratio: An Investigation Using Non-Invasive High-Resolution Ultrasound. **2022**, ○
- 157 Outpatient prescription of pulmonary vasodilator therapy to preterm children with bronchopulmonary dysplasia. ○
- 156 The prevalence of pulmonary hypertension after successful tuberculosis treatment in a community sample of adult patients. ○

- 155 The association between non-clinically apparent liver fibrosis and pulmonary arterial hypertension in Hispanic patients. ○
- 154 Semi-automatic thresholding of RV trabeculation improves repeatability and diagnostic value in suspected pulmonary hypertension. 9, ○
- 153 Endotyping COPD: hypoxia-inducible factor-2 as a molecular switch between the vascular and airway phenotypes?. **2023**, 32, 220173 ○
- 152 Transcription factors in the pathogenesis of pulmonary arterial hypertension: Current knowledge and therapeutic potential. 9, ○
- 151 The new 2022 pulmonary hypertension guidelines: some small steps and some giant leaps forward for evidence-based care. **2023**, 61, 2202150 ○
- 150 Portopulmonary hypertension: Management and liver transplantation evaluation. **2023**, ○
- 149 Apelin-17 to diagnose idiopathic pulmonary arterial hypertension: A biomarker study. 13, ○
- 148 β adrenergic agonism: A novel pathway which improves right ventricular-pulmonary arterial hemodynamics in pulmonary arterial hypertension. **2023**, 11, ○
- 147 Current Therapy and Liver Transplantation for Portopulmonary Hypertension in Japan. **2023**, 12, 562 ○
- 146 Comprehensive Ultrasound Imaging of Right Ventricular Remodeling Under Surgically Induced Pressure Overload in Mice. ○
- 145 Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network meta-analysis. 9, ○
- 144 PPAR γ /ETV2 Axis Regulates Endothelial-to-Mesenchymal Transition in Pulmonary Hypertension. ○
- 143 Sleep-Disordered Breathing and Nocturnal Hypoxemia in Chronic Thromboembolic Pulmonary Disease. ○
- 142 Hemodynamic Response to Oral Vasodilator Therapy in Systemic Sclerosis-Related Pulmonary Hypertension. ○
- 141 Effect of 5 weeks of oral acetazolamide on patients with pulmonary vascular disease: A randomized, double-blind, cross-over trial. **2023**, ○
- 140 Swietenine Alleviates Vascular Remodeling by Enhancing Mitophagy of Pulmonary Arterial Smooth Muscle Cells in Experimental Pulmonary Hypertension. **2023**, ○
- 139 Clinical phenotyping of plasma thrombospondin-2 reveals relation to right ventricular structure and function in pulmonary hypertension. 00528-2022 ○
- 138 Transpulmonary generation of cell-free hemoglobin contributes to vascular dysfunction in pulmonary arterial hypertension via dysregulated clearance mechanisms. **2023**, 13, ○

137	Perioperative Echocardiographic Prediction of Pulmonary Hypertension by Pulmonary Artery Acceleration Time During Cardiac Surgery with Cardiopulmonary Bypass. 2023 ,	0
136	Risk assessment validation in patients with pulmonary arterial hypertension: Data from a Southern Brazil Registry (RESPHIRAR Study).	0
135	BMPR2 Mutation and Metabolic Reprogramming in Pulmonary Arterial Hypertension. 2023 , 132, 109-126	2
134	Impact of the revised hemodynamic definition of pulmonary hypertension. 2023 ,	0
133	The predictive value of revised diastolic dysfunction in outcomes of liver transplantation: A propensity score matching analysis. 9,	0
132	A p53-TLR3 axis ameliorates pulmonary hypertension by inducing BMPR2 via IRF3. 2023 , 26, 105935	0
131	Ventricular Function and Cardio-Ankle Vascular Index in Patients With Pulmonary Artery Hypertension. Volume 18, 889-904	0
130	Latent trajectory modelling of pulmonary artery pressure in systemic sclerosis: a retrospective cohort study. 2022 , 8, e002673	0
129	Left Ventricular Fibrosis Assessment by Native T1, ECV, and LGE in Pulmonary Hypertension Patients. 2023 , 13, 71	1
128	Piezo1, a novel therapeutic target to treat pulmonary arterial hypertension. 14,	0
127	De-escalation of oxygen-therapy and medication in patients with chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty. 2023 ,	0
126	Multidisciplinary approach for the management of term pregnancy complicated by Eisenmenger syndrome. 2023 , 24, 89-93	0
125	Pulmonary Hypertension Phenotype Can Be Identified in Heart Failure with Reduced Ejection Fraction Using Echocardiographic Assessment of Pulmonary Artery Pressure with Supportive Use of Pressure Reflection Variables. 2023 ,	0
124	Neurophysiological Mechanisms of Exertional Dyspnea in Post-Pulmonary Embolism Syndrome.	0
123	Successful Patent Ductus Arteriosus Closure in Patients With Severe Pulmonary Arterial Hypertension. 31,	0
122	Cardiovascular Magnetic Resonance for evaluation of patients with cardiovascular disease. An overview of current indications, limitations and procedures. 2023 ,	0
121	Decreased plasma levels of the brain-derived neurotrophic factor correlate with right heart congestion in pulmonary arterial hypertension. 00230-2022	0
120	Usefulness of inhaled iloprost in managing exercise-induced pulmonary hypertension in a patient with systemic sclerosis-associated interstitial lung disease. 2023 , 4, e0271	0

- 119 Tensions in Taxonomies: Current Understanding and Future Directions in the Pathobiologic Basis and Treatment of Group 1 and Group 3 Pulmonary Hypertension. 4295-4319 ○
- 118 Impact of Pulmonary Hypertension Hemodynamic Presentation on Perioperative Outcomes in Patients Undergoing Elective Cardiac Surgery: An Observational Study. Publish Ahead of Print, ○
- 117 Safety and Efficacy of Sildenafil for Group 2 Pulmonary Hypertension in Left Heart Failure. **2023**, 10, 270 ○
- 116 Therapeutic targeting of mineralocorticoid receptors in pulmonary hypertension: Insights from basic research. 10, ○
- 115 A Case of Anti-synthetase Syndrome that Relapsed with Pulmonary Arterial Hypertension and Malignancy. **2023**, ○
- 114 ??????????. **2022**, 111, 836-843 ○
- 113 Pulmonary Hypertension in Congenital Heart Diseases. **2023**, 641-654 ○
- 112 Cardiotoxicity in autologous haematopoietic stem cell transplantation for systemic sclerosis. 239719832211456 ○
- 111 Maternal Outcomes Among Pregnant Women With Congenital Heart Disease Associated Pulmonary Hypertension. **2023**, 147, 549-561 ○
- 110 Parameter inference in a computational model of haemodynamics in pulmonary hypertension. **2023**, 20, ○
- 109 Monitoring of Hemodynamics With Right Heart Catheterization in Children With Pulmonary Arterial Hypertension. **2023**, 12, ○
- 108 Characteristic changes to pulsatile and steady-state load according to pulmonary hypertension classification. **2023**, 11, ○
- 107 Pulmonary artery smooth muscle cell phenotypic switching: A key event in the early stage of pulmonary artery hypertension. **2023**, 28, 103559 ○
- 106 AMPK activation by metformin protects against pulmonary hypertension in rats and relaxes isolated human pulmonary artery. **2023**, 946, 175579 ○
- 105 Pulmonary Hypertension. **2023**, 49, 345-357 ○
- 104 Association Between the Degree of Severity of Pulmonary Hypertension With the Presence of Pulmonary Artery Aneurysm: A Brief Updated Review for Clinicians. **2023**, 48, 101645 ○
- 103 Activation of PPAR- δ prevents TERT-mediated pulmonary vascular remodeling in MCT-induced pulmonary hypertension. **2023**, 9, e14173 ○
- 102 Effect of preoperative pulmonary artery pressure on the prognosis of end-stage heart failure patients after heart transplantation. **2023**, 18, ○

- 101 Electrocardiogram Detection of Pulmonary Hypertension Using Deep Learning. **2023**, 0
- 100 Ormeloxifene, a selective estrogen receptor modulator, protects against pulmonary hypertension. **2023**, 943, 175558 0
- 99 Predictors of Improvement in Exercise Tolerance After Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension. **2023**, 12, 0
- 98 Pulmonary vasodilator therapies in pulmonary arterial hypertension associated with CHD: a systematic review and network meta-analysis. 1-15 0
- 97 Editorial: Natural products targeting oxidative stress and cell death: Treatment potential in metabolic and cardiovascular diseases. 14, 0
- 96 Portopulmonary hypertension: May we agree to disagree?. **2023**, 29, 349-350 0
- 95 Physiological predictors of resting pulmonary hypertension associated with COPD: a retrospective analysis. **2023**, 17, 0
- 94 Inpatient Transition From Intravenous to Inhaled Treprostinil in a Pediatric Patient. **2023**, 28, 102-107 0
- 93 Acquired disorders of mitochondrial metabolism and dynamics in pulmonary arterial hypertension. 11, 0
- 92 Stenosis of the trunk of the left coronary artery in idiopathic pulmonary hypertension. Case report. **2023**, 24, 876-871 0
- 91 Mitochondrial Dysfunction in Pulmonary Hypertension. **2023**, 12, 372 0
- 90 Machine Learning Based on Computed Tomography Pulmonary Angiography in Evaluating Pulmonary Artery Pressure in Patients with Pulmonary Hypertension. **2023**, 12, 1297 0
- 89 Highlights from the International Chronic Thromboembolic Pulmonary Hypertension Congress 2021. **2023**, 32, 220132 1
- 88 Identification of novel genetic variants, including PIM1 and LINC01491, with ICD-10 based diagnosis of pulmonary arterial hypertension in the UK Biobank cohort. 3, 0
- 87 Maternal and infant outcomes of pregnancy complicated by pulmonary hypertension: a single-center retrospective study from China. **2022**, 1, 16 0
- 86 Pulmonale Hypertonie bei Lungenerkrankungen. **2023**, 12, 57-61 0
- 85 Aggrecan accumulates at sites of increased pulmonary arterial pressure in idiopathic pulmonary arterial hypertension. **2023**, 13, 0
- 84 Pulmonale Hypertonie ¶lte vs. neue Leitlinie H¶dynamische Definition und klinische Klassifikation ¶Was ¶dert sich 2022?. **2023**, 12, 16-21 0

- 83 Astragaloside IV improves pulmonary arterial hypertension by increasing the expression of CCN1 and activating the ERK1 /2 pathway. **2023**, 27, 622-633 ○
- 82 The role of Transmembrane Protein 16A (TMEM16A) in pulmonary hypertension. **2023**, 65, 107525 ○
- 81 Effect of multidisciplinary team (MDT) centred on pregnant women with pulmonary hypertension on treatment and outcomes of pregnancy. **2023**, 23, ○
- 80 Diagnosis and management of pulmonary hypertension in infants with bronchopulmonary dysplasia: a guide for paediatric respiratory specialists. **2022**, 18, 220209 ○
- 79 A pulmonary arterial hypertension diagnostic algorithm for a third-world context: SYMQUICK. 108155892311551 ○
- 78 Microvascular dysfunction following cardiopulmonary bypass plays a central role in postoperative organ dysfunction. 10, ○
- 77 Classification and Predictors of Right Ventricular Functional Recovery in Pulmonary Arterial Hypertension. ○
- 76 Significance of Pulmonary Hypertension in Cardiac Amyloidosis. **2023**, 192, 147-154 ○
- 75 Surgical and Device Interventions in the Treatment of Chronic Thromboembolic Disease. ○
- 74 Lung Dual-Energy CT Perfusion Blood Volume as a Marker of Severity in Chronic Thromboembolic Pulmonary Hypertension. **2023**, 13, 769 ○
- 73 Inhibition of Soluble Epoxide Hydrolase Does Not Promote or Aggravate Pulmonary Hypertension in Rats. **2023**, 12, 665 ○
- 72 Pulmonary Vascular Remodeling in Pulmonary Hypertension. **2023**, 13, 366 ○
- 71 Development of pulmonary arterial hypertension following long-term Qing-Dai use for ulcerative colitis. **2023**, ○
- 70 Effects of Acute Hypoxia on Heart Rate Variability in Patients with Pulmonary Vascular Disease. **2023**, 12, 1782 ○
- 69 iCPET calculator: a web-based application to standardize the calculation of alpha distensibility in patients with pulmonary arterial hypertension. ○
- 68 Perioperative Decision-Making in Pulmonary Hypertension. **2023**, 32, 454-466 ○
- 67 Sarcoidosis-associated pulmonary hypertension. **2022**, 25, 26-30 ○
- 66 State-of-the-art evidence in the treatment of systemic sclerosis. **2023**, 19, 212-226 ○

- 65 Bildgebende Diagnostik bei pulmonaler Hypertonie. **2023**, 23, 49-72 ○
- 64 Research on Pulmonary Artery Pressure Classifier Based on Pre-Trained Convolutional Neural Network. **2023**, 12, 147-156 ○
- 63 Pulmonalkreislauf. **2022**, 97-105 ○
- 62 Frequency and characterization of CTEPH and CTEPD according to the mPAP threshold ≥ 20 mm Hg: Retrospective analysis from data of a prospective PE aftercare program. **2023**, 210, 107177 ○
- 61 Fluid management in septic patients with pulmonary hypertension, review of the literature. 10, ○
- 60 The First Pulmonary Hypertension Registry in the United Arab Emirates (UAEPH): Clinical Characteristics, Hemodynamic Parameters with Focus on Treatment and Outcomes for Patients with Group 1-PH. **2023**, 12, 1996 ○
- 59 A Canadian, retrospective, multicenter experience with selexipag for a heterogeneous group of pediatric pulmonary hypertension patients. 11, ○
- 58 Revising the hemodynamic criteria for pulmonary hypertension: A perspective from China. **2023**, ○
- 57 A Rapidly Evacuated Pericardial Effusion in the Setting of Chronic Pulmonary Hypertension. **2023**, 163, e137-e139 ○
- 56 Systemic Lupus Erythematosus and Pulmonary Hypertension. **2023**, 24, 5085 ○
- 55 A 39-Year-Old Man With an Arteriovenous Malformation With New Dyspnea and Lower Limb Edema. **2023**, 163, e115-e118 ○
- 54 Prognostic role of pulmonary impedance estimation to predict right ventricular dysfunction in pulmonary hypertension. 1 ○
- 53 Pharmacology and Emerging Therapies for Group 3 Pulmonary Hypertension Due to Chronic Lung Disease. **2023**, 16, 418 ○
- 52 Associations and relative risks of pulmonary hypertension and lung diseases in individuals with methamphetamine use disorder. **2023**, ○
- 51 Postoperative Cardiovascular and Hemodynamic Management in Congenital Cardiac Surgery. **2023**, 759-767 ○
- 50 Right Ventricular Sarcomere Contractile Depression and the Role of Thick Filament Activation in Human Heart Failure with Pulmonary Hypertension. ○
- 49 Pulmonary hypertension in patients with multiple myeloma: A comprehensive review. **2023**, 13, ○
- 48 Potential Prognostic Value of Native T1 in Pulmonary Hypertension Patients. **2023**, 13, 775 ○

- 47 Technical Considerations for Performing Safe and Effective Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension. **2023**, ○
- 46 European Society of Cardiology quality indicators for the care and outcomes of adults with pulmonary arterial hypertension. Developed in collaboration with the Heart Failure Association of the European Society of Cardiology. ○
- 45 Loss of response to calcium channel blockers after long-term follow-up treatment in patients with idiopathic pulmonary arterial hypertension. e20220337 ○
- 44 Transcription factors and potential therapeutic targets for pulmonary hypertension. 11, ○
- 43 Cardiac Structure and Function and Subsequent Kidney Disease Progression in Adults With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. **2023**, ○
- 42 New Drugs and Therapies in Pulmonary Arterial Hypertension. **2023**, 24, 5850 ○
- 41 Exercise-based rehabilitation programmes for pulmonary hypertension. **2023**, 2023, ○
- 40 Pericytes: The lung-forgotten cell type. 14, ○
- 39 Skeletal muscle dysfunctions in pulmonary arterial hypertension: Effects of aerobic exercise training. 14, ○
- 38 Mildly Elevated Pulmonary Artery Systolic Pressure is Associated with Extracorporeal Membrane Oxygenation Support after Heart Transplantation. **2023**, 2023, 1-7 ○
- 37 Single Nucleotide Polymorphism rs9277336 Controls the Nuclear Alpha Actinin 4-Human Leukocyte Antigen-DPA1 Axis and Pulmonary Endothelial Pathophenotypes in Pulmonary Arterial Hypertension. **2023**, 12, ○
- 36 Role of cardiopulmonary exercise test in early diagnosis of pulmonary hypertension in scleroderma patients. **2023**, 160, 283-288 ○
- 35 Pharmacotherapy for Pulmonary Hypertension in Infants with Bronchopulmonary Dysplasia: Past, Present, and Future. **2023**, 16, 503 ○
- 34 Incidence of Bloodstream Infection in Patients with Pulmonary Hypertension under Intravenous Epoprostenol or Iloprost: A Multicentre, Retrospective Study. **2023**, 24, 6434 ○
- 33 A multidisciplinary approach to severe bronchopulmonary dysplasia is associated with resolution of pulmonary hypertension. 11, ○
- 32 Dramatically Improved Severe Pulmonary Arterial Hypertension Caused by Qing-Dai (Chinese Herbal Drug) for Ulcerative Colitis. **2023**, 64, 316-320 ○
- 31 The Role of Endothelial Cells in Pulmonary Hypertension: Old Concepts and New Science. **2023**, 100667 ○
- 30 Pathophysiology and new advances in pulmonary hypertension. **2023**, 2, e000137 ○

- 29 Current clinical understanding and effectiveness of portopulmonary hypertension treatment. 10, ○
- 28 Noninvasive estimation of mean pulmonary artery pressure by CMR in under 2 minutes scan time. ○
- 27 Advances in the discovery of drugs that treat pulmonary arterial hypertension. **2023**, 18, 445-466 ○
- 26 Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?. ○
- 25 Association between intraoperative pulmonary artery pressure and cardiovascular complications after off-pump coronary artery bypass surgery: a single-center observational study. **2023**, 23, ○
- 24 Pulmonary hypertension. **2024**, 411-432 ○
- 23 Interstitial lung diseases and secondary pulmonary hypertension. **2023**, 4, 65-74 ○
- 22 Anastrozole - off-label use in men. **2023**, 19, 11-14 ○
- 21 Chronic thromboembolic pulmonary hypertension and the post-pulmonary embolism (PE) syndrome. 1358863X2311651 ○
- 20 Pulmonary Hypertension in Orphan Lung Diseases. **2023**, 715-733 ○
- 19 Portopulmonary Hypertension and Hepatopulmonary Syndrome. **2023**, 177-192 ○
- 18 Angiotensin II Increases Oxidative Stress and Inflammation in Female, But Not Male, Endothelial Cells. **2023**, 16, 127-141 ○
- 17 Manifestations respiratoires de la drpanocytose. **2023**, ○
- 16 Prognostic Value for Mortality of Plasma Bioactive Adrenomedullin in Patients with Pulmonary Arterial Hypertension: A Sub Analysis of the Biomarker Study in the COHARD-PH Registry. **2023**, 59, 748 ○
- 15 Prevalence of pulmonary hypertension in patients with COVID-19 related lung disease listed for lung transplantation: A UNOS registry analysis. **2023**, 13, ○
- 14 Current Trends and Movements in Managing Pulmonary Arterial Hypertension in Korea. 53, ○
- 13 POINT: Is It Time to Lower the Cut-off for Increased Pulmonary Vascular Resistance? Yes. **2023**, 22, 62-66 ○
- 12 Review of Advances on Management of Chronic Thromboembolic Pulmonary Hypertension. ○

- 11 Cardiovascular assessment of candidates for liver transplant. **2023**, 10, 100153 ○
- 10 Incidence and prognostic significance of malignant arrhythmias during (repetitive) Holter electrocardiograms in patients with pulmonary hypertension. 10, ○
- 9 Clinical characteristics and predictors of pulmonary hypertension in chronic obstructive pulmonary disease at different altitudes. **2023**, 23, ○
- 8 Pulmonary assessment of the liver transplant recipient□**2023**, ○
- 7 Pulmonary artery blood flow dynamics in chronic thromboembolic pulmonary hypertension. **2023**, 13, ○
- 6 Cardiac Magnetic Resonance Derived Left Ventricular Eccentricity Index and Right Ventricular Mass Measurements Predict Outcome in Children with Pulmonary Arterial Hypertension. **2023**, 10, 756 ○
- 5 Hemodynamic characteristics in patients with pulmonary hypertension and chronic obstructive pulmonary disease: A retrospective monocentric cohort study. **2023**, 83, 101008 ○
- 4 Oxidative Stress and Antioxidant Therapy in Pulmonary Hypertension. **2023**, 12, 1006 ○
- 3 Protective effects of the Terminalia bellirica tannin-induced Nrf2/HO-1 signaling pathway in rats with high-altitude pulmonary hypertension. **2023**, 23, ○
- 2 Catheter ablation of atrial fibrillation and atrial tachycardia in patients with pulmonary hypertension: a randomized study. ○
- 1 Pulmonary hypertension, nephrotic syndrome, and polymyositis due to hepatitis C virus infection: A case report. 29, 3040-3047 ○